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Abstract 
Castration resistant-prostate cancer is largely impervious to feather hormonal therapy 
and hence the outlook for patients is grim. Increased FABP5 expression plays a crucial 
role in promoting castration-resistant prostate cancer. Here we use an approach to 
attach the recently discovered Achilles heel. The experimental treatment established 
in this study is based on the recent discovery that it is the FABP5-PPARγ-VEGF 
signalling axis, rather than the androgen receptor pathway, played a dominant role in 
promoting the malignant progression of castration resistant prostate cancer cells. 
Treatments have been established in mice by suppressing the biological activity of 
FABP5 using a chemical inhibitor SBFI26 and a novel bio-inhibitor, dmrFABP5. Both 
inhibitors significantly suppressed the proliferation, migration, invasiveness and 
colony formation of castration-resistant prostate cancer PC3-M cells in vitro. They 
also produced a highly significant suppression of both metastatic rates and average 
sizes of primary tumours developed from cancer cells implanted orthotopically into 
the prostate gland of the mice. Strikingly, the bio-inhibitor dmrFABP5, a mutated 
FABP5 incapable of binding to fatty acids, produced a much better suppression of both 
primary tumour growth and metastasis. Both inhibitors interfere with the FABP5-
PPARγ- signalling pathway, but by different mechanisms. The inhibitor SBFI26 
interferes with the FABP5-PPARγ-signalling pathway at the initial stage of the signal 
transduction by binding competitively to FABP5 to inhibit cellular fatty acid uptake. 
This avoids the fatty-acid stimulation of PPARγ and prevents it activating the down-
stream regulated cancer-promoting genes. In contrast, dmrFABP5 can block the fatty-
acid stimulation of PPARγ and prevent it activating the down-stream regulated cancer-
promoting genes. This is an entirely novel experimental approach and completely 
different from current treatments that are based on androgen-blockade therapy.  
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1.1 Epidemiology of prostate cancer  
1.1.1 Epidemiology of cancer  
Cancer is a serious public health problem worldwide. In 2012, there were an expected 
14.1 million new cancer cases diagnosed in the world: in men 7.4 million (53%) and 
in women 6.7 million (47%) (1). Lung, breast, bowel and prostate cancers are the most 
common types of cancer. In the UK, these cancers account for more than 42% of all 
new cases (1,2) (Fig.1.1). During the period 1979 to 2013, the European age-
standardised (AS) incidence for all cancers rose by 17% in men and by 37% in women, 
nearly all these total increases happened before the late 1990s. Over the last decade in 
the UK (between 2002-2004 and 2011-2013), the AS incidence rates increased by 3% 
in men and 8% in women (3) (Fig.1.2). In the future, if the trend in cancer incidence 
and population growth continue with the current rates, it is expected there will be 23.6 
million new cancer cases diagnosed globally each year by 2030 (1,4).  
 
Figure 1.1 The 10 most commonly diagnosed cancers in the world; 2012 estimates 
(5). 
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Figure 1.2 All cancer excluding non-melanoma skin cancer, European age-
standardised incidence rates, Great Britain, 1979-2013 (6). 
 
1.1.2 Epidemiology of prostate cancer 
1.1.2.1 Prostate cancer incidence  
Prostate cancer is the most common cancer amongst men in the developed world, with 
more than 1,111,000 new cases identified in 2012 (1,2,7). Increases in incidence rates 
of prostate cancer were seen for all nations. Prostate cancer incidences were more 
pronounced in the USA, Canada, Australia, France, while the incidences in medium-
risk countries were moderate. Increases in incidence ranged from 25%-114%, 24%-
55% and 15%-104% in high (USA, Canada, Australia, France, Sweden)-, medium 
(Denmark, England, Italy, Spain, Israel)- and low (Singapore, Japan, India, China)-
risk countries, respectively. In high risk countries, the increased incidence may not 
truly mean the risk elevation, but simply due to the improvement of diagnosis by the 
widely use of prostate-specific antigen (PSA) tests and transurethral resection of the 
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prostate (TURP). Whereas rises in the low risk countries are possibly associated with 
westernization in these Asian populations (7,8). In Europe, prostate cancer is the most 
frequent cancer for males; with around 417,000 new cases diagnosed in 2012. Norway, 
Sweden, Finland and Netherlands are the highest incidence countries for prostate 
cancer; the lowest is in Albania (7,9,10). In the UK, prostate cancer incidence rate is 
assessed to be the 17th in Europe (7). In 2014, prostate cancer was the most common 
cancer in men in Great Britain, accounting a quarter of all new cancer cases diagnosed 
in men. There were 46,690 new prostate cancer cases diagnosed each year in the UK 
(147 new cases for every 100,000 males) (11). 
Prostate cancer incidence is closely correlated with age; thus, a higher incidence rate 
is usually seen in older men. In the UK in 2012-2014, each year an average more than 
half (54%) of cases were identified in aged 70 years and over and only 1% were 
diagnosed in the under 50 years. The incidence rates were sharply increased from 
around age 50-54, reached to maximum in the 75-79 age group, and then dropped in 
the 80-84 age group, before increased steadily to the 90+ age group (11,12) (Fig.1.3).  
 
Figure 1.3 Prostate cancer: Average number of new cases per year and age-
specific incidence rates, UK, 2012-2014 (13). 
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Prostate cancer incidence trends have increased since the mid-1970s in many countries 
including the UK (12). In the UK, the largest increase has been happened in men aged 
25-49, with more than 8-fold (767% increase) between1979-1981 and 2011-2013, 
though averages to a relatively low at around 4/100,000. The rapid incidence rates 
have constantly increased during the early 1990s (due to the frequently use of PSA 
test) for the 50-59 and 60-69 age groups, with rises of 76% and 58%, respectively, 
between 1989-1991 and 1994-1996. Incidence rates have continued to increase for the 
50-59, 60-69 and 70-79 age groups, but for males aged 75-84 and 85+, rates have 
declined since the early 2000s, dropping by 6% and 22% respectively between 2002-
2004 and 2009-2013. PSA testing has fundamentally brought forward the age issue at 
diagnosis, meaning fewer men are diagnosed in older age (9) (Fig.1.4). 
 
Figure 1.4 Prostate cancer: European age-standardised incidence rate by age in 
males, Great Britain, 1979-2013 (14). 
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1.1.2.2 Prostate cancer mortality and survival 
Prostate cancer is the 5th most common cause of cancer death international for men, 
with around 307,000 deaths in 2012. Mortality rates rose more rapidly in less 
developed regions of the world including parts of South America, the Caribbean, Asia, 
and sub-Saharan Africa than in high risk countries (1,7,8). In Europe, prostate cancer 
is the 6th most common cause of cancer death, with around 92,300 deaths in 2012; UK 
prostate cancer mortality rates are assessed to be the 15th amongst the Europe countries 
(7-10). 
In the UK in 2014, prostate cancer is the second most common cause of cancer death 
with 36 cancer deaths for each 100,000 men (15). Age is strongly linked to prostate 
cancer mortality. Between 2012 and 2014, around 57% of prostate cancer mortalities 
were in men aged over 80. Mortality rates increase sharply from around age 55-59, 
with the maximum rates in aged over 90 (Fig.1.5). Prostate cancer mortality trends 
reminded to be stable in most age groups since the early 1970s, but dropped in men 
aged 70-79. In addition, a big rise was shown in men aged over 85, with an increasing 
by 47% from 1971-73 to 2012-14 (15-17) (Fig.1.6). 
 
Figure 1.5 Prostate cancer: Average number of deaths per year and age-specific 
mortality rates in males, UK, 2012-2014 (16). 
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Figure 1.6 Prostate cancer: European age-standardised mortality rates by age in 
males, UK, 1971-2014 (18). 
 
The survival rate of prostate cancer increased between 1970 and 2012; in 1970s nearly 
2 in 10 men survived their prostate cancer ten years after the diagnosis, whereas in 
2012 more than 8 in 10 survived. Nevertheless, the survival increase can be caused by 
the better early diagnosis via the widespread use of PSA testing in the UK (19,20). 
Prostate cancer survival rate is correlated with age and stage of the disease at the time 
of diagnosis, the relative survival for men with metastatic and advanced tumours is 
obviously worse than for localised diseases. Younger men are more probable to be 
treated effectively with prostatectomy than older men. Generally, they may have a 
lower grade cancer, and as a group, they have a much better 10-year survival rate. 
However, once the young men are diagnosed with high grade advanced prostate 
cancer, their survival rate is much worse than the older men (21) (Fig.1.7, 8). 
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Figure 1.7 Relative survival for prostate cancer, by age and stage, in England 
1999-2002 (22).  
 
 
Figure 1.8 Relative survival for prostate cancer, by time and stage, in England 
1999-2002 (22). 
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1.1.2.3 Predisposing factors of prostate cancer 
1.1.2.3.1 Ethnicity/ Race 
Worldwide, it is recognised that the prostate cancer risk is higher in black men than in 
white men. African Americans have the highest risk rates of prostate cancer in the 
world (275.3 per 100,000 men) (23). The risk factor in African Americans is 
approximately 60% higher than that in Caucasian or Asian/Pacific Islanders. In 
addition, mortality rate for African Americans is approximately two times of that of 
Caucasian. The effect of race/ethnicity in prostate cancer incidence and mortality is 
unclear. However, the incidence and mortality difference is explained by variances in 
socioeconomic status variables, stages at diagnosis, genetic factors, environmental 
factors or an interaction between them (24,25).  
1.1.2.3.2 Family history/ Genetics 
Familial component has long been recognized as an important risk factor for cancer 
(26). 5-10% of prostate cancers may be associated with hereditary factors; men with 
first degree relative having prostate cancer have 2-4 folds in risk of evolving prostate 
cancer comparing with the general population. Therefore, relatives with a stronger 
family prostate cancer history would be more probable to get prostate cancer, which 
means the more cases in a family the higher the risk for other male member to get 
cancer (25-29). In addition, it has been shown that family history with hormone-
dependent cancers (breast, uterus and ovarian cancer) can significantly increase 
prostate cancer risk to other male relatives (30,31). Furthermore, specific inherited 
mutation in BRCA1 and BRCA2 (breast cancer genes) can increase the risk of prostate 
cancer in male relatives (32,33).  
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1.1.2.3.3 Diet/ Lifestyle 
Many epidemiological studies showed that proper dietary complements and healthy 
lifestyle may be essential for reducing the risk of prostate cancer (34,35). High level 
consumption of fat and red meat has been significantly associated with the increased 
prostate cancer risk. In contrast, high level consumption of fatty fish has been 
associated with a reduced risk (34-36). The Mediterranean and Asian diets may 
provide some clues into the relationship between fat (it degrades to fatty acids) level 
in diet and prostate cancer. People in Asian countries with their high consumption of 
food containing relatively high level of omega-3 polyunsaturated fatty acids (PUFA), 
vegetables, complex carbohydrates, lean meats, and antioxidants have lower 
incidences of prostate cancer. This is opposite to those in countries consuming a 
Western-style diet with high omega-6 PUFA (37). The precise mechanism by which 
fat increases the risk of prostate cancer is now unclear. Nevertheless, it has been shown 
that high level of circulating insulin-like growth factor 1 (IGF-1) is associated with 
induced prostate cancer (34,38). PUFA, such as omega 3 and 6, are the most important 
fatty acids which can only obtained through dietary sources. Linoleic acid (LA) is an 
omega-6 PUFA and its high-level intake was related to increased risk of prostate 
cancer. Whereas the high-level intake of eicosapentaenoic acid (EPA), an omega-3 
polyunsaturated fatty acid, is related to a declined risk of prostate cancer (39,40). 
Green tea, Soy phytoestrogens, Tomatoes and Cruciferous vegetables have been 
suggested to decrease the risk of prostate cancer (41).        
1.1.2.3.4 Other factors 
Alcohol consumption, cigarette smoking, men who have had a vasectomy, 
inflammation of prostate gland and sexually transmitted infections, such as chlamydia, 
may have a link to an increased risk of prostate cancer (42).  
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1.2 The pathology of prostate cancer  
1.2.1 Anatomy and physiology of prostate gland 
The prostate gland is the largest male reproductive system accessory gland surrounds 
the proximal part of urethra. It  is composed of unstriped muscular, fibrous, connective, 
elastic, glandular, nerve, vascular, lymphatic, and a small amount of striped muscular 
tissue (43). It is located anterior to the rectum, posterior to the lower portion of the 
symphysis pubis, inferior to the urinary bladder in the sub-peritoneal compartment 
between the peritoneal cavity and pelvic diaphragm. A healthy human male prostate 
gland is slightly bigger than a walnut. The mean weight of the normal prostate gland 
in adult men is around 11 grams (44). Blood supply to the prostate gland is derived 
from the parts of the internal iliac artery, lymphatic drainage occurs mainly via the 
internal iliac nodes and nerve supply is originated from the prostatic plexus (43,44) 
(Fig.1.9). 
 
Figure 1.9 The prostate gland (45). 
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According to zonal anatomy, the prostate gland is divided into three zones. The 
peripheral zone (PZ) is the largest zone of prostate gland and forms 70% of the total 
gland volume. The peripheral zone, the area next to the rectum, surrounds the distal 
urethra at the apex of the prostate, and can be felt during a digital rectal examination. 
More than 64% of prostate cancer initiated from the peripheral zone. The central zone 
(CZ) takes up approximately 25% of the total prostate gland and covers the ejaculatory 
ducts. This zone accounts for only up to 2.5% of prostate cancers although these 
cancers tend to be more aggressive (46). The transition zone (TZ) is the central area of 
the prostate and compose of 5% of the total prostate gland, between the peripheral and 
central zones and surrounds the urethra as it passes through the prostate. In younger 
men, this zone is small. In some cases, as the growth of age, the transition zone starts 
to enlarge until it becomes the largest area of the prostate and this is called benign 
prostatic hyperplasia (BPH) (47-49) (Fig.1.10). 
 
Figure 1.10 Anterior oblique view of the prostate gland and urethra (50). The 
urethra originates proximally from the urinary bladder and follows a course distally 
through the prostate. The prostate is divided into three zones: central zone (CZ), 
transition zone (TZ) and peripheral zone (PZ). The ejaculatory ducts and seminal 
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vesicles are situated at prostate base. The anterior fibromuscular stroma (AFS) is 
located anteriorly. 
 
Functionally, prostate gland is an accessory sex organ, contributing to the total seminal 
ejaculation at the time of orgasm. The prostate gland naturally grows during 
adolescence under the effect of testosterone hormone, produces the fluid portion of 
semen volume. The prostatic secretions are slightly alkaline, milky white rich of 
simple sugars (fructose and glucose) which work as diet for sperm as they pass into 
the female body to fertilize ova. Prostate fluid also contains enzymes and PSA which 
break down proteins in semen to free sperm from the viscous semen. Prostate gland 
secretions also contains alkaline chemical and minerals (zinc, citrate) that maintain 
and neutralize acidic vaginal secretions to stimulate the survival of sperm (51).                
1.2.2 Normal prostate cells 
According to standard histology classification principles, the prostate gland has two 
general cell types: epithelial and stromal. Epithelial cells are composed of the luminal 
secretory, basal, neuroendocrine and intermediate cell types. The stromal part of 
prostate gland contains smooth muscle cells and fibroblasts (52,53). Peripheral nerves, 
blood vessels and ganglia are additional essential cell elements of the normal adult 
prostate gland (Fig.1.11).  
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Figure 1.11 Model of the maintenance of prostate epithelial parenchyma (54). The 
prostate gland consists of stromal and epithelial cells. Prostate stem cells located in the 
basal layer of the prostate epithelium and different from basal and neuroendocrine 
cells, and luminal progenitors; the latter give rise to luminal secretory cells (1). 
Another family of prostate cells is that correlates with increased expression of the 
connexins Cx26, Cx32 and Cx43 (2).  
 
The luminal secretory cells are columnar-shaped above the basal layer. They are the 
major type of prostate cells. They are exocrine compartment of prostate, secreting 
prostatic acid phosphatase (PAP) and PSA into the lumen (55). The secretory cells are 
androgen-dependant cells that need androgen for their survival. They will undergo 
apoptosis when androgen is removed. This cells expressing low molecular mass of 
cytokeratins (CK8, 18) and the cell-surface marker CD57 with high levels of AR (55-
57). In addition, endothelin-1 (ET-1) and low level of prostate surface membrane 
antigen (PSMA) have been identified in normal luminal cells (58). 
The basal cells are cuboidal to flattened shape cells above the basement membrane and 
believed to be the proliferative compartment of the prostate gland (59). They express 
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p63 (a homolog of the tumour suppressor gene p53), Bcl-2 (an anti-apoptotic factor), 
hepatocyte growth factor (HGF). The basal cells consist of androgen-independent cells 
that express the high molecular weight of CK5, 14 which marks them independent of 
androgen for their survival (55,60). 
The neuroendocrine cells are scattered between the secretory and basal cells. They are 
supposed to arise from the stem cells in the basal layer, even though there is some 
proof to propose that they may be neuronal in origin (61,62). The neuroendocrine cells 
are copious in the prostate gland at birth and then disappear, only to reappear during 
puberty, after which their number slowly increases during adult life (63). The precise 
function of these cells is not totally understood, but it is supposed to that they may play 
a role in the growth and differentiation of the developing prostate cancer. Many studies 
exposed that its number increases in high grade, particularly in hormonally treated and 
androgen-independent prostate cancer (62,64,65). 
The intermediate cells are identified with a cytokeratin phenotype intermediate 
between the basal and luminal epithelial cells that express high levels of CK5 and 18 
as well as hepatocyte growth factor receptor C-MET. These cells are enriched in 
proliferative inflammatory atrophy (PIA) lesions and support that may work as 
favoured target cells in prostate carcinogenesis (66).  
1.2.3 The initiation of prostate cancer 
1.2.3.1 Benign prostate hyperplasia 
BPH is a non-malignant increase in size of prostate gland observed very commonly in 
aging men. BPH, the actual hyperplasia of the prostate grows as gland epithelium and 
smooth muscle, most especially in the transition zone (67). BPH is an age-linked 
phenomenon in approximately all males. The histologic incidence of BPH, which has 
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been observed in several studies around the world, is around 10% for males in their 
30s, 20% for males in their 40s, reaches 50-60% for males in their 60s, and is 80-90% 
for males in their 80s (68,69). There is a definitive link between BPH and prostate 
cancer; both have remarkable similarities with regards to age increasing and androgen-
dependence, thus they are frequently found concurrently. Nevertheless, a causal 
relationship between these two cases has not been established (70).  
In addition, in both BPH and prostate cancer the level of serum PSA is increased (71). 
It has been estimated that each gram of prostate cancer tissue increased PSA level by 
about 3.5 ng/ml, while each gram of BPH tissue elevated PSA by around 0.3 ng/ml 
(71). For not entirely understood reasons, the ratio of non-protein bound (free) PSA to 
total PSA is higher in BPH than in prostate cancer (72). Using the ratio of free PSA to 
total PSA improved the ability to distinguish cases of BPH and prostate carcinoma 
based on PSA testing of men with total PSA levels in the range 4-10 ng/ml (73). 
Nevertheless, the specificity of PSA testing remains to be low in men with BPH (74). 
Another method which has been improved the ability to differentiate BPH from 
prostate cancer is to use transition zone PSA density, which is the ratio of PSA level 
to transition zone volume measured on trans-rectal ultrasound (75).  
It has been suggested that androgen/androgen receptor (AR) signalling shows key roles 
in development of BPH and that blockade of this signalling could be a major 
therapeutic method for BPH. However, the full mechanisms of this signalling, and 
especially the pathogenic roles of AR in BPH are still uncertain. Nevertheless, 
Androgen deprivation therapy (ADT) and 5-α-reductase inhibitors (5ARIs) which 
suppress testosterone translation into dihydrotestosterone (DHT) are used in the 
treatment of men with BPH (76,77). 
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1.2.3.2 Prostatic Intraepithelial Neoplasia 
Prostatic Intraepithelial Neoplasia (PIN) is the initially accepted and morphologically 
recognizable stage in prostate carcinogenesis owning many of the genotypic changes 
of cancer. PIN is also defined by the abnormal proliferation of the secretory epithelium 
within prostate duct without the invasion of the basement membrane (78,79). PIN is 
classified in two grades: low- and high-grade PIN (LGPIN and HGPIN) with a variety 
of increasing severity. Pathologists now use the term PIN to designate HGPIN because 
LGPIN is most possibly not a precancerous lesion and the difference between LGPIN 
and normal epithelium is somewhat subjective (80).  
In HGPIN, the degree of cellular abnormality is more pronounced than in LGPIN, 
including nuclear enlargement, make the lesions indistinguishable from invasive 
carcinomas. The presence of protuberant nucleoli within a duct structure is an easy 
way to identify PIN (78). Four main forms of HGPIN have been identified: tufting, 
cribriform, micropapillary, and flat.  Although multiple forms can be found in most of 
the cases at the same time, the most common form found in PIN lesion is tufting (81). 
HGPIN is the most probable precursor of prostatic carcinoma and it is associated with 
progressive abnormalities of genotype and phenotype, which are middle between 
normal prostatic epithelium and prostate cancer. Furthermore, HGPIN and prostate 
cancer share many other connections, including increased incidence with age and high 
occurrence in the peripheral zone of the prostate gland. In contrast to peripheral, the 
incidence of HGPIN in transition zone of the prostate gland is much less common. It 
is well established that the volume of PIN has a positive correlation with both 
pathologic stage and Gleason score (GS) (78,82).  
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1.2.3.3 Grading and staging of prostate cancer by the combined Gleason scores 
A commonly acknowledged method of grading the aggressiveness of adenocarcinoma 
of prostate was established in the 1960s and 1970s by Donald F Gleason and members 
of the Veterans Administration Cooperative Urological Research Group. GS system is 
constructed on the histologic pattern of carcinoma cells arrangement in H&E-stained 
sections (83,84). In this system, all prostate tumours range from Grade 1 (well 
differentiated and characterised by a closely packed, uniform gland, with no 
infiltration of the stroma) to Grade 5 (poorly differentiated and characterised by a lack 
of glands with sheets of cells) (Fig.1.12).  
 
Figure 1.12 The Gleason grading system diagram (85). Grade 1, well-differentiated 
and slight anaplasia. Grade 2, moderately-differentiated and moderate anaplasia. 
Grade 3-4 poorly-differentiated and marked anaplasia. 
 
Because of the histological variation within each tumour, two grades, the primary 
grade (predominant) and the secondary grade (second most prevalent) were recorded 
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in each case which can range from 2 to 10 by adding the primary grade pattern and the 
secondary grade pattern. Low GS (6 or lower) is indicative of a more indolent 
malignancy with a good prognosis while a high GS (8 or upper) is associated with an 
aggressive biological behaviour and bad prognosis (83,84,86,87).   
1.2.3.4 Prostate cancer cell lines 
Understanding the molecular pathogenesis and metastasis of prostate cancer is an 
important first step in the design of effective therapies. Consequently, cancer 
researchers have focused a significant amount of their energy into developing cell 
culture models. As a result, many cell lines have been developed in laboratory and the 
most common used prostate cancer cell lines are: PNT2, LNCaP, 22RV1, DU-145, 
PC3 and PC3-M.   
1.2.3.4.1 PNT2 
PNT2 cell line is obtained from a normal prostate of an old male at post mortem and 
has been immortalized by transfection with a vector containing SV40 genome with a 
defective replication origin. These cells have been cultured for more than 12 months 
and revealed to contain the SV40 genome (88). They express large amount of T protein 
and cytokeratin 8, 18 and 19 which are markers of differentiated luminal prostate cells, 
weakly positive for PSA and negative with a marker of epithelial basal cells (CK 14). 
Furthermore, these cells are non-tumorigenic in nude mice (88,89).   
1.2.3.4.2 LNCaP 
LNCaP cell line is derived from a needle aspiration biopsy of a metastatic lesion in the 
left supraclavicular lymph node of a 50-year-old Caucasian patient with human 
prostate adenocarcinoma in 1977 (90). Organic specific glycoproteins for example 
AR, PSA and PAP are expressed in LNCaP cultured cell line. LNCaP cells are 
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androgen sensitive, do not produce a uniform monolayer, but grow in clusters. In 
addition, in vivo LNCaP cells produced tumours at the site of injection. Male mice 
develop tumours at a higher frequency than in the female mice and hormonal 
manipulation showed that the incidence of tumour correlated to serum androgen levels 
(91).  
1.2.3.4.3 22RVI 
22RV1 cell line is an androgen-responsive human prostate carcinoma cell line 
obtained from a xenograft that was consecutively spread in mice after castration 
induced regression and relapse of the parental, androgen-dependent CWR22 xenograft 
(92). 22RV1 expresses PSA and AR. Its growth is weakly stimulated by DHT and the 
lysates are immune-detective with androgen receptor antibody by Western blot 
analysis. In addition, 22RV1 has a unique genotype and phenotype compared to DU-
145, PC-3, and LNCaP. 22RVl has fewer chromosomes and a simpler karyotype with 
a low degree of variation (92,93).  
1.2.3.4.4 DU-145 
DU-145 cell line was isolated from a lesion in the brain of a 69-year-old Caucasian 
male with metastatic prostate carcinoma. These cells are androgen-independent and do 
not express prostate specific markers (AR, PAP and PSA) (94). These cells possess 
moderate metastatic potential and exhibit epithelial cell morphology (95).  
1.2.3.4.5 PC3 and PC3-M 
PC3 was established from a bone marrow metastasis of a GS 4 prostatic 
adenocarcinomas from a 62-year-old male Caucasian (96). These cells, which do not 
express AR and PSA, are androgen-independent and proliferate normally in androgen-
deprived media. In addition, PC3 xenograft tumours proliferate rapidly with a high 
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incidence of tumorigenicity and metastasis in nude mice (97). Metastatic sublines of 
PC-3 (PC3-M) have been isolated from liver metastasis produced in nude mice 
subsequent to intra splenic injection of the PC3 cells. PC3-M has similar possessions 
with PC3 cell line but more aggressive (98).  
1.3 Androgen dependent and independent prostate cancer 
1.3.1 Androgen-dependent prostate cancer 
Androgen has a significant influence on development, growth, maintenance and 
function of prostate gland. Testosterone, more than 95% produced in testes, is the most 
abundant circulating androgen in men. The remaining 5% of testosterone is derived 
from the adrenal glands (99). The hypothalamus regulates the production and secretion 
of androgen. It releases luteinizing Hormone Releasing Hormone (LHRH) in pulses 
whenever levels of testosterone are reduced in blood. The stimulation of the LHRH 
receptors of the pituitary gland leads to release and increased synthesis of luteinizing 
hormone (LH) into the blood, which persuades steroidogenesis in Leydig cells. In 
prostate gland, testosterone is transformed into an active form, DHT by 5-alpha-
reductase enzymes, which promotes the growth and survival of prostate cells (99,100). 
DHT binds to the AR, causing displacement of the receptor from heat shock proteins 
followed by receptor dimerization and phosphorylation (101). Inside the nucleus, the 
stimulated receptor binds to androgen response elements (AREs) in promoter regions 
of different target genes such as PSA and regulates transcription (102,103). 
In prostate cancer, radical prostatectomy and external radiation are the most 
successfully treatments when the tumour is at the localized stage (104). Androgen 
deprivation therapy (ADT) by medical, surgical castration, anti-androgens, and 
combined androgen blockade is the standard treatment for locally advanced and 
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metastatic prostate cancer, thereby lead to a suppression of androgen signalling (105). 
Although ADT is an effective treatment and able to induce clinical response in 80-
90% of patients, after a median of 2–3 years, patients experience progression to 
androgen-independent prostate cancer (106). In most cases, the majority of androgen-
independent tumour cells remain expressing AR.     
1.3.2 Androgen-independent prostate cancer 
Androgen-independent prostate cancer, also identified as Castration-Resistant Prostate 
Cancer (CRPC), is a castration-insensitive phase of disease which carries a worse 
prognosis and decrease in survival time from the beginning of progression (106,107). 
The basic for the development of new treatments in CRPC is the identification of 
molecular mechanisms involved in the translation of prostate cancer cells from 
androgen-dependent to androgen-independent status. The molecular mechanisms of 
prostate cancer progression from androgen-dependent to androgen-independent are 
still not fully understood. Nevertheless, there are several mechanisms may contribute 
for the development of CRPC.        
1.4 Molecular mechanisms of CRPC progression 
CRPC is the result of regrowth of prostate cancer cells that have adapted to the 
androgen deprivation environment. The molecular mechanisms of CRPC progression 
has been the subject of research in most laboratories that have analysed the process 
from different perspectives. Because the growth of prostate cancer cells depends on 
the presence of androgen, ADT has been the main treatment for patients with prostate 
cancer since the important recognition of the disease as androgen-dependent by 
Huggins and Hodges in 1941 (108). Nearly all patients with prostate cancer firstly 
respond to ADT. Nevertheless, almost every patient will relapse due to the growth of 
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CRPC cells. CRPC cells often continue to express androgen-responsive genes such as 
PSA, and often express AR.  
The CRPC cells grow and proliferate at low concentrations of androgen or completely 
androgen-independently and show a very aggressive behaviour. At this stage, the ADT 
is neutralized, metastases progress and any curative treatment is no longer possible. 
Over the past few years, many of the molecular mechanisms during ADT were 
identified and they became clear that multiple AR-dependent and -independent 
pathways are influenced on the way to CRPC cells.   
1.4.1 The role of AR-dependent signalling pathway in CRPC 
AR is a member of the steroid hormone receptor family of ligand-dependant 
transcription factor. AR is composed of several functional domains, ligand-binding 
domain (LBD), a DNA-binding domain (DBD), a hinge region and a large N-terminal 
domain (NTD) (109). The expression of PSA occurring in the majority of CRPC cases 
is mediated through androgen response elements of the AR (110). In addition, it has 
been identified that one of the most significant mechanisms in CRPC growth is the 
continuous activation of AR in CRPC cells (111). Despite castration which reduces 
serum androgen level, tissue testosterone or DHT level in CRPC cases is similar to 
that in patients before ADT (112). Several molecular and cellular modifications are 
linked the development of CRPC, including AR amplifications, AR mutations, AR-
ligand signalling, aberrant AR co-regulating factors and the AR splice-variants (113).  
1.4.1.1 Overexpression of AR or AR Amplification in CRPC 
AR gene amplification is a powerful mechanism that enables CRPC cells to become 
more sensitive to reduced level of circulating androgen which promotes progression 
of CRPC. It has been reported that the incidence of AR gene amplification was 
Page | 50  
 
increased by 20-30% in CRPC patients after ADT, but very few cases were reported 
in untreated primary prostate cancer (114). ADT may lead to amplification of AR in 
the cytoplasm of CRPC cells and subsequently enable the tumour cells to react to low 
level of androgen, permitting the prostate cancer cells to continue androgen-dependent 
growth even after castration (115). Amplification of AR gene was associated with a 
substantially increment in both mRNA and protein levels in CRPC tissues (116). In 
addition, it has been shown that AR sensitivity amplification was most likely to occur 
in patients who initially responded well to ADT and it was rarely seen in those who 
did not respond to ADT (114). Other mechanisms that has been correlated to 
overexpression of AR are the reduction of retinoblastoma protein (RB) and the 
increase of E2F activity (117). AR amplification only occurred in a proportion of 
CRPC patients, suggesting that it is not the only mechanism responsible for 
development CRPC.   
1.4.1.2 Mutations of AR in CRPC 
According to the report from AR Gene Mutations Database, AR has the most 
mutations among hormone receptors with more than 1110 different mutations, 168 of 
which have been associated with prostate cancer (118). AR mutations occurred very 
rarely in the early stages of prostate cancer, but occurred in approximately 10-30% of 
CRPC patients who have been treated by ADT (119). It has been suggested that ADT 
works as a selective pressure for the increase of mutations in the AR gene (120). 
Mutations are mainly affect the LBD (94%) or the NTD (40%), and, less frequently, 
the DBD (7%) and hinge region (2%). Mutations in AR gene may lead to support 
CRPC cell progression and survival even with a very low level of androgen (121). The 
T877A mutation has been found within the LBD and occurs in around one-third of 
CRPC cases (122). Mutations in the LBD reduced binding specificity to allow prostate 
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cells to grow in an androgen-independent manner, and to allow the AR to bind and to 
be activated by other ligands which are normally present in the body, including 
estrogens, corticosteroids and progesterone and even the androgen antagonist 
flutamide (123,124). Several other mutations in LBD have been identified, such as 
L701H, H874Y, V730M and W742C, which increased the sensitivity of AR to other 
steroids such as glucocorticoids at normal concentrations (125). Although most of the 
mutations are mainly in the LBD, mutations in the NTD and DBD were also identified 
(126).  
1.4.1.3 Co-regulators and collaborating factors of AR in CRPC 
Interaction between AR and co-regulators is another important mechanism involved 
in the development of CRPC. Over the past decade, around 50 AR-associated co-
regulators have been identified to be aberrantly expressed in CRPC. The transcription 
activity of the AR can be altered by a deregulated expression of co-regulator proteins 
through direct interactions with the AR or components of the AR transcriptional 
complex. There are two types of co-regulators: co-enhancer (such as p160/SRC and 
CBP/p300) or repressor (such as NCoR and SMRT) (127). The co-regulators have 
different mechanisms to inﬂuence AR transcriptional output. These mechanisms 
include changes in the structure of the chromatin, facilitation of interaction with the 
RNA polymerase transcriptional machinery, modulation of activity of histone by 
enzymes and modulation of activity of AR-bound chaperones (128). The p160/steroid 
receptor coactivators (SRC) family mediates the transcriptional functions of nuclear 
receptors and other transcription factors. The SRC family, includes SRC-1, SRC-2 and 
SRC-3, has been demonstrated to be associated with prostate cancer progression (129). 
It has been identified that SRC1 plays an important role in IL-6–induced AR activation 
in CRPC (130). Overexpression of SRC-3, associated with poorly differentiated and 
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more advanced prostate cancer, is directly linked to prostate cancer progression (131). 
CBP/p300 has also been shown to be important for the ligand-independent 
transactivation of the AR in CRPC cells (132). On the other hand, co-repressors have 
been found at reduced levels in CRPC (133).  
Collaborating factors that contribute to AR transcriptional activity have been evolved 
from analyses of genome-wide androgen binding sites in prostate cancer cells. 
Bioinformatics analysis of the androgen binding sites revealed that there is an 
enrichment of DNA sequences for motifs of numerous collaborating factors for 
example, FoxA1, GATA2, and OCT-1(134). The functions of collaborating factors 
were attributed not only to the ability of directly interact with AR, but also to work as 
a pioneer factor for AR at sites of transcriptional regulation (135). FOX proteins, 
specifically the FOXA1 subclass and GATA2 have been shown to play an important 
role in CRPC through modulation of the expression of AR (136,137) 
1.4.1.4 AR splice variants in CRPC 
Several AR splice variants (AR-Vs) have been identified in CRPC cells, xenografts, 
and tissues (138,139). It has been established that the truncated AR-Vs lacking the 
LBD, which is the target of androgen therapy, resulting in ligand-independent 
constitutive AR activation and development of CRPC (140). The mechanisms 
facilitating the increased expression of these AR-Vs in CRPC cells are still unknown. 
The possible cause of splicing is the genomic rearrangement and/or intragenic 
deletions of the AR gene locus (141). AR-V7 and ARV567ES have been identified as the 
most abundant variant detected and high expression of these variants are correlated 
with poor prognosis in CRPC patients (142). The high expression of AR-V7 has been 
found in CRPC cell lines and tissue samples of CRPC patients (142,143). In mice, AR-
V7 levels cannot be suppressed, and may be improved by ADT including abiraterone 
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acetate and enzalutamide (144). It has been suggested that AR-V7 may act as a 
therapeutic target in CRPC (145). 
1.4.1.5 Post-translational modifications of AR in CRPC 
Ligand-independent activation of AR is generally based on post-translational 
modifications which is related to persistent AR activity. Various post-translational 
modifications of AR have been known including phosphorylation, acetylation, 
sumoylation, methylation and ubiquitination. Amongst these, phosphorylation is the 
most widely studied. The majority of post-translational modifications happen in the 
activation function-1 region (AF1) of the AR, which includes the transcriptional 
activation unit 1 (TAU1) and 5 (TAU5) (146). It has been confirmed that growth 
factors, which include epidermal growth factor (EGF), insulin growth factor 1 (IGF-I) 
and keratinocyte growth factor (KGF), stimulate directly and phosphorylate AR in the 
absence of androgen in CRPC (147,148). In addition, it has been found that CRPC 
cells expressed very high level of RTK HER-2/neu receptor tyrosine kinase which can 
be activated by different growth factors. RTK HER-2/neu overexpression motivated 
the AR pathway in the absence or low levels of androgen (149). Protein kinase A 
(PKA) is also known to phosphorylate and activate AR (150). There are many 
examples of tyrosine and serine/threonine kinases involved in AR phosphorylation and 
the most interesting is associated tyrosine kinase (Ack1) which promoted castration-
resistant growth of LNCaP cell lines (151).   
1.4.1.6 Transcriptional activity of AR in CRPC 
The expression of proteins, including AR, is regulated by several steps (transcription, 
translation, and post-translational modification) and the transcriptional step is thought 
to play a key role in gene expression. Throughout the progress of CRPC, AR 
transcriptional action is modified and abnormal regulation occurred in several genes 
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that promote cell proliferation and survival. It was reported that many of the AR target 
genes upregulated after ADT were no longer present before treatment; proposing a 
reactivation of the AR signalling pathway in the absence or low level of androgen 
(152). Moreover, it has been suggested that numerous alternative oncogenic pathways 
may play important roles to generate AR signalling which can enhance AR responses 
to low levels of androgen (153). It was clearly demonstrated that overexpression of 
E2F transcriptional factor with the knockdown of retinoblastoma protein (tumour 
suppressor) cooperatively upregulated AR transcription in LNCaP cells which may 
lead to androgen-independent activation of several AR stimulated genes (117).  
Depending on its expression level, AR can work as a transcriptional enhancer or 
repressor for downstream target regulatory genes during AR signalling (154). It was 
found that increased level of androgen binding ARBS2 enhancer which was located 
within intron 2 of the AR gene led to a suppression of AR gene expression by lysine-
specific demethylase 1 (LSD1) recruitment in androgen-dependent cells. However, 
when the level of androgen is decreased in CRPC cells, the low androgen level may 
lead to an increased stimulation of androgen enhancer elements and an enhanced AR 
gene transcriptional activity, but no stimulation on suppressor elements. Therefore, the 
deceased androgen level may cause an increased expression of AR and AR repressed 
genes that contribute to cellular androgen synthesis, DNA synthesis, and proliferation 
of CRPC cells (154).   
1.4.2 The role of growth and survival signalling pathways in CRPC 
Alternative growth and survival signalling pathways also play important roles during 
the transition of prostate cancer cells from androgen-dependence to castrate resistance 
state. Many of these pathways play important roles in normal growth and development 
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of prostate gland, but after ADT most of these pathways become oncogenic (155). 
Some frequently altered pathways in CRPC are summarized as the following. 
1.4.2.1 PI3K/Akt pathway in CRPC 
PI3K/Akt pathway is associated with several cellular procedures ranging from the 
growth and survival to the expansion and metastasis. PI3K/Akt pathway is activated 
by several receptor tyrosine kinases [EGF, IGF-I, and platelet derived growth factor 
(PDGF)]. After activation, PI3K phosphorylates phosphatidylinositol-diphosphate 
(PIP2), leading to formation of phosphatidylinositol-triphosphate (PIP3). PIP3 then 
activates Akt by phosphorylation and the Phosphorylated Akt normalises cellular state 
by phosphorylation of several molecules involved in cell survival and proliferation. 
These molecules include checkpoint kinase 1 (Chk1), the forkhead box O (FOXO), 
murine double minute (MDM2), c-myc, nuclear factor-kappa B (NF-κB) and mTOR 
(156,157). In prostate cancer, genetic alterations of PI3K/Akt pathway were reported 
in 42% of primary and 100% of metastatic cancers; suggested its importance in the 
progress of CRPC (155). 
The genetic alterations lead to the increased activity of PI3K/Akt signalling pathway 
and the decreased activity of the inhibitory phosphatases PTEN. Both the increased 
Akt activation and the reduced PTEN activity were associated with poor clinical 
outcome of the patients, as well as the facilitated transition of prostate cancer from 
androgen dependence to CRPC (158,159). In fact, the loss of PTEN, a negative 
inhibitor of PI3K/AKT pathway, is observed in nearly all CRPC cases (160). It was 
demonstrated that PI3K activity was closely related to AR signalling during the 
malignant progression of CRPC. In particular, loss of PTEN in prostate epithelial cells 
was found to lead to a reduction in transcription of AR target genes (159,161). In 
PTEN-deficient preclinical mice models, it was confirmed that PI3K/Akt and AR 
Page | 56  
 
pathways cooperate with each other to maintain tumour cell growth and survival. The 
combined pharmacologic inhibition of PI3K and AR signalling axis is more effective 
on CRPC suppression than either single inhibiting agent to AR or Akt alone (162). 
1.4.2.2 RSK/YB-1 pathway in CRPC 
Y-box binding protein-1 (YB-1) performs several biological actions in both cytoplasm 
and nucleus. It works as a transcription factor in the nucleus to bind to the Y-box 
nucleotide sequence 5′-ATTGG-3′ to modulate gene specific translation (163). 
Upregulation of YB-1 was detected during prostate tumour progression and during 
ADT in a mouse model, indicating that YB-1 played a key role in the progression of 
prostate cancer into CRPC (164). In addition, it was suggested that YB-1 promotes 
castration resistance in androgen-dependent prostate cancer cells by increase 
expression of AR (165). It was found that YB-1 was phosphorylated by p90 ribosomal 
S6 kinase (RSK) and the phosphorylated YB-1 increases transcriptional activation of 
growth enhancing genes, such as EGFR (166). The RSK family consists of four 
isoforms. RSK1 and RSK2 are most expressed isoforms in prostate cancer (167). 
Blocking AR signalling by ADT caused the activation of RSK/YB1 pathways which 
can induce AR in turn. It was confirmed that RSK/YB-1 pathway contributes in CRPC 
and inhibition of this pathway may be a novel therapy against CRPC (168).  
1.4.2.3 The apoptosis-related pathways in CRPC  
The AR pathway can be completely bypassed and prostate cancer cells can improve 
the ability to survive independent of ligand or non-ligand-mediated AR activation. 
These bypass pathways are either directly or indirectly related to apoptosis. An 
effective bypass of the AR pathway cascade would facilitate proliferation and supress 
apoptosis of CRPC cells (169). Inhibition of the pro-apoptotic protein PTEN and 
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activation of Akt can result in CRPC cells escaping apoptosis in the absence or low 
level of androgen (159). 
In addition, the anti-apoptotic members of the Bcl-2 gene family, including Bcl-2, Bcl-
x, and mcl-1 are noticeable bypass candidate genes that can inhibit apoptosis. It has 
been identified that Bcl-2 is not expressed in normal prostate but highly expressed in 
all primary prostatic carcinomas and metastases tissues obtained from patients after 
ADT (170,171). The expression of Bcl-2 can cause prostate cancer cells to escape from 
apoptosis; opposites to the aim of ADT treatment which is to induce apoptosis. 
1.4.3 Role of stem cells in CRPC 
It was identified that CRPC develops because a small number of androgen-
independent cells already exist in the carcinoma even before the ADT was initiated. 
These cells, which can grow and expand without androgen supply, were named cancer 
stem cells (CSCs). CSCs are originated from normal stem cells which are found in the 
basal layer of prostate gland. It was suggested that during carcinogenesis the normal 
stem cells accumulate mutations which make some genes more oncogenic and others 
less tumour-suppressive. Thus these mutations transferred the normal stem cells into 
the CSCs which are highly malignant and metastatic (172). In addition, it has been 
indicated that CSCs play key roles in epithelial-to-mesenchymal transition (EMT) 
during the development of CRPC. Normally, EMT is a functional procedure in which 
epithelial cells turn into mesenchymal cells by losing their epithelial phenotypes such 
as cell-cell adhesion and cell polarity and by obtaining mesenchymal functions such 
as high capability of migration, invasion, anti-apoptosis and disorganization of 
extracellular matrix (173). In prostate cancer, ADT will induce EMT which then result 
in cells to leave epithelium and to invade organs (174). CSCs are thought to be a 
subpopulation of tumour cells that express specific surface antigens, possess 
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mesenchymal phenotypes, and escape the ADT (169,175). It has been revealed that 
the tumorigenic prostate CSCs can express specific markers such as telomerase, CD44, 
CD133, aldehyde dehydrogenase, and low or undetectable levels of AR. Furthermore, 
many studies in mouse models confirmed that prostate CSCs could play critical role 
in metastasis and resistance to ADT (176,177). These cells became the origin of a 
tumour and after ADT the androgen-dependent cells would be removed but the CSCs, 
which have been lurking in the background all along, remain viable and become 
dominant (175). It is tantalizing to consider that prostate cancer resists proliferation 
and apoptosis by adopting structures of normal prostatic stem/progenitor cells. The 
putative stem/progenitor cells of the prostate, which express specific markers such as 
telomerase and CD44, are androgen-independent and possess the phenotype of 
androgen-independence as do most CRPC (178). 
1.4.4 Role of fatty acids in CRPC 
Dietary fat is a main contributor to obesity and specifically important for the 
progression of prostate cancer particularly advanced prostate cancer (179). One of the 
characteristics of Western diets is a high consumption of fat and several fatty acids 
such omega-6 PUFA. PUFA intake were related to the risk of advanced prostate cancer 
but not to local prostate cancer (39). On the other hand, the Western diet lacks of fish-
derived omega-3 fatty acid which was shown to enhance the malignant progression of 
prostate cancer cells by increasing their invasiveness. But this result was disputed by 
studies in human (39,180). It was demonstrated that a low omega-6 to omega-3 fatty 
acids ratio can delay the progression of prostate cancer to CRPC after ADT (181). 
Fatty acids and their metabolites are involved in prostate cancer progression in 
different pathways with potential impact on proliferation, cell progression and 
apoptosis (182). It has been confirmed that high level consumption of PUFA stimulates 
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the progression of prostate cancer cells from androgen-dependant to castration 
resistant by activation the PI3K/Akt/mTOR pathway (181). A key downstream target 
of Akt is the transcription factor NFκB which is increased significantly in CRPC. 
Reduction on the ratio of omega-6 to omega-3 fatty acids in diet may lead to a greater 
inhibition of NFκB transcriptional activity (181,183). In addition, maintaining a low 
omega-6 to omega-3 ratio in diet suppresses the overexpression of cyclin D, and 
activates caspase-3 (181). ADT up-regulates the expression of sterol response element-
binding proteins (SREBPs) as well as some of their downstream effectors involved in 
fatty acid biosynthesis, energy production, cholesterol synthesis and membrane 
production such as aceyl-CoA-binding protein, fatty acid synthase (FASN) (184). It 
was showed that FASN and acetyl-CoA, important enzymes involved in synthesis of 
fatty acids, are overexpressed in CRPC cells (185-187). Inhibition of FASN 
suppressed the growth of prostate cancer cells, including CRPC cells, via both 
androgen-dependent and -independent mechanisms (188).  
A protein involved in transporting fatty acids and overexpressed in prostate cancer is 
fatty acid binding protein 5 (FABP5) (189). FABP5 is a cytosolic protein of the fatty 
acid binding protein family, which binds with a high affinity to long chain fatty acids. 
FABP5 is highly expressed in androgen-independent cell lines (PC3 and PC3-M), 
moderately expressed in androgen responsive cells (22RV1), and rarely expressed in 
androgen-dependent cells (LNCaP) (190,191). In LNCaP cells, low level of fatty acids 
is transported by FABP5 and used as a source of nutrition and energy. In CRPC cells 
(PC3 and PC3-M), large amount of intracellular fatty acids transported into the nucleus 
where they act as signalling molecules to stimulate the nuclear receptor peroxisome 
proliferator-activated receptor gamma (PPARγ). The stimulated PPARγ then 
modulates the expression of its downstream target regulatory genes, which eventually 
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leads to an enhanced tumour growth and aggressiveness caused by an overgrowth of 
cells with a decreased apoptosis and an increased angiogenesis (192) (Fig.1.13).  
At the cell membrane, fatty acids uptake is principally regulated by transport proteins 
such as CD36, plasma membrane-associated FABP, and FABP family 
(193,194). Nevertheless, FABPs can also be involved in this uptake, and some 
evidence proposes that FABPs can interact directly with CD36 in cell membrane (195). 
At the nuclear membrane, FABPs transfer fatty acids into nucleus for initiating nuclear 
receptor transcriptional activity to stimulate different signalling pathways (196).  It has 
been found that direct and selective FABPs and PPAR interactions do occur and are 
functionally important (197,198). 
 
Figure 1.13 Schematic illustration of a possible C-FABP (FABP5)-related 
signalling pathway that lead to malignant progression in prostatic cancer cells 
(192). As illustrated in the above figure, in normal prostatic cells, intracellular fatty 
acids transported by FABP5 can be used as sources of nutrition to generate energy. In 
highly malignant prostatic cancer cells, high level of FABP5 transports a huge amount 
of fatty acids into cells. Whereas part of the fatty acids transported into cells by FABP5 
is used as sources of energy, the excessive amount of fatty acids may act as signalling 
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molecules to activate the nuclear receptor PPARγ. The PPARγ may then initiate, 
through its peroxisome proliferative responsive element (PPRE), a chain of molecular 
events that leads to an accelerated malignant progression of the cancer cells.  
 
1.5 Fatty acid binding proteins 
1.5.1 Fatty acid binding protein family (FABPs) 
Fatty acids are vital to the cell as a source of energy, as a substrate for membrane 
biogenesis and as a storage of metabolic energy. Recently, data show that fatty acids 
work as intracellular signalling molecules of many cellular processes for example 
membrane receptors, enzymes, and gene expression (182,199). Fatty acids are high 
soluble after they are generated in the cytoplasm of adipocytes. After their generation, 
free fatty acids may cross the plasma membrane of the cell to the extracellular 
environment and get into cancer cells by passive diffusion or through transporters. 
Fatty acids in cytoplasm can either enter a metabolic pathway or bind to intracellular 
fatty acid binding proteins which transport them to different organelles.  
FABPs are a family of cytoplasmic proteins with similar molecular masses around 14-
15-kDa that reversibly bind to saturated and unsaturated fatty acids with high affinity 
(200). Since the initial discovery of FABPs in 1972 (201), at least 12 members have 
been identified (Table 1.1). All these members were named after the organs in which 
they were first known or commonly predominate, but their expression is not limited to 
that specific tissue or cell type. Some tissues express more than one FABPs, which 
indicates that FABPs may have exclusive functions. For example, FABP1 (liver 
FABP) is not only expressed in liver, but also in pancreas, intestine, lung, stomach, 
and kidney. While FABP5 (epidermal FABP) is one of the most expressed FABPs and 
it is commonly expressed in skin, tongue, adipocyte, brain, intestine, macrophage, 
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kidney, liver, lung, mammary gland, heart, skeletal muscle, testis, retina, lens and 
spleen (202). FABPs are highly expressed in adipocytes, hepatocytes, and cardiac 
myocytes. Wherever fatty acids are localised, they are prominent materials for lipid 
biosynthesis and storage. Quantities of FABPs can increase with a mass arrival of fatty 
acids into the cell (203).  
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Protein Name Alternative 
names 
Tissue/cell expression 
FABP1 Liver FABP L-FABP Liver, intestine, pancreas, kidney, lung, 
stomach 
FABP2 Intestinal FABP I-FABP Intestine, liver 
FABP3 Heart/muscle 
FABP 
H-FABP Heart, skeletal muscle, brain, kidney, 
lung, stomach, testis, aorta, adrenal 
gland, mammary gland, placenta, ovary, 
brown adipose tissue 
FABP4 Adipocyte 
FABP 
A-FABP Adipocyte, macrophage, dendritic cell 
FABP5 Epidermal 
FABP 
E-FABP Skin, tongue, adipocyte, macrophage, 
mammary gland, brain, intestine, 
kidney, liver, lung, skeletal muscle, 
testis, retina, lens, spleen, prostate 
FABP6 Ileal FABP Il-FABP Ileum, ovary, adrenal gland, stomach 
FABP7 Brain FABP B-FABP Brain, glia cell, retina, mammary gland 
FABP8 Myelin FABP  M-FABP  Peripheral nervous system  
FABP9 Testis FABP T-FABP Testis, salivary gland, mammary gland 
Fabp10 Liver FABP L-FABP Liver of teleost fish 
Fabp11 – – Liver, intestine, muscle, brain, heart, 
eye, swim bladder, gills, kidney, skin, 
ovary and testis of teleost fish 
FABP12 – – Retinoblastoma cell from human. 
Retina, testicular germ, kidney 
Table 1.1 Fatty acid-binding protein multigene family (204).  
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1.5.2 Structure and affinity of FABPs 
Structures of FABPs have been examined by X-ray crystallography, nuclear magnetic 
resonance and other biochemical methods. FABPs exhibited only moderate amino acid 
sequence homology, varying from 20-70%. However, they have highly similar tertiary 
structures. In general, FABPs have a 10-stranded antiparallel β-barrel structure. The 
binding pocket is situated inside the β-barrel and framed on one side by an N-terminal 
helix-loop-helix motif that is thought to act as the major portal for fatty acids entry and 
exit (205). It has been showed that there are three-element fingerprints for all FABPs 
that provides a signature (Fig.1.14). 
 
Figure 1.14 The fingerprint for FABPs (206). Three motifs are presented with this 
diagram. Motif 1 (blue ribbon) forms part of the first -strand ( A). It also includes a 
nuclear localization signal (NLS) and a hormone sensitive lipase (HSL) binding site.  
The nuclear export signal (NES) domain is in Motif 2 (green ribbon) which includes 
strand 4 ( D) and strand 5 ( E). Motif 3 (red ribbon) encodes strands 9 ( I) and 10 (
J). 
 
As a result of small structural differences between FABPs, they bind fatty acids with 
differences in binding affinity, ligand selectivity, and binding mechanism. In general, 
Page | 65  
 
the more hydrophobic the ligand, the tighter the binding affinity; with the exemption 
of unsaturated fatty acids (205). In addition, it is possible that the needs of target cells 
determine the selectivity of the major FABPs present at different sites. For instance, 
FABP1 exhibits binding affinity for a broad range of fatty acids. In contrast, FABP7 
is highly selective for very long-chain fatty acids such as eicosapentaenoic acid (207).  
1.5.3 Biological function of FABPs 
Different biological functions have been identified for FABPs which assist the 
transport of fatty acids to specific organelles in the cell, for example to the lipid droplet 
for storage; to the peroxisome or mitochondria for oxidation; to the endoplasmic 
reticulum for signalling and membrane synthesis; to cytosolic to regulate enzymes 
activity (206). In addition, FABPs appear to entry the nucleus, and potentially transport 
fatty acids to transcription regulators, such as peroxisome proliferator-activated 
receptors (PPARs) family, thereby permitting PPARs to perform their biological 
functions (208,209). Evidences suggest that FABPs deliver fatty acids from the cytosol 
to their receptor PPARs in the nucleus. Moreover, it has been confirmed that the 
expression of FABPs in cancer tissues localised in the cytoplasm and nucleus 
(210,211). These evidences indicated that FABPs may involve in unique signalling 
pathways in the nucleus to control the specific gene expression. 
1.6 FABP5 and prostate cancer  
1.6.1 FABP5 and CRPC 
FABP5 is a 15kDa cytosolic protein of the fatty acid binding protein family (212), 
which binds with a high affinity to medium and long chain fatty acids (213). 
Previously, it was found that the gene coding for FABP5 was over-expressed in human 
prostate cancer cell lines and in prostate carcinoma tissue (189,190). When FABP5 
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gene was transfected into the benign Rama 37 model cells (214), it promoted growth 
of primary tumours and induced metastasis (190). In addition, it has been demonstrated 
that FABP5 act as a molecule involved in malignant progression of prostate and breast 
cancer, and its increased expression was able to induce metastasis in vivo through up-
regulation of expression of the Vascular endothelial growth factor (VEGF) (191,215). 
Previously, FABP5 has been confirmed to be a potential prognostic indicator to predict 
patient outcome and target for malignancy suppression (189). Suppression of FABP5 
by using siRNA can effectively inhibit prostate cancer in nude mice (216). It was 
established that the biological activity of FABP5 to promote tumorigenicity of prostate 
cancer cells depends on its ability of binding and transporting fatty acids which work 
as signalling molecules to stimulate their nuclear receptor PPARγ in CRPC cells (192). 
Furthermore, it was confirmed that the enhanced expression of cytoplasmic FABP5 
significantly correlated with the increased nuclear PPARγ, and the increased levels of 
both proteins related to a shorter patient survival (211). Recently, it has been confirmed 
that the fatty acids activate PPARγ throw the FABP5-PPARγ-VEGF signal pathway 
(Fig.1.15) and it is important therapeutic target for angiogenesis-suppression treatment 
of CRPC (217).  
 
Figure 1.15 Schematic illustration of FABP5-PPARγ-VEGF transduction pathway. 
Through this pathway, fatty acids transported by FABP5 can activate PPARγ which 
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ultimately upregulate VEGF. VEGF is a potent antigenic factor which can bind to its 
receptor VEGFR1 to promote formation of vessel networks that are essential for growth 
and expansion of the cancer cells. VEGF can also promote directly malignancy of the 
cancer cells through an autocrine mechanism to simulate the receptor that is highly 
expressed on the surface of the prostate cancer cells (VEGFR-2) (217). 
 
1.6.2 Targeting FABP5 in CRPC 
When highly malignant CRPC PC3-M cells were orthotopically implanted into the 
mouse prostate gland, knockdown of FABP5 gene by RNA interference produced 63-
fold reduction in average tumour size; 7-fold reduction in tumour incidence, and 100% 
reduction in metastasis (189). These results justified our hypothesis that FABP5 is indeed 
a treatment target for CRPC. Although knockdown FABP5 RNA is highly effective in 
inhibition of both tumourigenicity and metastasis of CRPC cells (189), siRNA molecules 
are not ideal agents for treatment due to their instability. Even when dissolved in a 
stabilizing agent (atolecollagen) and applied directly to treat prostate carcinomas already 
established in nude mice, it could only slow and stabilise tumour growth, but could not 
reverse malignant progression and reduce tumour size (216). Thus, for an effective 
suppression of FABP5 in vivo, inhibitors capable of suppressing the biological activity 
of FABP5, rather than completely knockdown the gene, may be more realistic tools for 
CRPC suppression. 
Despite the extensively studies in molecular mechanisms involved in cancer-
promoting activity of FABP5, it was not clear whether the FABP5-related signalling 
pathway can be used as an effective target for CRPC treatment. The availability of 
highly effective inhibitors is an essential first step.  SBFI26 is the active component of 
a Chinese herbal medicine (Incarvillea sinensis) which was used to treat pain and 
rheumatism (218,219). It was shown to be effective for treatment of inflammatory and 
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metabolic diseases with a better effect than a group of chemically synthesized 
compounds, e.g. BMS309403 (206,220-222). Recently developed FABP5 inhibitors 
were originally effective analgesic and anti-inflammatory agents in mice (223-225).  
These included SBFI26 (α-truxillic acid 1-naphthyl mono-ester). In this work, we have 
tested treatment effect of SBFI26 for CRPC in mice. 
FABP5 binds to fatty acids with its carboxylate group through a binding motif that 
consists of 3 key amino acids (Arg109, Arg129, and Tyr131) (226). In the past study, we 
found that the tumour-promoting effect of FABP5 in prostate cancer depends entirely 
on the structural integrity of the fatty acid-binding motif. Enlightened by the fact that 
mutant tumour suppressor p53 can promote tumorigenicity (227), we have produced a 
mutant FABP5 (dmrFABP5) by mutating 2 of the 3 amino acids in its fatty acid-
binding motif.  Thus, we have also tested the potential of dmrFABP5 as a bio-inhibitor 
of FABP5 to treat CRPC in experimental mice. 
1.7 Research scope 
1.7.1 Hypothesis of this study  
Based on previous long time investigations, it is reasonable to hypothesize that FABP5 
(and the fatty acids transported by it) is an important pharmacological target, and 
modulating FABP5 biological activity may provide an attractive method for treatment 
of CRPC. 
1.7.2 Specific Aims of this study 
 Production of recombinant FABP5s and assessment their biochemical 
activities. 
 Identification of lead inhibitor of FABP5 from a group of chemical compounds. 
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 Evaluation the inhibitory effect of SBFI26 and dmrFABP5 on malignant 
characteristics of PC3-M cells in vitro. 
 Evaluation the effect of SBFI26 and dmrFABP5 on tumourigenicity and 
metastatic ability of PC3-M cells in mouse prostate gland. 
 Comparing the effect of PPARγ antagonist with the effect of SBFI26 and 
dmrFABP5 on tumourigenicity of PC3-M cells in nude mice. 
 Identification the effect of SBFI26 and dmrFABP5 on fatty acid uptake of 
FABP5 in PC3-M cells. 
 Identification the effect of SBFI26 and dmrFABP5 on PPARγ activation. 
1.7.3 Research plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   
 
 
 
 
 
 
Testing the biochemical activity of the dmrFABP5 from E. coli cells 
 
Identifying the best chemical inhibitor with high binding affinity to FABP5 
 
Assessing the inhibitory effect of SBFI26 and dmrFABP5 on malignant 
progression of PC3-M cells in vitro and in vivo. 
 
Investigating the mechanism of inhibition of SBFI26 and dmrFABP5 in PC3-M 
cells 
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Chapter Two: 
Production of recombinant FABP5s and assessment of their 
biochemical activities 
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2.1 Introduction  
FABP5, a cytosolic protein of the fatty acid binding protein family (212), binds to 
medium and long chain fatty acids with high affinity (213). It was established that the 
tumour-promoting function of FABP5 on CRPC cells depends on its ability of binding 
and transporting fatty acids which work as signalling molecules to stimulate their 
nuclear receptor PPARγ (192). It was also confirmed that the expressed FABPs in the 
cancer tissue were localised in both the cytoplasm and the nucleus (210,211).  
FABP5 binds to fatty acids with its carboxylate group through a binding motif that 
consists of 3 key amino acids (Arg109, Arg129, and Tyr131) (226).  In the past study, we 
found that the tumour-promoting effect of FABP5 in prostate cancer depends entirely 
on the structural integrity of the fatty acid-binding motif. Thus, changing one amino 
acid from Arginine109 to Alanine109 (single mutation) has been shown to reduce the 
fatty acid-binding ability significantly by 72%.  Altering two of the 3 key amino acids 
in the fatty acid-binding motif (from Arginine109 to Alanine109 and Arginine129 to 
Alanine129, or double mutation) has almost completely deprived of the fatty acid-
binding ability of FABP5. Whereas wild type recombinant FABP5 (wtrFABP5), fully 
capable of binding to fatty acids, increased tumorigenicity of the LNCaP cells 
significantly by 13 times, the doubly mutated recombinant  FABP5 (dmrFABP5), 
which is incapable of binding to fatty acids, produced no increase in tumour sizes 
(192). Naturally, the singly mutated recombinant FABP5 (smrFABP5), which is only 
partially capable of binding to fatty acids, produced some increase in tumour sizes 
(192).   
Although our previous results proved that fatty acid-binding ability is essential for the 
tumour-promoting ability of FABP5 and depriving the fatty acid-binding ability of 
FABP5 can eliminate its tumour-promoting activity, it is not known what is exact the 
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effect of the inactivated FABP5 on the native FABP5 inside the cancer cells.  In order 
to investigate whether the inactivated FABP5 can be used as an effective inhibitor for 
the natural oncogenic FABP5, a large quantity of wtrFABP5 and dmrFABP5 is 
required to perform relevant experimental work. Thus, in this set of work, the 
recombinant protein production technique was used to produce and purify a large 
amount of wtrFABP5 and dmrFABP5. A large amount of smrFABP5 was also 
prepared for experimental control. The biological activity of the recombinant FABP5s 
produced from E. coli cells was tested by a DAUDA displacement assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 73  
 
2.2 Materials and Methods 
2.2.1 Materials 
Reagents are listed in Appendix A, Buffers in Appendix B and Equipment in Appendix 
C. 
2.2.2 Methods 
2.2.2.1 Molecular biology techniques 
2.2.2.1.1 Construction of expression vectors by molecular cloning  
2.2.2.1.1.1  Preparation of competent E. coli (DH5α) cells 
LB medium (10mls) with E. coli (DH5α) was set up and incubated overnight at 37°C 
in shaking incubator with 150×g. One ml of overnight bacterial culture was added to 
the flask containing 100ml of SOB medium with 1ml of 2M Magnesium salts solution 
and then incubated at 37°C in a shaking incubator with 150×g. The optical density 
(OD) of bacterial cultured was measured at 550nm using Spectrophotometer (Jenway, 
Genova, UK) after the start of culture. When OD 550nm reach 0.4, bacterial culture 
was stopped. The culture was dispensed into 8 universal tubes (approx. 12.5ml/tube) 
and cooled on ice for 10 minutes. The cells were centrifuged at 2000×g for 10 minutes 
at 4°C and supernatant was discarded and pellets were re-suspended in a total of 16ml 
of RF1 buffer (8.25ml/ tube) and incubated on ice for 10 minutes. Cells were 
centrifuged again and the pellets were re-suspended in a total of 16ml of RF2 buffer 
(2ml/tube). The samples were pooled together and dispensed into 1ml aliquots in 
cryovials, flash frozen in liquid nitrogen and transferred immediately to -80°C. 
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2.2.2.1.1.2  Isolation of vector DNA (Miniprep extraction of vector DNA) 
The wild type-FABP5 DNA was isolated from cloning vector pBluescript II SK (192). 
The single and double mutant-FABP5 DNAs were isolated from expression vector 
pQE-32 (192) by using Miniprep QIAGEN extraction kit. The overnight culture of 
DH5α E. coli cells containing vectors (10ml) in LB medium plus 100µg/ml ampicillin 
was collected by centrifuging at 6800×g for 1min and the supernatant was discarded. 
The pellet was re-suspended in 250µl of suspension buffer P1 (50mM Tris-HCL PH 
8.0, 10mM EDTA and 100mg/ml RNase), and 250µl of lysis buffer P2 (200mM NaOH 
and 1%w/v SDS) with gentle mixing and inversion of the tube for six times. 350µl of 
neutralization buffer N3 (4.2M GU-HCL, 0.9M potassium acetate PH 4.8) was added 
and mixed by inversion of tube for six times. The mixture was centrifuged at 17,900×g 
for 10 minutes and the supernatant was added to a Miniprep spin column. The column 
was centrifuged for 1 minute and the flow through was removed. The column was 
washed using 750µl of wash buffer PE (10mM Tris-HCL PH 7.5 and 80% ethanol) 
and centrifuged for 1 minute. The column was centrifuged for an additional 1 minute 
to remove the remaining of wash buffer. The column was placed on a clean 1.5ml tube 
and vector DNAs were eluted by loading 30-50μl EB buffer (10mM Tris-Cl, pH 8.5), 
stand for 1 minute and centrifuged for 1 minute. The DNAs concentration was 
examined by using the NanoDrop spectrophotometer (Labtech International, Ringmer, 
UK) and the vector DNAs were stored in a -20°C. 
2.2.2.1.1.3  Digestion of vector DNA by restriction enzyme 
The single and double mutant-FABP5 DNAs were digested from expression vector 
pQE-32 with KpnI and PstI to confirm the presence of insert in the vector (192). On 
the other hand, the wild type-FABP5 DNA was digested from cloning vector 
pBluescript II SK with KpnI and PstI and the empty pQE-32 was digested by the same 
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restriction endonucleases (192). Procedure of digestion was made by taking vector 
DNA and dilution buffer out of the freezer and thawing on ice. The mixture of 
restriction enzymes and vectors were prepared as shown in Table 2.1. The mixtures 
were incubated at 37°C for 1.5 hours to permit complete digesting of the vector DNA. 
After that, the enzymes were deactivated by heating to 65°C for 10 minutes and 
electrophoresis analysis in agarose gel was used to analysis the product.   
reaction pQE-32 (single or 
double mutant-FABP5 
DNAs) 
pBluescript II SK (wild 
type-FABP5 DNA)  
pQE-32 
(empty) 
DNA (1 µg) 15 µl (3 µg) 3 µl (2 µg) 20 µl 
Buffer 1 2.5 µl 2.5 µl 2.5 µl 
KpnI 1 µl 1 µl 1 µl 
PstI 1 µl 1 µl 1 µl 
Water 5.5 µl 17.5 µl 0.5 µl 
Total volume 25 µl 25 µl 25 µl 
 
Table 2. 1 The restriction enzyme digestion mixture. 
 
2.2.2.1.1.4  Electrophoresis analysis in agarose gel and the purification of gel 
Agarose gel electrophoresis was performed in 1×TBE buffer (0.089M Tris-base, 
0.089M Boric acid, 0.002M EDTA pH 8). The 0.8% to 2.0% (w/v) agarose was added 
to 200ml buffer and dissolved by boiling for 1-2 minutes and cooled down for 15 
minutes. When the temperature of agarose reached 50°C, 5µl of safe view was added 
to the gel for visualization of DNA bands. The gel mixture was poured and placed at 
4°C to solidify. Empty vectors and vectors contain the wild type, single and double 
mutant FABP5 DNAs samples were prepared by adding the required amount of DNA, 
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sterile distilled water and 6×DNA loading buffer to get total volume of 20µl. The 
mixture was heated at 65°C for 5 minutes before being loaded onto gel. The gel was 
run for 1 hour at 90V and checked under the UV light to confirm that expression vector 
pQE-32 contains the single and double mutant FABP5 DNAs. The digested wild type 
FABP5 DNA from pBluescript II SK vector and linearized expression vector pQE-32 
were purified from agarose gel by using Wizard® SV Gel and PCR Clean-Up System 
(Promega, WI, USA). The insert and linearized vector were excised under the UV light 
using a sterile blade. Each of the excised gel slices were weighed and same amount of 
the volume of QG buffer was added. The mixture was dissolved by incubating in water 
bath (50-65°C) for 10 minutes. The melted agarose was applied to a QIAquick spin 
column and centrifuged for 1 minute and the flow through was discarded. The column 
was washed by 750µl of PE buffer and re-centrifuged for 1 minute. The DNA was 
collected by adding 30µl of distilled water and the concentration was examined by 
using the Nano-Drop and stored at -20°C. 
2.2.2.1.1.5  DNA ligation 
The wild type FABP5 DNAs were digested from cloning vector pBluescript II SK and 
ligated with linearized expression vector pQE-32 using T4 DNA ligase. In this study 
the molar ratios of 10:1 insert to vector has been performed to get more clones with 
inserts. However, absence of clones with inserts when the molar ratios of 3:1 insert to 
vector has been performed.  The ligation reaction mixture was shown in Table 2.2. 
After overnight incubation at 16°C, 10µl of this reaction was transformed into the 
competent E. coli (DH5α) cells as described in section 2.2.2.1.1.7 to produce sample 
of bacteria containing expression vector pQE32-wild type FABP5 DNA. 
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Insert DNA(176ng/µl) 11 µl 
Vector DNA(100ng/µl) 1.5 µl 
Ligation buffer 2 µl 
T4 DNA Ligase 1 µl 
Water 4.5 µl 
Total volume  20 µl 
 
Table 2. 2 The ligation reaction mixture.  
 
2.2.2.1.1.6 Transformation of competent bacteria with vector DNA 
Competent E. coli (DH5α) cells were thawed on ice from -80°C. After that, 10µl of 
the ligation mixture for wild type FABP5 DNAs and 50ng of expression vector pQE-
32 contains single and double mutant FABP5 DNAs were added to 200µl of competent 
E. coli (DH5α) cells, swirled gently and incubated on ice for 30 minutes. The cells 
were transferred into water bath at 42°C for 90 seconds and moved on ice for a further 
2 minutes. 800µl of SOC was added to the cells and DNA (0.5% w/v yeast extract, 2% 
w/v bactotryptone, 10mM NaCl, 10 mM MgCl, 10mM MgSO4, 2.5mM KCl, 20mM 
glucose) and incubated for 1 hour at 37°C in the shaking incubator at 150×g. 200µl of 
transformed Competent E. coli cells was plated onto LB plates containing 100µg/ml 
ampicillin and incubated at 37°C overnight. Colonies were picked from plate and 
grown in LB broth containing 100µg/ml ampicillin at 37°C overnight. The digestion 
of plasmid DNA were carried out to confirm that E. coli (DH5α) cells contains 
expression vector pQE-32- wild type, single and double mutant FABP5 DNAs. 
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2.2.2.1.1.7 DNA sequencing 
Expression vector pQE-32-wild type, single and double mutant FABP5 DNAs were 
sent for nucleotide sequencing at Beckman Coulter (UK), 100ng/µl of plasmid was 
analyzed.   
2.2.2.1.2 Expression and purification of wtrFABP5, smrFABP5 and 
dmrFABP5 
2.2.2.1.2.1  Preparation of competent E. coli (BL21) cells 
Competent bacterial (BL21) cells were prepared as described in section 2.2.2.1.1.1. 
2.2.2.1.2.2  Transformation of competent bacteria with plasmid DNA 
Competent E. coli (BL21) cells were transformed with expression vectors pQE-32- 
wild type, single and double mutant FABP5 DNAs as described in section 2.2.2.1.1.6. 
2.2.2.1.2.3  Growing E. coli cells and inducing expression 
A single colony from LB agar plates (with ampicillin 100µg/ml) of E. coli (BL21) 
cells with expression vectors pQE-32-wild type, single and double mutant FABP5 
DNAs were picked and incubated in 10ml LB medium (with ampicillin 100µg/ml) at 
37°C overnight in a shaking incubator 150×g. The overnight medium was added to 
250ml of pre-warmed media (with ampicillin) and incubated at 37°C with vigorous 
shaking until an OD600 of 0.6 is reached. After that, the E coli cells were induced by 
adding 1mM of IPTG (Isopropylthiogalactoside) (Sigma, USA). Time course analysis 
was performed by collection of 0.5 ml bacterial samples before and after induction at 
different times of induction from 1-6 hours to find the specific time at which the 
highest amount of protein was produced. The cell pellets were harvested by 
centrifugation at 4000×g for 20 minutes and stored at -20°C. SDS-PAGE analysis was 
performed to check the induction of the protein. 
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2.2.2.1.2.4  Purification of wtrFABP5, smrFABP5 and dmrFABP5 
The protein produced in E. coli (BL21) cells was purified by the gravity-flow 
chromatography on a column containing Ni-NTA agarose conjugated with an antibody 
against the 6xHis-tag that could bind to the 6xHis-tag FABP5 fusion proteins. The 
purification of the recombinant protein was conducted with a QIAGEN Ni-NTA Fast 
Start Kit, following the manufacturer’s instructions. The cell pellets were lysed by 
incubating at room temperature for 1 hour in 10ml native lysis buffer (50mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). The lysate was centrifuged at 
14,000×g for 30 minutes to remove the cellular debris and 5µl of supernatant was taken 
for SDS-PAGE analysis. The cell lysate supernatant was applied to the column and 
5µl of the flow-through was collected for SDS-PAGE analysis. Then the 6×His-tagged 
bounding proteins were washed 2 times with 4 ml of native wash buffer (50mM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and 5µl of both wash fractions 
were collected for SDS-PAGE analysis. The 6×His-tagged proteins were eluted by 
native elution buffer (50mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8.0) 
into two separate tubes and 5µl of both eluates were collected for SDS-PAGE analysis.  
2.2.2.1.2.5  Dialysis of wtrFABP5, smrFABP5 and dmrFABP5 
The D-Tube dialyzer (Novagen) was used to remove the high concentration of 
imidazole from purified recombinant proteins. First, Deionized water was added to the 
D-Tube and incubated upright for at least 5 minutes. Then, the water was removed 
using pipette and protein was added to the tube and the tube was placed in a beaker 
containing 1000-fold PBS using floating rack. The protein was collected after stirring 
gently in 4°C for at least 3 hours and stored at -80°C after flash freezing in Liquid 
Nitrogen.     
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2.2.2.1.2.6  Bradford assay  
Bio-Rad protein assay (Bio-Rad Laboratories GmbH, Munchen, Germany) was used 
to measure the concentration of purified proteins. A standard curve established using 
serial concentration of BSA (from 50-500μg/μl) in 50μl PBS. Appropriate volume of 
protein samples was also diluted with 50μl PBS. Controls and samples were incubated 
with 1ml of diluted (1/5) dye reagent (Bio-Rad GmbH, Munchen, Germany), for 15 
minutes before measuring the absorbance at 595nm using the MultiSkan plate reader 
(BioTek Instruments, USA). Standard curve was used to calculate the concentration of 
proteins. 
2.2.2.1.2.7 Sodium dodecyl sulphate-polyacrylamide protein gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE is a very common method for separating proteins according to their 
molecular weight, based on their differential rates of migration through a gel under the 
effect of an applied electrical field. This method uses a polyacrylamide gel as a support 
medium and sodium dodecyl sulfate (SDS) to denature the proteins. The glass plate 
sandwich was performed and the resolving gel was prepared by mixing 10ml next gel, 
60µl of 10% Ammonium Persulfate, 6µl of TEMED and immediately poured using a 
glass pipette until approximately the edge of plastic. Comb was inserted in the gel and 
gel was allowed to polymerize for 40 minutes. Then, comb was removed carefully and 
the gel was put into the tank with running buffer. The proteins were added to SDS-
PAGE sample loading buffer (1M Tris PH 6.8, 40% Glycerol, 10% SDS, 2-
mercaptoethanol and 1% Bromophenol Blue) and boiled at 95°C for 10 minutes and 
chilled on ice for 2 minutes and the samples were loaded in each well. Finally, the gel 
was run at 150V for 1 hour.       
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2.2.2.1.2.8 Coomassie staining of SDS-PAGE gels 
The gel was incubated in Coomassie staining solution (Bio-Rad GmbH, Munchen, 
Germany) for 1 hour with gentle shaking and washed with distilled water overnight. 
After that the gel was photographed to show the degree of purification. 
2.2.2.1.2.9 Transfer of protein from SDS gel to nitrocellulose membrane  
The proteins were transferred from gel to nitrocellulose membrane by making 
sandwich with soaking the fiber pad, 3 sheets of Whatman paper, gel, nitrocellulose 
membrane, 3 sheet of Whatman filter paper and fiber pad respectively in transfer buffer 
(3.03g Tris, 14.4g Glycine and distilled water). The air bubbles were removed from 
each step using a glass roller. The transfer was performed at 100V, 4°C for 1.5 hour.        
2.2.2.1.2.10  Immunodetection of 6×His-tagged proteins 
The membrane was washed twice for 10 minutes with TBS-T (Tris, Sodium Chloride, 
distilled water). The membrane was incubated for 1 hour in blocking buffer (5% TBS-
T-milk) and washed by TBS-T two times for 10 minutes. The membrane was incubated 
once in Penta-His antibody solution (1/12000) (QIAGEN) and then in polyclonal 
rabbit anti-human FABP5 antibody (1/500) (Hycult) in blocking buffer. The 
membrane was washed 3 times for 10 minutes with TBS-T and then incubated with 
secondary antibody solution [peroxidase-conjugated rabbit anti-mouse (1:1000) 
(Dako) and polyclonal goat anti-rabbit (1:2000) (Hycult)] for 1 hour, washed 4 times 
for 10 minutes with TBS-T. Finally, ECL (GE Healthcare, Buckinghamshire, UK) 
solution was used to detect protein expression by chemiluminescence. The membrane 
was exposed to X-ray (Kodak film GE Healthcare, UK).    
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2.2.2.2 Fluorescence displacement DAUDA assay 
2.2.2.2.1 WtrFABP5 delipidation 
Removal of fatty acids from wtrFABP5 was performed by delipidation using Lipidex-
1000 (Hydroxyalkoxypropyl-Dextran). Lipidex-1000 (Sigma) was suspended in 
10mM-Tris HCL pH 7.5 and incubated with wtrFABP5 at a ratio of 10:1(w/w) at 37°C 
for 1 hour with occasional mixing. The mixture was centrifuged for 4 minutes at 
10,000×g and then the supernatant was collected. Finally, the protein concentration 
was measured by Bradford assay as described in section 2.2.2.1.2.6.   
2.2.2.2.2 Fluorescence emission spectroscope for wtrFABP5 
Fluorescent labelled fatty acid DAUDA 11-[5-(dimethylamino)-1-naphthalenyl 
sulfonyl amino]-undecanoic acid (Cayman) was used to check the emission 
wavelength of wtrFABP5 after binding with DAUDA. DAUDA was dissolved in 
methanol for a 100mM stock. Each time 0.1mM fresh stock was prepared by dilution 
in PBS. Fluorescence measurement spectra were recorded at 25°C using a Varioskan 
Flash (Thermo Electron Corporation, Waltham, MA) in white 96 well opaque tissue 
culture plates, flat bottom and Thermo Scientific SkanIt software for collection of data. 
Excitation, emission wavelengths and fluorescence intensity were measured by fixing 
the excitation wavelength on 345nm and emission wavelength from 450-600nm. The 
reactions were set as PBS, 3µM wtrFABP5 in PBS and presence or absence of 3µM 
wtrFABP5 in 2µM DAUDA. The reactions were incubated for 10 minutes to 
determine fluorescence peak emission wavelength.  
2.2.2.2.3 Fatty acids binding ability of the purified recombinant FABP5s 
The binding ability of all purified recombinant FABP5s (wtrFABP5, smrFABP5 and 
dmrFABP5) to fatty acid (linoleic acid) was examined using the fluorescent labelled 
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fatty acid analogue DAUDA. Fluorescence measurement spectra were recorded at 
25°C using a Varioskan Flash Reader and Thermo Scientific SkanIt software for 
collection of data. Excitation and emission wavelengths were fixed on 345 and 530nm. 
Fatty acid binding ability of all purified recombinant FABP5s was measured by 
monitoring the changes in fluorescence intensity and wavelength after adding 2µM 
DAUDA in the present or absence of 2µM linoleic acid. 
2.2.2.3 Statistical analysis 
Student’s t-test was carried out using GraphPad Prism software to compare the 
differences of the means between control and experimental groups and the data is 
presented with SE. The difference is regarded as significant when p<0.05; in the 
results, p value is represented by asterisks as follow:  ***, P < 0.0001. 
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2.3 Results 
2.3.1 Construction of expression vectors harboring wild type FABP5 DNAs  
  
2.3.1.1 Isolation of wild FABP5 DNAs from cloning vector and cutting the 
expression vector 
Wild type FABP5 DNA was isolated from E. coli (DH5α) cells harboring cloning 
vector pBluescript II SK by using Miniprep Qiagen extraction kit. The cloning vector 
pBluescript II SK was digested by using KpnI and PstI to confirm that cloning vectors 
contain the wild type FABP5 DNA. At the same time the expression vector pQE-32 
was linearized by using same restriction enzymes to be ready for ligation, as showing 
by electrophoresis analysis in agarose gel in Fig. 2.1. 
 
 
 
 
 
 
 
Figure 2.1 Enzymatic release of the wild type FABP5 DNA from the cloning 
vector and cutting the expression vector. After digestion with two restriction 
enzymes. Lane 1, the control or undigested pBluescript II SK-FABP5 DNA vector. 
Lanes 2, pBluescript II SK-FABP5 DNA was digested with KpnI and PstI; the 
appearance of the small band (600bp) representing wild type FABP5 DNA and the 
large band is linearized vectors. Lane 3, undigested expression vector pQE-32. Lane 
4, linearized expression vector pQE-32 by digestion with KpnI and PstI. M: Molecular 
markers.   
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2.3.1.2 Ligation of wild type FABP5 DNA with linearized pQE-32 vector   
The wild type FABP5 DNA was ligated with the linearized expression vector pQE-32 
using T4 DNA ligase. The reaction mixture was transformed into the competent E. coli 
(DH5α) cells to produce clones of bacteria harboring the expression vector pQE-32-
FABP5 DNA. After the mini-preparation, DNA was extracted from different colonies, 
the successful ligation was confirmed by electrophoresis analysis in agarose gel after 
digesting the expression vector with two restriction enzymes KpnI and PstI. A small 
fragment of DNAs, representing the inserted FABP5 DNA, were existed out from the 
expression construct in 4 out of 5 colonies analyzed. Thus, any positive colonies 
containing the expression construct pQE-32-FABP5 DNA, as shown in Fig.2.2, can 
be selected and cultured for large scale production of wtrFABP5.  
 
 
 
 
 
 
 
 
Figure 2.2 Enzymatic release of the wild type FABP5 DNA from the expression 
vector pQE-32-FABP5. 5 E. coli colonies (C1-5) were cultures separately and the 
expression vector pQE-32 was digested with two restriction enzymes. Lane 1, 3, 5, 7 
and 9: the control or undigested pQE-32-FABP5 DNA.  Lanes 2, 4, 6, 8 and 10: the 
digested pQE-32-FABP5 DNA; the appearance of the small band (600bp) representing 
wild type FABP5 DNAs and the large band representing linearized vector. All the 
analysed colonies contained the inserted FABP5 DNA, except clone 2 (C2). M: 
Molecular Markers.   
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2.3.2 Enzymatic digestion analysis of mutant FABP5 DNAs  
Single and double mutant FABP5 DNAs were isolated from E. coli (DH5α) cells 
containing the expression vectors pQE-32 by mini-DNA preparation using the 
Miniprep Qiagen extraction kit. Then, the expression vectors were digested by KpnI 
and PstI to confirm that the expression vectors contain the gene of interest, as showing 
by electrophoresis analysis in agarose gel in Fig. 2.3.  
 
 
 
 
 
 
 
Figure 2.3 Enzymatic release of the single and double mutant FABP5 DNAs from 
the expression constructs. Lane 1 and 3, the control (undigested) expression vectors 
pQE-32-mutant FABP5 DNAs. Lanes 2 and 4, the digested expression vectors pQE-
32-mutant FABP5 DNAs. Expression constructs containing the properly inserted 
genes was confirmed by the appearance of a small band (600bp) representing single 
and double mutant FABP5 DNAs, respectively. M: Molecular markers.  
 
2.3.3 DNA sequencing analysis of pQE-32-FABP5 
The expression constructs containing wild type and mutant types of FABP5 DNAs 
were subjected to nucleotide sequence analyses. As shown in Fig 2.4, nucleotide 
sequences of all 3 expression constructs contained the genes of interest and the 
sequences for the wild type, single and double mutant FABP5 DNAs were correct.  
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A 
NNNNATATANNNNANTNACCTATAAATAGGCGTATCACGAGGCCCTTTCGTCTTCCCTCGAGAAAT
CATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCAATTGTGAGCGGATAAC
AATTTCACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGAGGATCTCACCATCACCATCACCA
TGGGTACCGGGCCCCCCCTCGAGATCTTCGAATTCGGCTTACCGCCGACGCAGACCCCTCTCTGCA
CGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCAGCAGCTGGAAGGAAGATGGCGCCTGGTGG
ACAGCAAAGGCTTTGATGAATACATGAAGGAGCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGC
GCAATGGCCAAGCCAGATTGTATCATCACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGC
ACTTTGAAAACAACACAGTTTTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGC
AGAAAAACTCAGACTGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGG
AAGGAAAGCACAATAACAAGAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAA
TGTCACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGGAGTT
AATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTCTTTTTTTTTTCA
TTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTTCAAAGTGTGTTGGATTAAT
TAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCTAAAGCCGAATTCCGCGGCCGCAGGC
CTCTAGAGTCGACCTGCAGCCAAGCTTAATTAGCTGACCTTGGACTCCTGTTGATAGATCCAGTAA
TGACCTCANAACCTCN 
 
 
B 
CTTTTTCTGACTTACCTATAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCACCTCGAGAAATCAT
AAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCAATTGTGAGCGGATAACAATTTC
ACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGAGGATCTCACCATCACCATCACCATGGGT
ACCGCATGCGAGCTCGGTACCGGGCCCCCCCTCGAGATCTTCGAATTCGGCTTACCGCCGACGCAG
ACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCAGCAGCTGGAAGGAAGAT
GGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGAGCTAGGAGTGGGAATAGCTTTG
CGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCATCACTTGTGATGGTAAAAACCTCACCATA
AAAACTGAGAGCACTTTGAAAACAACACAGTTTTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACC
ACAGCTGATGGCAGAAAAACTCAGACTGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAG
GAGTGGGATGGGAAGGAAAGCACAATAACAGCAAAATTGAAAGATGGGAAACTAGTGGTGGAGT
GTGTCATGAACAATGTCACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACT
TTGGACAGGAGTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCT
TTCTTTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTTCAAAG
TGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCTAANGCCGAATTC
CGCGGCCGCAGGCCTCTAGAGTCGACCTGCAGCCNAGCTTAATTAGCTGAGCTGGGACTCCTGTTG
ATAGATCCAGTAATGACCTCAGANCTCCATCTGGATTNGTTCAGANCGCTCGGTTGCCCGCCGGGC
GTTTTTTTTGGTGAAATCCAGCTAGCTNGGCGAGATTTNNGGAGCTANGGAGCTAAATGGAAAAAA
AATCCTGGATTACCCNGTTGATTTTCCNATGGCTCGTAANA 
 
 C 
CTTTTTCTGACTTACCTATAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCACCTCGAGAAATCAT
AAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCAATTGTGAGCGGATAACAATTTC
ACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGAGGATCTCACCATCACCATCACCATGGGT
ACCGCATGCGAGCTCGGTACCGGGCCCCCCCTCGAGATCTTCGAATTCGGCTTACCGCCGACGCAG
ACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCAGCAGCTGGAAGGAAGAT
GGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGAGCTAGGAGTGGGAATAGCTTTG
CGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCATCACTTGTGATGGTAAAAACCTCACCATA
AAAACTGAGAGCACTTTGAAAACAACACAGTTTTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACC
ACAGCTGATGGCAGAAAAACTCAGACTGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAG
GAGTGGGATGGGAAGGAAAGCACAATAACAGCAAAATTGAAAGATGGGAAACTAGTGGTGGAGT
GTGTCATGAACAATGTCACCTGTACTGCGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACT
TTGGACAGGAGTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCT
TTCTTTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTTCAAAG
TGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCTAANGCCGAATTC
CGCGGCCGCAGGCCTCTAGAGTCGACCTGCAGCCNAGCTTAATTAGCTGAGCTGGGACTCCTGTTG
ATAGATCCAGTAATGACCTCAGANCTCCATCTGGATTNGTTCAGANCGCTCGGTTGCCCGCCGGGC
GTTTTTTTTGGTGAAATCCAGCTAGCTNGGCGAGATTTNNGGAGCTANGGAGCTAAATGGAAAAAA
AATCCTGGATTACCCNGTTGATTTTCCNATGGCTCGTAANA 
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Figure 2.4 DNA sequencing analysis of the expression constructs. A, the vector 
containing wild type FABP5 DNA. B, the vector containing the singly mutated FABP5 
DNA. C, vector containing the doubly mutated FABP5 DNA. D, the sequences of 
human FABP5 gene (Genbank-BLAST). The sequences alignment showed a 100% 
sequences match between Query (wild type FABP5 DNA) and subject (database 
sequence). After the starting codon ATG, a short sequence (blue) coding for 6xHis-tag 
was contained in the vector. The recognition sequences for KpnI (GGTACC) and for 
PstI (CTGCAG) are bold and underlined. GC represents single mutation [the 
Alanine109 codon (GCA) was mutated from the Arginine109 codon (AGA)]. GC and 
GC represent double mutations [(the Alanine codon109 (GCA) was mutated from the 
Arginine109 codon (AGA) and the Alanine129 codon (GCG) was mutated from the 
Arginine129 codon (CGG)]. 
 
 
D 
   Query 250 CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA 309  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 68  CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA 127  
   Query 310 GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA 369  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 128 GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA 187  
   Query 370 GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT 429  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 188 GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT 247  
   Query 430 CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT 489  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 248 CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT 307  
   Query 490 TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC 549  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 308 TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC 367  
   Query 550 TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG 609  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 368 TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG 427  
   Query 610 CACAATAACAAGAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATGT 669  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 428 CACAATAACAAGAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATGT 487  
   Query 670 CACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGGA 729  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 488 CACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGGA 547  
   Query 730 GTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTCT 789  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 548 GTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTCT 607  
   Query 790 TTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTT 849  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 608 TTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTT 667  
   Query 850 CAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCT 909  
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
   Sbjct 668 CAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCT 727 
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2.3.4 Expression and purification of the wild type and mutant recombinant 
FABP5s 
2.3.4.1 Determination the optimal time of maximum amount of protein synthesis 
in E. coli cells.   
All three expression vectors containing different FABP5 DNAs (wtrFABP5, 
smrFABP5 and dmrFABP5) were isolated from E. coli (DH5α) cells respectively and 
transformed again into competent BL21 E. coli cells for protein production. Bacterial 
samples were removed, once per hour from culture, for up to 6 hours after 1mM IPTG 
induction. Expression of human recombinant FABP5s from the engineered vectors 
was not lethal to E. coli cells as demonstrated by normal growth rate of bacteria by 
using Western blot. After induction, the wtrFABP5 recognized by the anti-His tag 
antibody was gradually expressed and reached its maximum after hour 4, as shown in 
Fig. 2.5. 
 
 
Figure 2.5 Determination the optimal experimental time point at which the 
maximum amount of recombinant protein was synthesized in bacterial cells. 
Bacterial samples were removed, once per hour from culture, for up to 6 hours after 
IPTG induction. 6×His-tag bound protein bands were recognized by the Penta-His 
antibody. The wtrFABP5 protein synthesized in bacterial cells at different time points 
is shown in 8 separate lanes. 
 
2.3.4.2 Purification and Immunodetection of the 6xHis-tagged FABP5s 
The protein produced in BL21 E. coli cells was purified by gravity-flow 
chromatography on a column containing Ni-NTA agarose conjugated with an antibody 
15 kDa His-tag FABP5 
Hours after induction  
    0            1            2            3            4            5           6 
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against the 6xHis-tag that was able to bind to the 6xHis-tag FABP5 fusion proteins. 
The purification of the recombinant proteins was conducted with a Qiagen Ni-NTA 
Fast Start Kit, following the manufacturer’s instructions. SDS-PAGE gel (Coomassie 
Blue staining) analysis showed that the degree of purification from other bacterial 
proteins and the purity of the end products in the first and the second elution are very 
high with only one band of approximately 15 kDa (Fig. 2.6). At the final stage of the 
purification, immunodetection of the first and second elution with a monoclonal anti-
human FABP5 showed that this protein in a single band on the blot reacted to the anti-
FABP5 antibody very well. Thus, the band size plus the specific immuno-response 
confirmed that these 3 recombinant FABP5s eluted from the first fraction were the 
targets proteins wtFABP5, dmrFABP5 and smrFABP5, respectively (Fig. 2.7).   
 
 
 
 
 
 
Figure 2.6 Purification of the recombinant FABP5s. After the cell pellets were lysed 
by native lysis buffer, the cell lysate was subjected to SDS-PAGE to separate and to 
visualize the bacterial proteins and the 6xHis-tagged protein. Cell lysate supernatant 
was applied to the column. After washing the column with the washing buffer, the 
6xHis-tagged bounding protein was eluted with an elution buffer and the protein in the 
first 2 fractions was collected into two separate tubes (1E, 2E). A, purification of 
wtrFABP5. B, purification of smrFABP5. C, purification of dmrFABP5. M: Molecular 
markers. CL: the cell lysate. FW: flow-through fraction. W: wash fraction. 1E and 2E: 
elution fractions. 
 
M CL FW W 1E 2E  M  CL FW W  1E  2E   M CL FW W 1E  2E  
A B C 
15 kDa 
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Figure 2.7 Immunodetection of the purified recombinant FABP5s. The 2 eluates 
(E1 and E2) collected from the chromatography were subjected to immunodetection 
for the purified wtrFABP5, smrFABP5 and dmrFABP5.  FABP5 protein bands on the 
blot were recognized by a monoclonal anti-human FABP5 antibody. 
 
2.3.5 Testing the biological activities of the recombinant FABP5s 
The fatty acid-binding affinity of the recombinant FABP5s was tested by the 
fluorescently labelled fatty acid DAUDA [11-(Dansylamino) undecanoic Acid] 
displacement assay (228). The florescence measurement spectrum was recorded at 
25°C using a Varioskan Flash to determine the fluorescence peak emission wavelength 
for wtrFABP5. After the excitation was fixed at 345nm, then the emission wavelength 
was fixed from 450-600nm. The fatty acid-binding affinity of wtrFABP5 for DAUDA 
was tested and the maximum affinity was detected at 530nm with a left shift of 
wavelength of emission from 560nm for DAUDA alone to 530nm upon addition of 
wtrFABP5 to DAUDA, accompanied by an increase in fluorescence intensity, as 
shown in Fig. 2.8. 
 
 
 
Anti-human FABP5  15 kDa 
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Figure 2.8 Effect of wtrFAcBP5 on the fluorescence emission spectra of DAUDA. 
Effect of wtrFABP5 on the fluorescence emission spectra of DAUDA ligand at the 
excitation wavelength of 345nm. PBS (1) and wtrFABP5 in PBS (2) did not produce 
any emission; whereas 2µM DAUDA produced emission at 560nm (3); 2µM DAUDA 
in the presence of 3µM wtrFABP5 (4) caused an increase in the fluorescence intensity 
and a left shift to 530nm compared to DAUDA alone. 
 
The fluorescence intensity of displaced DAUDA from each recombinant FABP5 by a 
competitive unlabeled linoleic acid was used as an indication of their relative binding 
affinity (192). After adding wtrFABP5 to DAUDA, the complex led to an increase in 
fluorescence intensity and a left shift of the emission to 530nm as compared to that 
produced by DAUDA alone 560nm. The addition of linoleic acid to wtrFABP5-
DAUDA complex created a noticeable drop in the fluorescence intensity with right 
shift of emission wavelength from 530 nm for the complex to 560 nm upon adding of 
linoleic acid (Fig. 2.9, A), indicating that linoleic acid can displace DAUDA from the 
primary binding site of wtrFABP5. However, the fatty acid binding affinity of 
smrFABP5 and dmrFABP5 which is single and double mutated in fatty acid binding 
motif was checked by adding of linoleic acid to smrFABP5- or dmrFABP5- DAUDA 
complexes. This complexes were not able to decrease the fluorescence intensity (Fig. 
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2.9, B and C), indicating that linoleic acid cannot displace DAUDA from the primary 
binding site of smrFABP5 and dmrFABP5. 
 
 
 
 
 
Figure 2.9 Fatty acid binding properties of the recombinant FABP5s by DAUDA. 
A, Competitive inhibition of DAUDA-wtrFABP5 binding to linoleic acid.  PBS alone 
(1) or 2µM DAUDA alone (2) give the same results as (Fig. 2.8). 3µM wtrFABP5 plus 
2µM DAUDA caused an increase in fluorescence intensity and a left shift to 530nm 
compared to DAUDA alone (3). 3µM wtrFABP5 and 2µM DAUDA plus 2µM linoleic 
acid exhibited a reduced fluorescence intensity and a right shift to 560 nm; indicating 
an inhibition and displacement of DAUDA-wtrFABP5 binding (4). B, Competitive 
inhibition of DAUDA-smrFABP5 binding to linoleic acid.  PBS alone (1) or 3µM 
smrFABP5 in PBS (2) did not produce any emission. 3µM smrFABP5 and 2µM 
DAUDA (3) caused an increase in fluorescence intensity and a left shift to 550nm 
compared to DAUDA alone (see A). 3µM smrFABP5 and 2µM DAUDA plus 2µM 
linoleic acid produced an increase in fluorescence intensity and a right shift to 560 nm; 
indicating no inhibition and displacement of DAUDA-smrFABP5 binding (4). C, 
Competitive inhibition of DAUDA-dmrFABP5 binding to linoleic acid. PBS alone (1), 
or 3µM dmrFABP5 in PBS (2) did not produce any emission. 3µM dmrFABP5 and 
2µM DAUDA (3) caused an increase in fluorescence intensity, but no shift in emission 
spectrum compared to DAUDA alone (see A). 3µM dmrFABP5 and 2µM DAUDA 
plus 2µM linoleic acid produced an increase of fluorescence intensity but no shift in 
emission wavelength; indicating no inhibition and no displacement of DAUDA-
dmrFABP5 binding (4). 
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In addition, the fluorescence intensities of displacement DAUDA from different 
FABP5s was confirmed by adding 10µM linoleic acid to each recombinant FABP5-
DAUDA complex in triplicate to verify their relative binding affinity. When the level 
of fluorescence intensity of DAUDA (D) + Buffer (B) was set at 1 (Fig. 2.10), the 
fluorescence intensity of the complex of wtrFABP5, D and B without linoleic acid was 
3.25 ± 0.07. When linoleic acid was added to the complex, the level of fluorescence 
intensity was significantly reduced by 43.7% to 1.83 ± 0.6 (Student’s t test, p < 
0.0001). Thus, wtrFABP5 exhibited a strong ability to bind to linoleic acid and 
displaced 43.7% DAUDA. When linoleic acid was added to complexes of either 
smrFABP5 + B + D or dmrFABP5 + B +D, no displacement was observed, indicating 
that smrFABP5 and dmrFABP5 were not capable of binding to fatty acids anymore 
and dmrFABP5 was selected as inactive form of FABP5.  
 
 
 
 
 
 
 
 
 
Figure 2.10 Fluorescence intensities of displaced DAUDA from recombinant 
FABP5s by linoleic acid.  The value of fluorescence intensity produced by the buffer 
and DAUDA plus recombinant FABP5s was set as control. The results (mean ± SE) 
were obtained from 3 separate experiments (2-tailed unpaired Student’s t test, ***, P 
< 0.0001).    
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2.4 Discussion  
FABP5 binds to fatty acids with its carboxylate group through a binding motif that 
consist of 3 key amino acids (Arg109, Arg129, and Tyr131) (226,229). During the past 
study on molecular mechanisms involved in the tumour-promoting activity of FABP5, 
it was found that the malignancy-promoting function of FABP5 in prostate cancer 
depends on its structural integrity of the 3 key amino acids-binding motifs. In addition, 
it was shown that the weakly malignant prostatic cancer cells LNCaP transfected with 
wild type FABP5 DNA can greatly increase tumorigenicity and decrease apoptosis. 
The wtrFABP5, which is capable of binding and transporting fatty acids, can fully 
perform its tumour-promoting role. However, the mutated FABP5 DNAs (either 
dmrFABP or smrFABP5), which had a greatly reduced capability or incapable of 
binding to fatty acids, lost or reduced their tumour-promoting function (192). 
Enlightened by the fact that mutant tumour suppressor p53 can promote tumorigenicity 
(227), we were curious to know whether the mutated FABP5s can play an opposite 
role to their wild type counterpart. The availability of a large quantity of recombinant 
materials is a prerequisite to perform further investigations.  
To obtain 3 recombinant proteins (wtrFABP5, smrFABP5 and dmrFABP5), full length 
FABP5 cDNAs were cloned into the expression vector pQE-32 to form 3 expression 
vectors that were transformed into the E coli cells, respectively (Fig. 2.2) (Fig. 2.3). 
The maximum amount of protein synthesized in the E coli cells after IPTG induction 
was identified at the time point of hour 4. The fact that the no further increase in the 
amount of protein synthesised (or even decrease was observed) after 4-hour incubation 
in E coli cells suggested that the production of recombinant protein was ceased 
inside E. coli cells or even the synthesised protein started to degrade from their peak 
amount (Fig. 2.5). After purification, the results from the Western blot analysis showed 
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that all 3 recombinant proteins isolated from E. coli cells are not only recognised by 
the specific anti-FABP5 antibody, but also exhibited a unique size, indicating a high 
purity (Fig. 2.7). 
The fatty acid-binding ability of all 3 recombinant FABP5s was tested by an assay 
using fluorescently labelled fatty acid DAUDA which binds with specific and 
nonspecific binding sites. If DAUDA binds to the protein, it will alter its fluorescence 
emission spectra and intensity (230). The degree of wavelength left shifting when 
DAUDA binds to protein indicate that DAUDA binds with specific and nonspecific 
site (polar and non-polar site) (231,232). Our results showed that Compared to 
maximum emission wavelength of DAUDA alone which is 560 nm. Reaction of 
wtrFABP5-DAUDA caused a significant left shift to 530nm (Fig. 2.9, A). However, 
the reaction of DAUDA-smrFABP5 caused a left shift to 550nm (Fig. 2.9, B) and no 
shift in emission spectrum for dmrFABP5 (Fig. 2.9, C). This results indicate that the 
degree of polarity of their binding sites is different and the dmrFABP5 loss the specific 
binding site. 
In addition, a competitive study was performed by adding unlabelled linoleic acid to 
the reaction protein and DAUDA to displace DAUDA from the specific binding site 
(232). Our results showed that addition of fatty acid (linoleic acid) to wtrFABP5, 
DAUDA complex created a noticeable drop in the fluorescence intensity (Fig. 2.9, A). 
Nevertheless, the addition of fatty acid to smrFABP5 or dmrFABP5, DAUDA 
complex was not able to decrease the fluorescence intensity (Fig. 2.9, B and C). This 
results were confirmed by three separate experiment (mean ± SE). The results showed 
that when the fatty acid-binding ability of wtrFABP5 was set as 100%, it is 
significantly reduced to 43.7% after adding natural fatty acid to the reaction of 
wtrFABP5-DAUDA (Student’s t test, p < 0.0001). However, for smrFABP5 and 
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dmrFABP5, no reduction in fluorescent intensity was showed after adding natural fatty 
acid to the reaction smrFABP5 and dmrFABP5-DAUDA (Fig. 2.10). These results 
showed that mutating 2 of the 3 key amino acids in the fatty acid-binding motif 
(dmrFABP5) can almost completely deprive of the fatty acid-binding ability of this 
protein. These results showed that dmrFABP5 loss fatty acid-binding ability and can 
be used as a bio inhibitor to play a reverse function to the native FABP5.  
Previous work in our research group proved that the tumour-promoting activity of 
FABP5 was reduced as the reducing fatty acid-binding capability and completely lost 
as the loss of fatty acid-binding capability (192). The availability of a large quantity of 
biologically inactive FABP5 obtained from this set of experiments will enable us to 
investigate whether the inactive FABP5 can play an opposite role to the native FABP5 
inside the cancer cells.  
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Chapter Three 
Identification of lead inhibitor of FABP5 from a group of 
chemical compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 99  
 
3.1 Introduction 
The normal function of FABP5 is binding and transporting medium and long chain fatty 
acids into cells (212). Fatty acids are used as sources of energy in cancer cells and they 
are also used as signalling molecules (233) to play important roles in tumorigenicity and 
metastasis of cancer cells (234). After crucial role of FABP5 in promoting malignant 
progression of cancer cells was initially demonstrated (191,215), increased FABP5 
expression in archival prostate cancer tissues is found to be significantly associated with 
a reduced patient survival time (189). Moreover, investigations in the past few years 
established that there is a novel fatty acid-initiated signalling pathway leading to 
malignant progression of prostatic cancer cells. Thus, when FABP5 expression is 
increased, excessive amounts of fatty acids are transported into the nucleus, where they 
act as signalling molecules to stimulate their nuclear receptor PPARγ. The activated 
PPARγ then modulates expression of its down-stream regulatory genes which finally 
lead to enhanced tumour expansion and aggressiveness caused by an overgrowth of 
cells with increased angiogenesis and reduced apoptosis (235).  
To suppress the malignant progression of highly malignant CRPC cells by inhibiting 
FABP5 and its related signalling pathway, the availability of a highly effective FABP5 
inhibitor is an important first step. Inhibition of FABPs activity was shown to be 
effective for treatment of inflammatory and metabolic diseases by chemically 
synthesized inhibitors, e.g. BMS309403 (206,220-222). Recently developed FABP5 
inhibitors (SBFI26, SBFI19, SBFT27, SBFI31), which exhibited a higher inhibitory 
effect than BMS309403, were originally used effectively as analgesic and anti-
inflammatory agents in mice (223-225). SBFI26 (α-truxillic acid 1-naphthyl mono-
ester) was in fact, the active component of a Chinese herbal medicine (Incarvillea 
sinensis) which was used to treat pain and rheumatism in humans in Chinese traditional 
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medicine since hundreds of years ago (218,219). In a recently developed strategy to 
develop anti-inflammatory and anti-nociceptive reagents by targeting fatty acid protein 
anandamide transporters, SBFI26 was used to increase the brain anandamide levels 
and thus to produce analgesia effect (223,224).  
To find out whether the above described, chemically synthesized FABP5 inhibitors 
can be used to suppress the malignant progression of the CRPC cells, identification of 
the most effective inhibitor which can produce a maximum suppressive effect is the 
first step. Thus, in this section, we tested this group of chemical inhibitors by 
comparing their binding affinities to FABP5 with wtrFABP5 through using the 
fluorescent displacement DAUDA assay. The most effective candidate was identified 
as the leading compound to be used for the treatment of CRPC in nude mouse.    
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3.2 Materials and Methods 
3.2.1 Materials 
Reagents are listed in Appendix A, Buffers in Appendix B and Equipment in Appendix 
C. 
3.2.2 Methods 
3.2.2.1 Fluorescence displacement DAUDA assay 
3.2.2.1.1 wtrFABP5 delipidation 
Removal of fatty acids from wtrFABP5 was performed as described in chapter 2 
section 2.2.2.2.1.   
3.2.2.1.2 Fluorescence emission spectroscope for wtrFABP5 
Fluorescence emission spectroscope for wtrFABP5 was identified as described in 
chapter 2 section 2.2.2.2.2.   
3.2.2.1.3 Calculation of dissociation DAUDA binding constants Kd (affinity)  
The dissociation constant (Kd) is the concentration of ligand (DAUDA) which 
occupies half of the receptors (protein) at equilibrium. A small Kd means that the 
receptor has a high affinity for the ligand. However, a large Kd means that the receptor 
has a low affinity for the ligand (236). The Kd of wtrFABP5 was measured by titrating 
different concentration of DAUDA from (0.4-3µM) to a solution of 3µM wtrFABP5 
in PBS for a total volume of 200µl per well. For calculation of Kd value, 345 and 530 
nm were used as the excitation and emission wavelength. The fluorescence data was 
normalized to the peak fluorescence intensity for each experiment and subtracted from 
the data of samples without protein. To estimate the Kd and maximal fluorescence 
intensity (Bmax) for wtrFABP5, the data was fitted by nonlinear regression techniques 
using GraphPad Prism software to a saturation binding curve model. 
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3.2.2.1.4 Inhibition constant Ki for different fatty acids and FABP5 chemical 
compounds  
The inhibition constant (Ki) is the equilibrium dissociation constant for binding of the 
unlabelled ligand (fatty acids or chemical compounds) that will bind to half the binding 
sites of the protein at equilibrium in the presence of labelled ligand (DAUDA). The 
Ki is proportional to the IC50. If the Ki is low (i.e. the affinity is high), the IC50 will 
also be low (237). The affinities of several unlabelled ligand for wtrFABP5 were 
determined using DAUDA as a fluorescent probe. Ligand binding affinities (Ki) for an 
unlabelled ligand were measured to determine the binding affinity of different fatty 
acids (Linoleic, Oleic, Palmitic acid) (Sigma) for wtrFABP5 by evaluating their ability 
to displace DAUDA occupying wtrFABP5. In addition, the Ki values of different 
chemical compounds (SBFI26, SBFI19, SBFI27, and SBFI31) (ChemDiv) were 
evaluated by displace DAUDA occupying wtrFABP5 to determine the lead compound. 
3µM wtrFABP5 was incubated with 2µM DAUDA in PBS in the presence or absence 
of each fatty acid and chemical inhibitor in different concentrations (0.5-20µM). The 
loss of fluorescence intensity was measured with Varioskan Flash with the excitation 
and emission of 345 and 530 nm and the data was fitted by nonlinear regression 
techniques using GraphPad Prism software to a one site binding affinity model to 
estimate the binding affinity. The Ki of each ligand was determined using the equation 
Ki=IC50/1+ (DAUDA concentration /Kd) (238).  
In addition, the chemical compounds and the fatty acids were then added to the assay 
at 10µM and tested in triplicate to confirm their activity by determine the degree of 
DAUDA displacement from wtrFABP5 by loss of fluorescence intensity. 
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3.2.2.2 Statistical analysis 
Student’s t-test was carried out using GraphPad Prism software to compare the 
differences of the means between control and experimental groups and the data is 
presented with SE. The difference is regarded as significant when p<0.05; in the 
results, p value is represented by asterisks as follow:  ***, P < 0.0001. 
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3.3 Results  
3.3.1 Determination of DAUDA binding constant (Kd) to wtrFABP5 
The dissociation constant (Kd) of the wtrFABP5 was estimated by adding increasing 
concentrations of DAUDA analog from (0.4-3µM) to a solution of 3µM wtrFABP5. 
Then for calculation of Kd values, fluorescence data was normalized to the peak 
fluorescent intensity for each experiment and corrected for the background 
fluorescence of the ligand (DAUDA) alone at each concentration. The data was fitted 
by nonlinear regression techniques using GraphPad Prism software to a saturation 
binding curve model to estimate the apparent dissociation constant (Kd) and maximal 
fluorescence intensity (Bmax) for the wtrFABP5. The Kd of DAUDA-wtrFABP5 was 
1.86 ± 0.16 µM with Bmax 3.58 µM (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
Figure 3.1 Titration curve of DAUDA binding to wtrFABP5. For calculation of the 
dissociation constant Kd values, the excitation and emission used was 345 and 530 nm, 
respectively. The apparent dissociation constant (Kd) for DAUDA to wtrFABP5 was 
calculated to be 1.86 ± 0.16 µM. 
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3.3.2 Detection of binding affinities (Ki) of 3 fatty acids and 4 candidate 
compounds to wtrFABP5  
The Ki of 3 natural fatty acids (linoleic, oleic, palmitic acid) which inhibited 50% of 
DAUDA binding to wtrFABP5 were measured to find out the best fatty acid by 
measuring their ability to displace DAUDA from the wtrFABP5 binding cavity. In 
addition, the Ki of 4 chemical compounds (SBFI26, SBFI19, SBFT27 and SBFI31) 
which inhibited DAUDA binding to wtrFABP5 were measured to identify the most 
potent inhibitor by measuring their ability to displace DAUDA from the wtrFABP5. 
3µM wtrFABP5 were incubated with 2µM DAUDA in the presence or absence of each 
fatty acid in different concentrations (0.5-20µM) to determine the best binding fatty 
acid. The loss of fluorescence intensity was measured with Varioskan Flash with the 
excitation and emission of 345 and 530 nm. The data was fitted by non-linear 
regression techniques using GraphPad Prism to a one site binding affinity model to 
determine the Ki of these select competitors by using the equation Ki=IC50/1+ 
(DAUDA concentration /Kd). The Kd of DAUDA-stearate for wtrFABP5 from the 
previous results. The calculated Ki (µM) values of Linoleic, Oleic and Palmitic acid 
were 1.58 ± 0.14, 1.89 ± 0.18 and 4.30 ± 0.4, respectively (Fig. 3.2, A, B, C) 
(Table3.1). Thus, linoleic acid had the strongest binding affinity for wtrFABP5. 
Furthermore, the same protocol was performed to the other four candidate chemical 
compounds (SBFI26, SBFI-19, SBFI-27 and SBFI-31) to find out the lead inhibitor of 
FABP5 from these ligands. The most potent compound to bind wtrFABP5 was SBFI26 
(Ki =1.69 ± 0.15 µM), whose affinity was about 7.4-times higher than those of SBFI19 
and SBFI27 (Ki =12.54 ± 2.25 and 12.50 ± 2.07 µM, respectively). The Ki of SBFI31 
did not converge (Fig. 3.3, A, B, C, D) (Table3.1).  Taken together, the binding 
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affinity (Ki) of the lead compound (SBFI26) for wtrFABP5 was similar to that of the 
best-binding fatty acid (linoleic acid).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Chart records of binding affinity analysis of 3 different fatty acids of 
FABP5. Inhibition constant Ki (binding affinity) of A, Linoleic B, Oleic and C, 
Palmitic acids binding to wtrFABP5.  
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Figure 3.3 Chart records of binding affinity analysis of 4 different candidate 
chemical inhibitors of FABP5. Inhibition constant Ki of A, SBFI26 B, SBFI19 C, 
SBFI27, and D, SBFI31 to wtrFABP5.  
Fatty acids/ 
Chemical inhibitors 
Binding affinity 
(Ki) (µM) 
Linoleic acid 1.58  
Oleic acid  1.89 
Palmitic acid 4.30 
SBFI26 1.69 
SBFI19 12.54 
SBFI27 12.50 
SBFI31 ----- 
Table 3.1 Ki values of 3 different fatty acids and 4 different candidate chemical 
compounds. 
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In addition, the activity of the lead compound was confirmed by adding 10µM of each 
fatty acid and candidate chemical compound to 3µM wtrFABP5 plus 2µM DAUDA 
to ascertain the degree of DAUDA displacement from wtrFABP5 by loss of 
fluorescence intensity and the results are shown in (Fig. 3.4). The relative level of 
fluorescence intensity of wtrFABP5 with DAUDA was 2.65 ± 0.14. This was reduced 
to 1.37 ± 0.07, 1.68 ± 0.09 and 1.80 ± 0.08 after adding linoleic, oleic and palmitic 
acids, respectively, to the complex. After SBFI26, SBFI19, SBFT27, and SBFI31 were 
added to the complex, the intensity was reduced to 1.48 ± 0.06, 2.33 ± 0.08, 1.95 ± 
0.17 and 2.58 ± 0.79, respectively. Linoleic acid and SBFI26 produced highly 
significant reductions in fluorescence intensities (Student’s t test, P < 0.0001) and 
there was approximately similar binding affinity between the Linoleic acid and 
SBFI26 to the wtrFABP5.  
 
 
 
 
 
 
 
 
 
Figure 3.4 Fluorescence intensity of displacement of DAUDA from wtrFABP5 in 
the presence of 3 different fatty acids and 4 different candidate chemical 
inhibitors. The value of fluorescence intensity produced by the buffer and DAUDA 
plus wtrFABP5 was set as control. The results (mean ± SE) were obtained from 3 
separate experiments (2-tailed unpaired Student’s t test, ***, P < 0.0001). 
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3.4 Discussion  
Recently several studies showed that inhibition of FABPs activity is an effective 
method for treatment of inflammatory and metabolic diseases by using chemically 
synthesized inhibitors (206,220-222). A group of 4 chemical compounds capable of 
suppressing the biological activity of FABP5, was originally used as anti-nociceptive 
agents by increasing levels of brain anandamide transported by FABP5 and produced 
analgesia (223,224).  
Using DAUDA displacement assay, we aimed to identify the lead compound from 4 
different potential chemical inhibitors. It has been confirmed that DAUDA binds to 
FABPs in a similar location to fatty acids (239). Ligand binding to wtrFABP5 using 
DAUDA as a fluorescent probe has been previously investigated (192). We found that 
a dissociation constant (Kd) of titration DAUDA with delipidated wtrFABP5 was 
1.86µM, which was within the range of the other FABPs (240) (Fig. 3.1). 
The affinities of several ligands for wtrFABP5 were determined using DAUDA as a 
fluorescent probe. The Ki for a range of ligands were determined by measuring their 
ability to displace DAUDA from the wtrFABP5 binding cavity. Binding of non-fatty 
acid ligands to FABPs has been exemplified by their ability to displace bound 
fluorescent probes such as DAUDA from FABP (241,242). Although there is limited 
structural information on the binding sites of DAUDA within the different FABPs, 
they have been shown to bind competitively with fatty acids (239). To determine the 
best-fit value of Ki (the concentration of unlabelled ligand that blocks 50% of the 
specific binding of DAUDA), the nonlinear regression was used to determine the 
specificity at 100% (specific and nonspecific) (top plateaus) and 0% (nonspecific) 
(bottom plateaus) (243). If the labelled and unlabelled ligand compete for a single 
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binding site, the steepness of the competitive binding curve is determined by the law 
of mass action. The steepness of a binding curve can be quantified with a slope factor, 
or a Hill slope. A one-site competitive binding curve that follows the law of mass 
action has a slope of -1.0. If the curve is more shallow, the slope factor will be a 
negative fraction (-0.85 or -0.60) (236). Our result showed that the slope factor follows 
the law of mass action, indicating the labelled and unlabelled ligand compete for a 
single binding site of wtrFABP5.  
Different natural fatty acids (Linoleic, Oleic, Palmitic acid) and chemical inhibitors 
(SBFI26, SBFI19, SBFI27, and SBFI31) were used to perform competitive 
experiments with DAUDA to bind to wtrFABP5. The calculated Ki values of different 
ligands in the presence of wtrFABP5 (via DAUDA displacement) are summarized in 
Table 3.1. DAUDA displacement assays showed that all 3 fatty acids had the ability 
to bind to wtrFABP5 (Fig. 3.2). Linoleic and oleic acids are the better fatty acids with 
low Ki value 1.58 and 1.89µM respectively as compared with Palmitic acid 4.30µM. 
These results are in line with previous findings (192). In addition, this assays showed 
that 3 of these 4 compounds had the ability to bind to wtrFABP5, just as well as the 3 
fatty acids tested (Fig. 3.3). SBFI26 is the lead compound with low Ki value 1.58µM 
as compared with others.   
We found that the fluorescence intensity reduced with increasing concentrations of 
Linoleic acid and SBFI26, suggesting that these two significantly displaced DAUDA 
from wtrFABP5 (mean ± SE) (Student’s t test, P < 0.0001). While Linoleic acid had 
the highest binding ability amongst the 3 fatty acids, SBFI26 exhibited the highest 
FABP5 binding ability amongst the 4 compounds. Thus, SBFI26 was identified as the 
lead inhibitor of FABP5 (Fig. 3.4).  
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Chapter Four 
Suppressing the malignant progression of the PC3-M cells 
by SBFI26 and dmrFABP5 in vitro and in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 112  
 
4.1 Introduction  
Increase expression of FABP5 may result in accumulation of excessive amounts of fatty 
acids in CRPC cells where fatty acids can act as signalling molecules to stimulate their 
nuclear receptor PPARγ. The activated PPARγ then modulates expression of its down-
stream regulatory genes which finally lead to enhanced tumour expansion and 
aggressiveness caused by an overgrowth of CRPC cells with increased angiogenesis 
and reduced apoptosis (235). Recently, it was suggested that the FABP5-PPARγ-
VEGF signalling transduction axis, rather than AR-modulated signal transduction 
pathway, that is the dominant signalling route in promoting malignant progression of 
CRPC cells (217). Based on previous long time investigations, it is reasonable to 
hypothesize that FABP5 is an important pharmacological target, and modulating 
FABP5 biological activity may provide an effective therapy for treatment of CRPC in 
vitro and in vivo.  
When highly malignant CRPC PC3-M cells were orthotopically implanted into the 
mouse prostate gland, knockdown of FABP5 gene by RNA interference produced 
reduction in average tumour size and metastasis (189). These results justified our 
hypothesis that FABP5 is indeed a treatment target for CRPC. Although knockdown 
FABP5 RNA is highly effective in inhibition of malignancy of CRPC cells (189), siRNA 
molecules are not ideal agents for treatment due to their instability even when dissolved 
in a stabilizing agent (atolecollagen) (216). Thus, for an effective suppression of FABP5 
function in vivo, inhibitors capable of suppressing the biological activity of FABP5, rather 
than completely knockdown the gene, may be more realistic tools for CRPC suppression. 
In this section, we targeted the FABP5-related signalling pathway to treat CRPC cells 
in vitro and in mouse model by using the bio-inhibitor (dmrFABP5) and chemical 
synthetic inhibitor (SBFI26) to suppress the biological activity of FABP5 and to cut 
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off the FABP5-related signalling transduction chain in CRPC cells. This is an entirely 
novel experimental approach to treat CRPC and is completely different from current 
treatments that are based on androgen-blockade therapy. 
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4.2 Materials and Methods 
4.2.1 Materials 
Reagents are listed in Appendix A, Buffers in Appendix B and Equipment in Appendix 
C. 
4.2.2 Methods 
4.2.2.1 In vitro assays     
4.2.2.1.1 Cell growth assay 
4.2.2.1.1.1  Preparation of standard curve  
PC3-M cells were grown to 60-80% in median flask and harvested as previously 
mentioned and suspended in RPMI complete culture medium. Cells were counted 
using a haemocytometer as previously outlined and were diluted to 5×105 cells /ml of 
culture medium. Twenty-four well plate was used to set up serial dilution of cells as 
follow: 5x105/ml, 2.5×105/ml, 1×105/ml, 5×104/ml, 2.5×104/ml, 1.25×104/ml and 
6.25×103/ml. After that, 200µl from each dilution was seeded into a 96-well plate in 
triplicate. Plate was incubated overnight at 37°C, 5% CO2 and the cell growth of the 
standard curve was checked by MTT assay.  
4.2.2.1.1.2 Measuring number of cells by MTT assay 
The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] 
tetrazolium assay is built on the capacity of a mitochondrial dehydrogenase enzyme 
from viable cells to convert MTT into a purple coloured known as formazan crystals 
product which are accumulate in live cells. The purple crystals were liquefied by 
adding DMSO. When cells die, they lose the ability to convert MTT into formazan, 
therefore colour formation serves as a valuable marker of viable cells.  The MTT stock 
solution is prepared in PBS at a final concentration of 5mg/ml and stored at 4°C. After 
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overnight incubation of cells, 50µl of MTT solution was added to each 96-well plate 
and incubated at 37°C, 5% CO2 for 4 hours. 200µl of MTT and culture medium was 
removed slowly and carefully to avoid cells being disturbed. 200µl of DMSO was 
added to each well and blank and incubated at 37°C for 10 minutes. The optical density 
(OD) of the cells was measured with a Multiscan plate reader at 570nm. The standard 
curve for PC3-M was made by plotting OD against the number of cells. The growth 
rate was measured against its own standard curve to get the number of the cells per 
well. 
4.2.2.1.1.3 Effect of SBFI26 and dmrFABP5 on cell growth  
The growth rate of PC3-M treated by SBFI26 and dmrFABP5 were checked using 
MTT assay. Firstly, the optimal dose for both compounds was measured by seeding 
PC3-M cells in a 96 well plates (5x104/well) in a complete medium in triplicate with 
positive control and blank and incubated overnight at 37°C, 5% CO2. The cells were 
washed with PBS and treated with different doses of SBFI26 (25-150µM) and 
dmrFABP5 (5-70µM) and incubated for 24 hours at 37°C, 5% CO2. The MTT solution 
was added and incubated at 37°C, 5% CO2 for 4 hours. The cells were subsequently 
solubilized using DMSO and OD was measured at 570nm. The growth rate was 
measured against its own standard curve to get the best dose which caused high 
cytotoxicity. Furthermore, the anti-proliferative effect of the best concentration for 
each inhibitor was determined after 6 days of treatment with respect to the vehicle 
control using same assay. 
4.2.2.1.2 Cell migration assay (scratch assay) 
Scratch assay is an efficient and cheap method to estimate cancer cell migration in 
vitro. This method is constructed on the observation time that a new artificial wound 
gap (scratch) on a confluent cell monolayer will move toward the gap to close the 
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scratch until new cell–cell contacts are established again. PC3-M cells were grown to 
60-80% in median flask and harvested as previously mentioned and suspended in 
RPMI complete culture medium. The assay was carried out in 24 well plates. When 
the cells become confluent, 1ml pipette tip was used to scratch and cells were removed 
from discrete area to form a cell free zone and wells were washed two times with PBS. 
Complete medium was added to control PC3-M cells and PC3-M treated with 100µM 
SBFI26 inhibitor or 50µM dmrFABP5 and the wells were photographed using 
microscopy at 0, 12, and 24 hours after treatment. A marker was used to create a 
reference point near the scratch in each well and analysed the minimum distance in 
micro meters between the wound edges of the scratch area using Image J software. All 
experiments were performed in triplicate. 
4.2.2.1.3 Soft agar colony formation assay 
The soft agar assay is a technique usually used to assess cellular tumorigenicity in 
vitro. The assay was carried out in 6-well plates which were pre-coated with 2ml of 
1% (w/v) low melting agarose in routine culture medium and the mixture was 
solidified in refrigerator for 10 minutes. PC3-M cells were grown to 60-80% in median 
flask and harvested as previously mentioned and suspended in RPMI complete culture 
medium. The control PC3-M cells and cultures treated with 50µM dmrFABP5 or 
100µM SBFI26 were seeded in triplicates into 0.5% agar in routine culture medium 
on top of a bed of first layer at 5×104 cells per dish and placed in refrigerator for 10 
minutes until solidified. The 6-well plates were placed in the incubator at 37°C, 5% 
CO2 for two weeks. After one week of incubation, approximately 200µl of medium 
alone or medium with dmrFABP5 or SBFI26 according to the treatment plan were 
added to the dishes to avoid drying out and to ensure the cells had sufficient nutrients 
and treatment. After 2 weeks of growing, plates were treated with MTT at a 
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concentration of 0.5mg/ml and incubated for 4 hours in the incubator at 37°C, 5% 
CO2. Colonies larger than 250µm in diameters were counted by the GelCount (Oxford 
Optronix, UK).  
4.2.2.1.4 Cell invasion assay using Boyden chamber system 
The Boyden Matrigel chamber assay provides the condition to measure the invasive 
property of cancer cells in vitro. This assay is based on a chamber of two different 
medium compartments separated by 8 micron-pore size membrane. In general, cancer 
cells are seeded in the upper compartment and allowed to transport to the lower 
compartment through a membrane pores response to the presence of a chemo-
attractant agents. After an incubation time, the membrane is stained and the cells that 
have migrated to the lower part of the membrane are counted by using microscope. 
For invasion assay, after PC3-M cells were grown up to 60-80% in median flask, cells 
were put in starvation by adding serum-free medium for 24 hours in the incubator at 
37°C, 5% CO2. The invasion chambers were left in room temperature and the 
membrane was rehydrated by adding 0.5ml of warm serum-free medium for 2h in the 
incubator at 37°C, 5% CO2. The control PC3-M cells and cultures treated with 50µM 
dmrFABP5 or 100µM SBFI26 were seeded in triplicates at a density of 2.5×104 cells 
per well in 0.5ml serum-free medium in the upper chamber and allowed to invade 
through the Matrigel using medium containing 10% FCS in the lower chamber as a 
chemo-attractant for 24h in the incubator at 37ºC with 5% CO2. After 24h, cells in the 
upper chamber were removed with a cotton swab and cells on the bottom surface of 
the filter stained with 2% Crystal Violate for 10 minutes and washed with plane water. 
Chambers were left in the incubator for 2 hours for drying and the number of the 
invaded cells was counted under microscope. Every sample was analysed in triplicate 
and migrated cells were counted in mean ±SE.  
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4.2.2.2 Nude mouse tumorigenicity and metastasis assay 
4.2.2.2.1 Nude mouse orthotopic tumour models 
4.2.2.2.1.1 Establishment of a PC3-M cell lines stably expressing the luciferase 
gene 
4.2.2.2.1.1.1 Stable transfection of PC3-M cell lines 
PC3-M cells (2×105) were seeded in a 6 well plate and grown overnight in complete 
culture medium to reach 60-80% confluency. In the meantime, 3.3µg of the pGL4.50 
[luc2/CMV/Hygro] vector (Promega) was added to total volume of 155µl Opti-MEM 
I medium (Gibco, Invitrogen, Paisley, UK). Then, 9.9µl of FuGENE HD reagent 
(Promega) was added and mixed carefully by pipetting (15 times). The mixture was 
incubated at RT for 10 minutes and added drop wise to the wells. The transfection 
mixture was distributed evenly by rocking the plate back and forth. After 48-hour 
incubation, cells were split into 9cm cell culture plate and cultured in selective medium 
containing 200μg/mL Hygromycin (InvivoGen) which has been changed every three 
days for two weeks. Unsuccessfully transfected cells were killed by Hygromycin while 
successfully transfected cells were survived. 
4.2.2.2.1.1.2 Ring cloning of transfected cells  
After two weeks of incubation with antibiotic, colony formation was observed. 
Medium was removed from the dish and the colonies were washed with PBS. Glass 
cloning cylinders (Sigma) were fixed around the colonies. To isolate colonies, 100µl 
trypsin/EDTA solution was added and incubated for 3-4 minutes or until the cells were 
rounded-up at 37°C. The detached cells were re-seeded in 24 well plates and the 
medium was changed next day. Cells were allowed to grow within a controlled 
atmosphere of 5%CO2 at 37°C before they analysed for expression of luciferase.  
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4.2.2.2.1.1.3 In vitro identification of stably luciferase expressing PC3-M 
colonies  
To select the best colony with the highest luciferase gene expression, PC3-M parental 
cells and 33 different colonies of PC3-M cell transfected with luciferase vector were 
seeded at 1×105 in 96-well plate in triplicate. After 24 hours, the medium was removed 
and replaced with fresh medium containing 150μg/mL D-luciferin (Promega). Cells 
were immediately imaged in the Varioskan Flash Reader (Thermo Scientific) for a 
minute exposure. The wells that showed the highest relative luminescent units (RLU) 
were deemed to be the most highly expressing cells and were chosen as the colonies 
to take through into further in vitro check. To confirm that the luminescence intensity 
was associated with the number of cells, serial dilutions were performed on the PC3-
M parental cells and three PC3-M luciferase expression cells at concentrations ranging 
from 20-100000 cells in black 96-well plate in duplicate. After overnight incubation, 
a fresh medium containing 150μg/mL D-luciferin was added and the plate was image 
for a minute by using IVIS imaging system (Perkin Elmer). The bioluminescent 
intensity was quantified as Total Flux (photons/second).    
4.2.2.2.1.2 Surgical orthotopic implantation of PC3-M-luc cells 
Before operation, (8-10 weeks old) Balb/c male nude mice (Charles River, UK) were 
analgised with Novalgin and then constantly anaesthetised with isofluorane during the 
operation. The mouse was placed in a supine position and immobilized using surgical 
adhesive tape. The lower abdomen was disinfected by 10% povidone-iodine and (1-
1.5cm) midline skin and peritoneal incision approximately 1.5cm superior to the 
external genitalia was made using scissors. The urinary bladder was lifted as a yellow-
light spherical organ and externalized using tissue forceps. Two distinct lobes of 
prostate gland (left and right) were located directly beneath the bladder. Suspension of 
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PC3-M-luc Cells (5×105) in 30µL PBS were injected orthotopically into the prostate 
gland and small bubble was observed in the prostate, as described previously (244). 
The peritoneum and skin were sutured with two layers using 6.0 absorbable vicryl 
monofilament. Post operationally, the mouse was subcutaneously analgised with 
Novalgin (Fig. 4.1). In all mice, the same surgical conditions were preferred.  
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Figure 4.1 Orthotopic implantation of prostate cancer cells. a. Midline incision 
above the external genitalia. b. Midline incision in the peritoneal cavity. c. Light press 
on both sides of incision to protrude urinary bladder. d. Exteriorization of urinary 
bladder. e. Injection of cancer cells into one lobe of prostate gland. f. Suturing the 
peritoneal cavity using simple continuous suture method. g. Skin suturing using 
subcuticular suture method. h. End of the surgical operation 
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4.2.2.2.2 Experimental treatment of mice 
One week after orthotopic implantation of PC3-M-luc cells, tumour bearing mice were 
divided into 4 groups (8 each) and subjected to following intraperitoneal injections: 1) 
control with PBS; 2) SBFI26, 1mg/kg; 3) dmrFABP5, 20µg/kg; 4) 1mg/kg SBFI26 
plus 20µg/kg dmrFABP5. Injections were repeated every two days for 25 days. 
4.2.2.2.3 Bioluminescence imaging of mice 
Mice were imaged using IVIS imaging system (Perkin Elmer). 15mg/ml potassium D-
luciferin (Promega) was dissolved in PBS and filtered through a 0.2µm filter. All mice 
were anesthetized with isoflurane and injected subcutaneously with 150mg/kg D-
luciferin and imaged 15 minutes from injection. Tumour loci were monitored weekly 
using the IVIS after injection with D-luciferin. In the IVIS imaging chamber, mice 
were remained sedated with isoflurane administrated through nasal cones. After 
acquiring photographic images of mice, bioluminescent images were acquired with 
auto exposure time. The bioluminescent images were normally superimposed by the 
IVIS Living Image Software (Xenogen) and the measurements were based on total 
photons/second (p/s) within separate defined region of interest (ROI). ROI was 
manually drawn over the hull animal to assess the signal intensity emitted. Animal 
study was performed in accordance with UKCCCR guidelines under the Home Office 
Project License PPL40/2963.  
4.2.2.3 Histological experiments and staining  
4.2.2.3.1 Dissection of mice tissues 
To check the metastasis of tumour in mice, samples of the livers and lungs were 
removed from the mice and fixed in 10% neutral buffered formalin (NBF) at least for 
24 hours before processed routinely for histological examination. 
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4.2.2.3.2 Embedding in paraffin wax and sectioning  
The fixed tissue samples were trimmed and placed within an embedding cassette and 
processed on a Tissue processor. Processed tissues were then embedded in paraffin 
wax at 60°C and cooled on iced plat. After solidification, the blocks were sectioned on 
a Microm HM355 microtome using a microtome knife containing a stainless steel 
disposal blade. Sections were cut to 4µm thickness and placed on 3-aminopropyl 
triethoxy-saline (APES) coated Superfrost microscope slides and incubated at 37°C 
overnight prior to processing with Haematoxylin and Eosin.   
4.2.2.3.3 Haematoxylin and Eosin (H/E) staining of tissue sections 
Paraffin-embedded tissue sections were deparaffinised and rehydrated in two-times 
xylene and a decreasing alcohol series (2×100%, 2×95% and 2×80% ethanol). The 
sections were stained in haematoxylin for 3-5 minutes and in eosin for 20 seconds, 
dehydrated in an alcohol series (2×80%, 2×95% and 2×100% ethanol) and rehydrated 
in two-times xylene before Coverslip slide were fixed 
by using Permount (xylene based). 
4.2.2.4 Statistical analysis 
For all the results in this work, Student’s t-test and Fisher’s Exact test were carried out 
using GraphPad Prism software to compare the differences of the means between 
control and experimental groups. All in vitro experiments were conducted in triplicate 
and repeated at least three times. The difference is regarded as significant when 
p<0.05; in the results, p value is represented by asterisks as follows:  *, P < 0.05; **, 
P < 0.001; ***, P < 0.0001. 
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4.3 Results  
4.3.1 Inhibitory effect of SBFI26 and dmrFABP5 on malignant characteristics 
of PC3-M cells in vitro 
4.3.1.1 Effect of SBFI26 and dmrFABP5 on PC3-M cell growth  
MTT assay was conducted to test the inhibitory effect of SBFI26 and dmrFABP5 on 
PC3-M cell growth in vitro. PC3-M cells standard growing curve, established as 
described in methods, was shown in Fig. 4.2.  
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Standard curve of PC3-M cell lines. Using linear regression analysis, 
standard curve was established for the PC3-M cells by plotting absorbance (OD at 570 
nm) (Y axis) against the cell numbers (X axis). The linear regression of the standard 
curve is presented in the figure and R=0.99. The numbers of cells were obtained by 
relating the OD values to the standard curve.  
 
Cytotoxicity tests showed that treatment with either SBFI26 or dmrFABP5 
significantly suppressed growth of PC3-M cells in a concentration-dependent pattern 
as compared to untreated cells. Maximum suppression was produced at 100µM for 
SBFI26 by 26% (Student’s t test, P < 0.001); further increase in doses did not produce 
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any further significant suppression (Fig. 4.3). Similarly, PC3-M cells were sensitive 
to treatment with dmrFABP5 and the Maximum suppression was found at 50µM for 
dmrFABP5 by 35% (Student’s t test, P < 0.001); more increase in doses did not 
produce any further significant suppression (Fig. 4.4).   
 
 
 
 
 
 
 
 
Figure 4.3 Determination of the optimal inhibitory concentration of SBFI26 on 
PC3-M cells. MTT assay was performed to measure the viable PC3-M cell numbers 
of the control (untreated) and those treated with different concentrations of SBFI26 
(25-150µm) for 24h. Results were obtained from three separate measurements (mean 
± SE). 
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Figure 4.4 Determination of the optimal inhibitory concentration of dmrFABP5 
on PC3-M cells. MTT assay was performed to measure the viable PC3-M cell 
numbers of the control (untreated) and those treated with different concentrations of 
dmrFABP5 for 24h. Results were obtained from three separate measurements (mean 
± SE). 
 
In addition, the inhibitory effect of 100µM SBFI26 or 50µM dmrFABP5 on 
proliferation of PC3-M cells was assessed over one-week experimental period by using 
MTT assay. The results showed that 100µM SBFI26 significantly reduced the 
proliferation rate of PC3-M cells at the end of the 7th day by 17-times (1667.6 ± 50.7) 
as compared to PC3-M cells without treatment (28290.6 ± 2068.6) (Student’s t test, P 
< 0.0001) (Fig. 4.5). 50µM dmrFABP5 reduced the proliferation rate of PC3-M cells 
at the end of the 6th day to 6414.3± 583.4; whereas in PC3-M cells without treatment 
was increased to 30046.6 ± 452.9. This dose significantly reduced the proliferation 
rate of PC3-M cells 4.7-times (Student’s t test, P < 0.0001) (Fig. 4.6). 
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Figure 4.5 Inhibitory effect of 100µM SBFI26 on growth of PC3-M cells over the 
7day experimental period. Results were obtained from three separate measurements 
(mean ± SE) and the differences between the control and the treatment was assessed 
at the last day by 2-tailed unpaired Student’s t test. ***, P < 0.0001.  
 
 
 
 
 
 
 
 
Figure 4.6 Inhibitory effect of 50µM dmrFABP5 on growth of PC3-M cells over 
the 6day experimental period. Results were obtained from three separate 
measurements (mean ± SE) and the differences between the control and treatment was 
assessed at the last day by 2-tailed unpaired Student’s t test. ***, P < 0.0001. 
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4.3.1.2 Effect of SBFI26 and dmrFABP5 on migration of PC3-M cancer cells 
To assess the effects of 100µM SBFI26 and 50µM dmrFABP5 on metastatic potential 
of PC3-M cells, cell migration was evaluated using wound healing assay. PC3-M cells 
were grown in 24-well plates to form a monolayer. Scratches were made using 1 mL 
sterile pipette tip. Cell migration capacity was measured by the reduction in wound 
size in control (untreated) and in cultures treated with 100µM SBFI26 or 50µM 
dmrFABP5, respectively. The photos were taken at 0, 12 and 24 hours, respectively, 
after treatment (Fig. 4.7). Treatments with 100µM SBFI26 and 50µM dmrFABP5 
produced only 19% and 21% reduction in wound sizes, respectively in 24h. These 
treatments significantly suppressed the migration rates of PC3-M cells (Student’s 
t test, p < 0.0001), leading only to small changes in wound gaps for treated groups 
compared to an almost complete gap closure (94%) for the control (Fig. 4.8). 
 
 
 
 
 
 
 
 
 
Figure 4.7 Representative photos of the wound healing assay. Cell migration 
capacity was measured by the reduction in wound size in control (1) and in cultures 
treated with 100µM SBFI26 (2) or 50µM dmrFABP5 (3) isolated at 0, 12 and 24 hours 
after treatment. Scale bar is 250µm. 
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Figure 4.8 Average wound sizes (µm) of the control PC3-M and cultures treated 
groups. Average wound sizes (µm) of the control PC3-M and cultures treated with 
100µM SBFI26 and 50µM dmrFABP5 isolated at 0, 12 and 24 hours after treatment. 
Data was collected by measuring image of the wound space and analysed by ImageJ 
software (National Institutes of Health). Results were obtained from three separate 
measurements (mean ± SE). 
 
4.3.1.3 Effect of SBFI26 and dmrFABP5 on invasiveness of PC3-M cancer cells 
The effect of SBFI26 and dmrFABP5 on invasiveness of PC3-M cancer cells was 
assessed using BD Matrigel coated invasion chambers. PC3-M cells in an active 
growth phase with confluency less than 80% were maintained in serum-free RPMI 
1640 medium for 24 hours prior to setting up the invasion assay. After 24h starvation, 
cells were harvested and counted to prepare a mixture containing 5×104 cells in serum-
free medium. Chambers were rehydrated for 2 hours before 2.5×104 cells in 0.5ml 
medium with inhibitors were loaded into every upper compartment of chambers. 
Routine medium (with 10% (v/v) FCS) was placed in lower compartments. Cell lines 
were set as triplicate and assay was run in a humidified tissue culture incubator for 24 
hours. Finally, remaining cells in upper part were removed by gently using cotton 
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swabs and washed with PBS. Migrated cells were fixed and stained using 2% crystal 
violet for 10 minutes and counted in different random fields-of-view (5mm) using light 
microscope. Mean number of invaded cells from the control and the PC3-M cells 
treated with SBFI26 and dmrFABP5 were 22 ± 3, 1 ± 1 and 2 ± 1, respectively, 
representing significant suppressions of invasion by 95.5% and 91%, respectively 
(Student’s t test, P < 0.0001) (Fig. 4.9, A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 The impact of dmrFABP5 or SBFI26 on invasiveness of PC3-M cells.  
A, Representative fields-of-view (5mm) of invasion assay; Number of invading cells 
from the control PC3-M cells (1) and cultures treated with 50µM dmrFABP5 (2) or 
100µM SBFI26 (3) for 24h after different treatments. Scale bar is 250µm. B, Number 
of invaded cells per field (5mm) in invasion assay. Results were obtained from three 
separate measurements (mean ± SE). 
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4.3.1.4 Effect of SBFI26 and dmrFABP5 on anchorage-independent growth of 
PC3-M cancer cells 
To investigate the effect of SBFI26 and dmrFABP5 on tumorigenicity of PC3-M cells, 
their anchorage-independent growth in the soft agar were assessed. PC3-M cells, PC3-
M cells treated with 50µM dmrFABP5 or 100µM SBFI26 were seeded in triplicates 
into 0.5% agar in routine culture medium on top of a bed of first layer at 5  104 cells 
per dish. After 1 week of incubation, approximately 200µl of medium alone or medium 
with dmrFABP5 or SBFI26 according to treatment were added to the dishes to avoid 
drying out and to ensure the cells had sufficient nutrients and treatment. Assay was set 
as triplicate and cells were grown for 2 weeks. Colonies were stained by adding 0.5ml 
of 2% MTT for 4 hours. Colonies larger than 250μm were counted using Gel Count. 
The soft agar showed that the number of colonies formed after 2 weeks by control 
PC3-M cells, PC3-M cells treated with dmrFABP5 or with SBFI26 were 124 ± 18, 27 
± 2, or 0, respectively, representing significant inhibitions by 78% and 100%, 
respectively, in comparison to control cells (Student’s t test, p < 0.0001) (Fig. 4.10, A 
and B).  
 
 
 
 
 
 
 
Page | 132  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 The impact of dmrFABP5 or SBFI26 on the anchorage-independent 
growth of PC3-M cells. A, Representative plates of soft agar colony formation with 
the control PC3-M cells (1) and cultures treated with 50µM dmrFABP5 (2) or 100µM 
SBFI26 (3). B, Colony counts of different treatments; Results (mean ±SE) are obtained 
from three separate plates in each treatment. 
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4.3.2 Effect of SBFI26 and dmrFABP5 on tumourigenicity and metastatic 
ability of PC3-M cells in mouse prostate gland  
4.3.2.1 Establishment of stable PC3-M cells expressing strong bioluminescence 
signals  
PC3-M cells were transfected with the pGL4.50 [luc2/CMV/Hygro] vector using 
FuGene HD transfection reagent. After 48-hour incubation, cells were split into 9cm 
cell culture plate (petri dish) and continued to grow with selective medium containing 
200μg/mL Hygromycin which has been changed every three days for two weeks. 
Single clones were appeared and visualized with naked eye. Then, using ring cloning 
method, thirty-three single colonies of PC3-M cells transfectants with pGL4.50 were 
picked up and transferred onto a 24 well plates. The medium was changed next day 
and colonies were grown in normal cell culture conditions. To select the best colony 
with the highest luciferase gene expression, PC3-M parental cells and 33 different 
colonies of transfected PC3-M cell were imaged using Varioskan Flash Reader after 
adding fresh medium containing D-luciferin. The results showed that 2 transfectant 
colonies generated high luminescence signals and named PC3-M-Luc8 and 21 (Fig. 
4.11). The wells that showed the highest relative luminescent units were deemed to be 
the most highly expressing cells and were chosen as the colonies to take through into 
further in vitro check. To confirm that the luminescence intensity was associated with 
the number of cells, serial dilutions were performed on the PC3-M parental cells and 
three PC3-M luciferase expression cells. After overnight incubation, a fresh medium 
containing D-luciferin was added and the plate was image for minute by using an IVIS 
imaging system. The results showed that PC3-M-Luc8 produced the highest level of 
bioluminescence signal (Fig. 4.12, A) and there was a correlation between total flux 
and the number of labelled cells (R2 =0.98) (Fig. 4.12, B).   
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Figure 4.11 Establishment of stable PC3-M colonies expressing strong 
bioluminescence signals. Relative luminescent units (mean ±SE) of the PC3-M 
parental cells and 33 colonies derived from PC3-M cells were obtained from 3 separate 
measurements.  
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Figure 4.12 The intensities of the bioluminescence images of the serially-diluted 
PC3-M cells and 3 representative PC3M-Luc transfectants by IVIS. A, Detailed 
observation of the intensities of the bioluminescence images of the serially-diluted (20-
100000) parental PC3-M cells and 3 representative PC3M-Luc transfectants. The 
colour bar on the right indicates the signal intensity range (photons/second/cm2). B, 
Correlation between the bioluminescence flux intensity (photons/second) and the 
number of cells derived from 3 different PC3-M-Luc colonies. 
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4.3.2.2 Inhibitory effect of SBFI26 and dmrFABP5 on tumorigenicity and 
metastatic ability of PC3-M cells implanted orthotopically into the nude 
mouse prostate gland. 
Luciferase-labelled PC3-M-Luc8 Cells (5×105) were suspended in 30µL PBS and 
orthotopically implanted into the dorsal prostate of male Balb/c nude mice. One week 
later, tumour-bearing mice were divided into 4 groups (8 each) and subjected to the 
following intraperitoneally injections: 1) control with PBS, 2) SBFI26 (1mg/kg), 3) 
dmrFABP5 (20µg/kg), 4) SBFI26 plus dmrFABP5. Injections were repeated every two 
days for 25 days and the metastatic loci were monitored weekly using the IVIS after 
mice were subcutaneously injected with D-luciferin. At day 25, there was a massive 
decrease in bioluminescence signal (p/sec/cm2) in SBFI26 (6.66×108), dmrFABP5 
(2.53×108) and combination of SBFI26, dmrFABP5 (3.67×108) groups, compared 
with control (31.5×108). On the basis of bioluminescence, our results showed about 
4.9, 13 and 9-fold suppression in tumour mass by SBFI26, dmrFABP5 and a 
combination of both over those of control group (Student's t test, P < 0.0001) (Fig. 
4.13).  
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Figure 4.13 Whole body tumour bioluminescence flux produced by each group of 
nude mice after orthotopic implantation of luciferase-labelled PC3-M cells and 
different treatments for 25 days. Values were normalised to day 0. Values were 
plotted as mean ± SE (error bars) (n = 8); the difference between the control and each 
of the testing groups was assessed by two-tailed unpaired Student’s t test ***, P < 
0.0001.  
 
In the control group, 7/7 (100%) mice produced metastases. In the group treated with 
SBFI26, 4/8 (50%) of mice produced visceral metastasis. In groups treated with 
dmrFABP5 and a combination of SBFI26 and dmrFABP5, no mice with metastases 
were detected, significant suppressions in metastasis was seen when compared to the 
control group (Fisher's Exact test, P < 0.05) (Fig. 4.14, A and B). Histological staining 
showed that all mice developed metastases in the control group, mainly in the liver 
and lung. In the SBFI26 treated group, half of the mice developed liver metastases; 
none were found in groups treated with either dmrFABP5 or a combination of SBFI26 
and dmrFABP5. One representative stained slide from each group/organ is shown in 
(Fig. 4.15).   
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Figure 4.14 Inhibitory effect of SBFI26 and dmrFABP5 on tumorigenicity and 
metastatic ability of PC3-M cells implanted orthotopically in mice.  A, Numbers 
of mice developed 1 or more metastases (or metastasis incidence, detected by 
bioluminescence signal) in the control and experimental groups, 15 and 25 days after 
treatment. The difference between the control and each of the experimental groups was 
assessed by 2-tailed Fisher's Exact test *, P < 0.05. B, Ventral bioluminescence images 
of primary tumours and metastases in all 4 groups of experimental mice 25 days after 
treatment. The colour bar on the right indicates the signal intensity range 
(photons/second/cm2).  
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Figure 4.15 Representative photomicrographs of detection of liver and lung 
metastases. Representative photomicrographs of detection of liver and lung 
metastases (arrows) from mice which received injection of PBS (1), SBFI26 (2), 
dmrFABP5 (3) and combination of SBFI26 and dmrFABP5 (4). Sections of tissues 
were stained with H&E. Scale bar is 100µm.  
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4.4 Discussion  
Androgen-independent prostate cancer cell line PC3-M (CRPC cells), expressing high 
levels of FABP5 and PPARγ, was an extremely malignant and metastatic cell line 
(217,245,246). When the biological function of FABP5 in the PC3-M CRPC cells was 
inhibited using SBFI26, significant anti-proliferation (by 17-time) (Fig. 4.5), anti-
invasive (by 95%) (Fig. 4.9), anti-migration (by 81%) (Fig. 4.8) and anti-anchorage-
independent growth (by 100%) (Fig. 4.10) were observed as compared to the control 
group. In addition, the effect of dmrFABP5 in the PC3-M cells was also tested.  
DmrFABP5 produced highly significant suppression of PC3-M cellular proliferation 
(by 4.7-time) (Fig. 4.6), invasiveness (by 91%) (Fig. 4.9), migration (by 97%) (Fig. 
4.8) and colony formation (by 78%) (Fig. 4.10) in vitro as compared to the control 
group. This results were confirmed by three separate experiment (mean ± SE). 
We tested whether suppressing FABP5 biological function could inhibit the growth of 
PC3-M CRPC cells in vitro. In PC3-M cells, SBFI26 and dmrFABP5 inhibited growth 
in a dose-dependent manner with optimal doses of 100 and 50µM respectively. Our 
results indicate that both SBFI26 and dmrFABP5 at concentrations >100 and >50 µM, 
respectively, are able to significantly inhibit PC3-M cells growth (Student’s t test, P < 
0.001).  In the current study, we demonstrate the inhibitory effects of 100µM SBFI26 
and 50µM dmrFABP5 on the proliferation of PC3-M cells in vitro. The results show 
that SBFI26 and 50µM dmrFABP5 each significantly suppressed the proliferation of 
human PC3-M cells after 1 week treatment (Student’s t test, P < 0.0001). Interestingly, 
the results show that SBFI26 reduced the proliferation of human PC3-M cells below 
the initial density which indicated the cytotoxic effect. However, dmrFABP5 
approximately kept the proliferation of PC3-M cells at the same as the initial density 
which indicated the cytostatic effect.   
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The major fatal event in cancerous disease is the metastasis, whereby, the cancer cells 
disseminate themselves from the primary site to the secondary site of the body. The 
effects of both inhibitors on migration and invasiveness of PC3-M cells were 
conducted (Fig. 4.8) (Fig. 4.9). When cells were treated with SBFI26 or dmrFABP5 
at concentrations of 100 or 50µM, significant differences were observed on the 
migration and invasiveness of PC3-M cells between treated and untreated cells 
(Student’s t test, P < 0.0001). It was observed that the lack of migration and invasion 
of PC3-M cells treated with SBFI26 was due to cell death after 24-hour incubation 
(Fig. 4.5). However, the lack of migration and invasion of PC3-M cells treated with 
dmrFABP5 may be due to loss of the proliferative activities after 24-hour incubation 
(Fig. 4.6). 
In line with these, SBFI26 as a lead inhibitor of FABP5 showed efficient anti-tumour 
roles in the mouse model for primary tumours implanted in the prostate gland (by 4.9- 
fold) (Student's t test, P < 0.0001) (Fig. 4.13). Compared to the control group, in which 
all mice (100%) developed metastases, SBFI26 treatment suppressed metastases in 
half of the mice of the treated group (50%) (Fig. 4.14). These results suggest that 
SBFI26 can be used as an anti-tumour agent to treat CRPC, which reduced the primary 
tumours by 4.9-times and suppressed the metastases by 50% in the experimental 
period.  
In this study, the effect of dmrFABP5 was also tested. Here for the first time, we 
showed that dmrFABP5 has a dominant negative effect on tumorigenicity and 
metastatic ability of human PC3-M cells by suppressing the biological activity of 
FABP5. When tested in nude mice, dmrFABP5 was highly effective in suppressing 
the primary tumour growing in the prostate gland. Thus dmrFABP5 produced a 13-
fold reduction in tumour mass in the prostate gland (Student's t test, P < 0.0001) (Fig. 
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4.13). Most importantly, dmrFABP5 produced a 100% suppression of metastasis in 
mice with CRPC cells implanted into the prostate gland (Fisher's Exact test, P < 0.05) 
(Fig. 4.14).  
Compared to SBFI26, the suppressive effect of dmrFABP5 was 2.7-fold higher in 
tumours growing in the prostate gland (Fig. 4.13). Whilst, the suppression effect of 
dmrFABP5 on metastasis was 2 times that of SBFI26 (Fig. 4.14). These results suggest 
that although both SBFI26 and dmrFABP5 are potent inhibitors, the suppression effect 
of dmrFABP5 is much stronger than that of SBFI26. 
. 
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Chapter Five 
The molecular mechanisms involved in the inhibitory effect 
of SBFI26 and dmrFABP5 on malignant progression of the 
CRPC cells 
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5.1 Introduction   
Recently, it was confirmed that the increased expression of oncogenic cytoplasmic 
FABP5 significantly correlated with the increased nuclear PPARγ in CRPC cells. The 
increased levels of both proteins were associated with increased GS and connected 
with reduced patient survival time (211). It has been confirmed that the fatty acids, 
transporting by FABP5, stimulate PPARγ to activate the FABP5-PPARγ-VEGF 
signalling transduction axis which is the dominant signalling route in promoting 
malignant progression of CRPC cells (217). Previous studies also showed that 
suppression of FABP5 or PPARγ expression by RNAi in CRPC cells significantly 
reduced invasiveness in vitro and inhibited the tumorigenicity in mouse model 
(190,216,217).  
In the previous set of experiments of this study, we tried to cut off the FABP5-related 
signalling transduction chain in CRPC cells to suppress the malignant progression of 
CRPC. To achieve this aim, we targeted FABP5 to treat CRPC in mice by using the 
chemical inhibitor SBFI26 and the bio-inhibitor dmrFABP5 to supress the biological 
activity of FABP5. Results of this work showed that suppression of FABP5 in CRPC 
cells by using both inhibitors produced a significant reduction in growth rate, 
invasiveness, migration and anchorage-independent growth. In addition, by orthotopic 
implantation of CRPC cells into prostate gland in nude mice, it was shown that both 
inhibitors could significantly reduce the size of tumours formed into the gland and the 
metastasis of the tumours.  
To investigate whether the FABP5 inhibitors suppressed the malignant progression of 
CRPC through inhibiting the FABP5-related signalling transduction pathway, in this 
set of experiments, we first investigated whether these inhibitors inhibited 
tumourigenicity of CRPC cells in a similar manner to that of the PPARγ antagonist. 
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Then we investigated how these inhibitors cut off the FABP5-related signal 
transduction route and what connection points of the signal transduction chain were 
broken by these inhibitors so that the tumourigenicity and the metastatic ability of the 
CRPC cells was suppressed.   
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5.2 Materials and Methods 
5.2.1 Materials 
Reagents are listed in Appendix A, Buffers in Appendix B and Equipment in Appendix 
C. 
5.2.2 Methods 
5.2.2.1 Cell culture 
5.2.2.1.1 Routine cell culture 
Cells were grown in cell culture flasks and incubated in a humidified incubator at 37°C 
which contains 5% (v/v) CO2. Tissue culture hood found in the tissue culture 
laboratory was used for all routine cell culture procedures. Six cell lines were grown 
which are benign prostate cells (PNT2), low malignant prostate cancer cells (LNCaP), 
moderately malignant prostate cancer cells (22RV1) and highly malignant prostate 
cancer cells (DU145, PC3 and PC3-M). LNCaP cells were cultured in RPMI 1640 
nutrient medium with 10% (v/v) fetal calf serum (FCS), 100IU 
penicillin/streptomycin, 2mM L-glutamine, 1mM sodium pyruvate. PNT2, 22RV1, 
DU145, PC3 and PC3-M cells were culture in the same complete medium without 
sodium pyruvate. Routine culture medium was replaced every three days.  
5.2.2.1.2 Cells thawing 
Vials of cells from liquid nitrogen were thawed in water bath at 37°C and directly 
moved into 10 ml of completed cell medium in a universal tube. The cell pellet was 
centrifuged for 3 minutes at 600×g. The supernatant was discarded and the pellet was 
suspended in a suitable volume of complete medium. The cells were cultured in a cell 
culture flask and incubated in a humidified incubator 
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5.2.2.1.3 Sub-culture of cell lines 
Cells were sub-cultured when their confluency reached 60-80%. Medium was 
removed from the flask. Cells were washed by phosphate buffered saline (PBS) and 
adequate amount of 2.5% trypsin/versene solution was added to the flask and 
incubated at 37°C for 3-5 minutes until the cells were starting to detach from the flask. 
Double amount of medium was added to deactivate the effect of trypsin/versene 
solution and the cells were transferred to a universal tube and centrifuged at 600×g for 
3 minutes. The supernatant was removed and pellet was washed with PBS and 
centrifuged. Finally, the cells were seeded at the required concentration and incubated 
in a humidified incubator.   
5.2.2.1.4 Cell count 
Improved double counting chambers hemocytometer was used to calculate the number 
of the cells. Cells were detached as described previously, suspended in complete 
medium and 20µl of cell suspension was loaded to a counting chamber of 
hemocytometer with 9 (3×3) squares. The cells were counted in four corner squares 
under the microscope. The total number of cells was calculated using the equation 
below. 
Total number of cells= Average cell count per square × Dilution× 104 × Total volume 
(ml)   
5.2.2.1.5 Freezing down Cells 
Cells were frozen down when their confluency reached to approximately 60-80%. The 
cells were detached and washed as described previously. After washing the supernatant 
was removed and the cell pellet broke up by repeated pipetting with freezing medium 
(complete medium and 7.5% (v/v) DMSO). Cell suspension (1ml) were put into 
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cryogenic vials and placed into a Nalgene cryo-preserver box containing 250ml of 
isopropyl alcohol. The box was stored in a freezer at -80°C overnight before vials were 
transferred to liquid nitrogen for long term storage. 
5.2.2.2 Nude mouse xenograft tumour models  
Two rounds of animal studies were performed using 6-8 weeks old male Balb/c nude 
mice (Charles River, UK). They were weighted in their arrival and ranged between 18-
20g. After one week of settling down, PC3-M cell lines were cultured up to 80% 
confluency. On the day of inoculation, cells were harvested and re-suspended in PBS 
at the concentration of 1×107/ml. 2×106 PC3-M cells in 200µL PBS were 
subcutaneously injected into the right flank region of the mouse to test the suppression 
effect of the inhibitors on tumorigenicity. In the first round, 5 groups of mice (8 each) 
were used: 1) control with PBS; 2) 1mg/kg SBFI26, injected from the 1st day after cell 
inoculation; 3) 1mg/kg SBFI26, injected from the 7th day after cell inoculation; 4) 
20µg/kg dmrFABP5, injected from the 1st day after cell inoculation; 5) 20µg/kg 
dmrFABP5, injected from the 7th day after cell inoculation. In the second round, 4 
groups of mice (5 each) were used and at 7 days after the cell inoculation, each group 
was subjected to different intra-tumoural injections: 1) control with PBS; 2) 1mg/kg 
SBFI26 plus 20µg/kg dmrFABP5; 3) PPARγ antagonist (GW9662, 1mg/kg) (Sigma); 
4) 1mg/kg SBFI26, 20µg/kg dmrFABP5 plus 1mg/kg GW9662. The injections were 
repeated every 2 days for 30 days and tumour size measured every 3-4 days and 
calculated by the formula of L×W×H×0.5236 (247). All animal studies were 
performed in accordance with UKCCCR guidelines under the Home Office Project 
License PPL40/2963.  
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5.2.2.3 Fatty acid uptake assay 
Fatty acid uptake assay offers a sensitive and simple method for the measurement of 
long-chain fatty acids (LCFAs) uptake in cells containing fatty acid transporters. The 
red fluorescence-labelled LCFA, BODIPY 558/568C12 [4, 4-difluoro-5-(2-thienyl)-4-
bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid] (Invitrogen) was used as a 
fluorescently labelled fatty acid that permits fatty acid transport to be measured using 
flow cytometry (248). BODIPY analogue acts as natural fatty acid for the detection of 
fatty acid uptake in cells and to screen for inhibitors of fatty acid binding proteins. 
Fluorescent fatty acid stock solution of 2mM were prepared in ethanol as suggested by 
the company and stored at −20°C.  
5.2.2.3.1 Fatty acid uptake for different prostate cells 
PNT2, LNCaP, 22RV1and PC3-M cells were plated (1×105 cells) in 2ml routine 
culture medium into 6-well plates in triplicate and incubated at 37°C, 5% CO2 
overnight. The medium was replaced with 2ml of solution (PBS containing 5% FBS) 
containing 2µM of BODIPY 558/568C12 with a blank solution, and cells were 
incubated for 30mins at 37°C, 5% CO2. The fatty acid uptake was finished by removal 
of labelled fatty acid solution and adding 3ml of an ice-cold stop solution (PBS 
containing 5% FBS). The cells were washed another two times using 3ml of fresh ice-
cold solution and were kept on ice for 2 minutes. Cells were detached using 2.5% (v/v) 
trypsin/versene on ice and then re-suspended using fresh ice-cold solution. The 
fluorescence intensity of the cell was measured with an EPICS XL Cytometer 
(Beckman) at the wavelength of 570nm to assess the different expression of FABP5 
between different cell lines by measuring fatty acid uptake 30 min before and after 
adding fluorescence-labelled fatty acid.                 
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5.2.2.3.2 Effect of SBFI26 and dmrFABP5 on the fatty acid uptake of PC3-M 
cells 
Fatty acid uptake assay was performed to determine the inhibitory and competitive 
effect of SBFI26 and dmrFABP5 which inhibit fatty acid uptake of PC3-M cells. 
Highly malignant prostate cancer cells (PC3-M) were seeded in 6 well plates as 
mentioned in 5.2.2.2.1. The medium was replaced with 2ml of solution (PBS 
containing 5% FBS) containing 2µM of BODIPY 558/568C12 and different 
concentration of unlabelled SBFI26 (50-200µM) or dmrFABP5 (25-75µM) with a 
blank solution to make competition between inhibitors and BODIPY 558/568C12 for 
binding with FABP5, the cells were incubated for 30mins at 37°C, 5% CO2. The next 
steps were as mentioned in section 5.2.2.2.1.  The fluorescence intensity of PC3-M 
cells was measured with an EPICS XL Cytometer at 570nm wavelength. 
5.2.2.4 Analysis of protein expression using Western blot 
5.2.2.4.1 Treatment of cultured cells  
1×106 of different prostate cells were grown in 6-well plate and incubated overnight at 
37°C, 5% CO2. The medium was removed and new medium containing different 
compounds (inhibitors or activators) was added and incubated for 24 hours. 
5.2.2.4.2 Isolation of protein extracts from cultured cells 
After 24 hours’ treatment, the cells were detached and suspended in 2ml of medium to 
inactivate the trypsin. Cell suspensions were centrifuged at 600×g for 3 minutes, the 
supernatant was decanted and washed with PBS which was removed by centrifugation. 
The cell pallet was lysed by adding CelLytic-M reagent supplemented with protease 
inhibitor and incubated on roller mixer for 15 minutes at room temperature. The 
mixture was centrifuged for 20 minutes at 10,000×g to remove the cellular debris. The 
supernatant containing proteins was collected into a fresh micro-centrifuge tube.         
Page | 151  
 
5.2.2.4.3 Determination of protein concentration 
Protein concentration was calculated as described in chapter 2 section 2.2.2.1.2.6. 
5.2.2.4.4 Sodium dodecyl sulphate polyacrylamide protein gel electrophoresis 
(SDS-PAGE)  
SDS-PAGE was performed as described in chapter 2 section 2.2.2.1.2.7.  
5.2.2.4.5 Transfer of proteins from SDS gel to nitrocellulose membrane 
Transfer of proteins from SDS gel to nitrocellulose membrane SDS-PAGE was 
performed as described in chapter 2 section 2.2.2.1.2.9. 
5.2.2.4.6 Immunoblotting for detection of protein expression  
In general, Immunoblotting for detection of protein expression was performed as 
described in section 2.2.2.1.2.10 using different primary and secondary antibodies. 
Here, the membrane was incubated on a shaker with a primary antibody in an 
appropriate concentration (Table 5.1) at 4°C overnight. The following day, the 
membrane was washed with TBS-T, 3 times to remove the primary antibody and then 
incubated with secondary antibody with an appropriate concentration (Table 5.1) for 
1 hour at RT. To standardise the loading difference, the expression level of β-actin 
expression was examined. The expression level (EL) of each target protein was 
calibrated using the formula listed below.  
Normalised EL of target protein= EL of target protein/ El of β-actin 
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Target protein Primary antibody Secondary antibody 
PPARγ Monoclonal Mouse Anti-
Human PPARγ (1:200) 
Polyclonal Rabbit Anti- 
Mouse IgG-HRP 
(1:2000) 
p-PPARγ Polyclonal Rabbit Anti-
Human p-PPARγ (1:200) 
Polyclonal Goat Anti-
Rabbit IgG-HRP (1:2000) 
β-actin Monoclonal Mouse Anti- 
β-actin (1:5000) 
Polyclonal Rabbit Anti-
Mouse IgG-HRP 
(1:2000) 
 
Table 5. 1 Primary and secondary antibodies used in Western blot. 
 
5.2.2.5 Statistical analysis 
Student’s t-test were carried out using GraphPad Prism software to compare the 
differences of the means between control and experimental groups. All experiments 
were conducted in triplicate and repeated at least three times. The difference is 
regarded as significant when p<0.05; in the results, p value is represented by asterisks 
as follows:  *, P < 0.05; **, P < 0.001; ***, P < 0.0001. 
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5.3 Results 
5.3.1 SBFI26 and dmrFABP5 inhibited tumourigenicity of PC3-M cells in 
nude mice in a similar way to PPARγ antagonist  
PC3-M cancer cells (2×106) in 200µL PBS were subcutaneously implanted into right 
flank of Balb/c male nude mice and the FABP5 inhibitors were injected 
subcutaneously to compare their anticancer effect with that of PPARγ antagonists. In 
the first round, 5 groups of mice (8 each) were subcutaneously injected with PBS 
(control), SBFI26 (1mg/kg) and dmrFABP5 (20µg/kg) every other day for 4 weeks; 
started from day 1 or from day 7 after the inoculation. Tumour sizes were measured 
every 3-4 days and the volume calculated by the formula of L×W×H×0.5236. 
Although remarkable suppression of tumour growth was found in mice treated with 
both inhibitors (Fig. 5.2), no significant difference in treatment effect was found when 
inhibitors were applied from day 1 or from day 7 after the inoculation. On termination, 
average volumes of tumours in groups treated with SBFI26 and dmrFABP5 were 302 
± 86 mm3 and 161± 61 mm3, respectively, compared to 627± 120 mm3 in the control 
group; significant suppressions of 52% and 75% (Student's t test, p < 0.001 and P < 
0.0001), respectively (Fig. 5.1, A and B). When tumours were weighed on termination, 
the difference amongst control and treated groups were similar to those measured by 
tumour volume (Fig. 5.3). 
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Figure 5.1 Effect of SBFI26 and dmrFABP5 on tumorigenicity in prostate cancer 
xenograft mice. A, Average volume of tumours produced by each group of male nude 
mice after subcutaneous inoculation of PC3-M cells and treated with PBS (control) or 
SBFI26 (1mg/kg) for 4 weeks; started on day 1 and day 7 after inoculation. Values are 
plotted as mean ± SE (error bars) (n = 8); difference between the control group and the 
experimental groups were assessed by 2-tailed unpaired Student’s t test, **, P < 0.001. 
B, Average volume of tumours produced by each group of male nude mice after 
subcutaneous inoculation of PC3-M cells and treated with PBS (control) or dmrFABP5 
(20µg/kg) for 4 weeks, starting on day 1 or day 7 after inoculation. Values were plotted 
as mean ± SE (error bars) (n = 8); differences between the control and the experimental 
groups were assessed by 2-tailed unpaired Student’s t test ***, P < 0.0001.   
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Figure 5.2 Representative mouse and its corresponding tumours from control (1), 
SBFI26 (2) and dmrFABP5 (3) groups. 
 
 
 
 
 
 
 
Figure 5.3 Average weight (mg) of tumours from control and treated groups of 
mice. Values were plotted as mean ± SE (error bars). The differences between the 
control and the experimental groups were assessed by 2-tailed unpaired Student’s t test 
**, P < 0.001; ***, P < 0.0001. 
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day 7 after inoculations: SBFI26 plus dmrFABP5; GW9662; and SBFI26 plus 
dmrFABP5 plus GW9662 (Fig. 5.5). Compared to the average size of tumours (774 ± 
202 mm3) in control group, the average sizes of tumours in these 3 groups of mice 
were 186 ± 25 mm3, 252 ± 84 mm3, and 244 ± 22 mm3, respectively, highly significant 
reductions by 76%, 67%, and 68%, respectively (Student's t test, p < 0.0001) (Fig. 
5.4). No significant differences were found in inhibitory effects between these 3 
treatments. When tumour weight was measured at autopsy, any differences between 
control and treated groups were similar to those measured by tumour volume (Fig. 
5.6). 
 
 
 
 
 
 
 
 
Figure 5.4 Effect of SBFI26, dmrFABP5 and GW9662 on tumorigenicity in 
prostate cancer xenograft mice. Average volume of tumours produced by each group 
of male nude mice after subcutaneous inoculation with PC3-M cancer cells and treated 
with PBS (control), SBFI26 (1mg/kg) plus dmrFABP5 (20µg/kg), PPARγ antagonist 
(GW9662;1mg/kg) and the combination of SBFI26, dmrFABP5, GW9662 for 4 
weeks. Values were plotted as mean ± SE (error bars) (n = 5); differences between the 
control and the experimental groups were assessed by 2-tailed unpaired Student’s t test 
***, P < 0.0001. 
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Figure 5.5 Representative mouse and its corresponding tumour. Control (1), 
GW9662 (2), SBFI26 and dmrFABP5 (3) and the combination of SBFI26, dmrFABP5, 
GW9662 (4) groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Average weight (mg) of tumours in the control and experimental 
groups of mice. Values were plotted as mean ± SEM (error bars). Differences between 
the control and the experimental groups were assessed by 2-tailed unpaired Student’s 
t test **, P < 0.001; ***, P < 0.0001.  
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5.3.2 SBFI26 inhibited fatty acid uptake of FABP5 in PC3-M cells  
5.3.2.1 Determination the fatty acid uptake of different prostate cells 
Fatty acid uptake assay offers a sensitive and simple method for the measurement of 
long-chain fatty acids (LCFAs) uptake in cells containing fatty acid transporters. The 
red fluorescence-labelled LCFA, BODIPY 558/568C12 was used as a fluorescently 
labelled fatty acid that permits fatty acid transport to be measured using flow 
cytometry. To identify the uptake of fatty acids in benign prostate epithelial cells 
(PNT2), and low (LNCaP), moderately (22RV1) and highly (PC3-M) malignant 
prostate cancer cells. Cells were incubated with BODIPY for 30 mins at 37°C and the 
fluorescence intensity of cells was measured with an EPICS XL Cytometer at the 
wavelength of 570nm. Unstained cells (without BODIPY) were present in M1 zone 
(Fig.5.7, A) but fluorescence-labelled BODIPY stained cells were present in the M2 
zone after 30mins incubation with BODIPY (Fig. 5.7, B). The fatty acid uptake of 
PNT2, LNCaP, 22RV1and PC3-M cells were 68, 66, 88 and 93%, respectively. In 
contrast to benign PNT2, significantly more than 20% and 25% of cells took up fatty 
acid in moderately malignant 22RV1 and highly malignant PC3-M (Student's t test p 
< 0.01 and p < 0.001) cells, respectively. Levels of fatty acid uptake between benign 
PNT2 and weakly malignant LNCaP cells were similar (Fig. 5.8). 
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Figure 5.7 Fatty acid uptake of different prostate epithelial cell lines. A, 
Representative histograms for unstained PNT2, LNCaP, 22RVI and PC3-M cells 
without adding BODIPY-labelled fatty acid. The marker M1 highlights negative peaks 
of the subclass control. B, Representative histograms for fluorescence of 
stained PNT2, LNCaP, 22RVI and PC3-M cells 30min after adding BODIPY-labelled 
fatty acid and the marker M2 is placed to the right of M1 to highlight positive events 
(total percentage of cells with BODIPY-labelled fatty acid). 
 
 
 
 
 
 
 
 
 
Figure 5.8 Percentages of cells taking up BODIPY-labelled fatty acid from 
different prostate epithelial cell lines. Values were plotted as mean ± SE (error bars). 
The differences between groups were assessed by 2-tailed unpaired Student’s t test.  *, 
P < 0.01; **, P < 0.001. 
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5.3.2.2 Effect of SBFI26 or dmrFABP5 on the fatty acid uptake of FABP5 in 
PC3-M cells 
To investigate possible effect of FABP5 inhibitors on fatty acid uptake of PC3-M cells, 
Fatty acid uptake assay was performed to determine the effect of increasing 
concentration of SBFI26 or dmrFABP5 on fatty acid uptake in PC3-M cells. PC3-M 
cells were seeded in 6 well plates for 24h. The medium was replaced with 2ml of 
solution (PBS containing 5% FBS) containing 2µM of BODIPY and different 
concentration of SBFI26 (50-200µM) (Fig. 5.9, A) or dmrFABP5 (25-75µM) (Fig. 
5.9, B) with a blank solution to make competition between inhibitors and BODIPY for 
binding with FABP5. When inoculated with SBFI26, cellular fatty acid uptake into 
PC3-M cells was reduced from 92.9% in the control in a dose-dependent manner, the 
significant maximum reduction with 100µM was 67.7% (Student's t test p< 0.001). 
No reduction was produced by dmrFABP5 on fatty acid uptake in PC3-M cancer cells 
(Fig. 5.10). 
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Figure 5.9 Inhibitory effect of increasing concentration of SBFI26 or dmrFABP5 
on fatty acid uptake in PC3-M cells.  A, Representative histograms for fatty acid 
uptake of PC3-M cells at a fixed concentration of BODIPY-labelled fatty acid with 
different concentrations of SBFI26. M1, unstained cells; M2, stained cells. B, 
Representative histograms for fatty acid uptake of PC3-M cells at a fixed concentration 
of BODIPY-labelled fatty acid with different concentrations of dmrFABP5. M1, 
unstained cells; M2, stained cells.  
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Figure 5.10 Percentages of cells with fatty acid uptake from PC3-M control 
(untreated) and those treated with different concentrations of SBFI26 or 
dmrFABP5 for 30min with a fixed concentration of BODIPY. Fluorescence 
intensity of each cell line was measured with an EPICS XL Cytometer (Beckman) at 
570nm and data analysis was performed with SYSTEM II™ Software. Values were 
plotted as mean ± SE (error bars). The differences between the control and the 
experimental groups were assessed by 2-tailed unpaired Student’s t test. **, P < 0.001. 
 
5.3.3 SBFI26 and dmrFABP5 inhibited PPARγ activation  
The effect of FABP5 inhibitors on levels of PPARγ or biologically active 
phosphorylated PPARγ (p-PPARγ1 and p-PPARγ2) in benign and malignant prostate 
epithelial cells was checked by using Western blot. Western blot detected a PPARγ 
band at 55kDa in most of the cell lines used (Fig. 5.11, A). When the level of PPARγ 
in PNT2 was set at 1.0, relative levels of PPARγ in LNCaP, 22RV1, DU145, PC3 and 
PC3-M were 0.70 ± 0.03, 0.02 ± 0.01, 0.22 ± 0.001, 0.4 ± 0.0 and 0.64 ± 0.04, 
respectively (Fig. 5.11, B). When Western blot was used to detect p-PPARγ, 2 bands 
representing isoforms of p-PPARγ1 and p-PPARγ2 were found at 54 and 57kDa, 
respectively (Fig. 5.12, A). If levels of p-PPARγ1 and p-PPARγ2 in PNT2 were set at 
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and 9.5 ± 0.5; 25.4 ± 1.8 and 47.0 ± 1.7; 26.99 ± 1.72 and 85.5 ± 14.5; 12.08 ± 1.8 and 
30 ± 5; and 21.99 ± 2.63 and 80 ± 5, respectively (Fig. 5.12, B).  Levels of p-PPARγ, 
particularly p-PPARγ2, were significantly increased in all malignant cell lines 
(Student's t test, p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 The expression of PPARγ in benign and malignant prostate epithelial 
cells.  A, Western blot of PPARγ expression in benign and malignant prostate 
epithelial cells.  B, Quantitative assessment of levels of PPARγ in benign and 
malignant prostate epithelial cells. The level of PPARγ in the benign prostate PNT2 
cells was set at 1; levels in the other prostate cell lines were obtained by comparison 
with that in PNT2. For each Western blot, anti-β-actin was incubated with the same 
blot to normalize for possible loading errors. Results (mean ± SE) were obtained from 
3 separate experiments. 
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Figure 5.12 The expression of p-PPARγ in benign and malignant prostate 
epithelial cells. A, Western blot analysis of p-PPARγ1 and p-PPARγ2 in benign and 
malignant prostate epithelial cells. B, Quantitative assessment of the levels of p-
PPARγ1 and p-PPARγ2 in prostate cells. Levels of p-PPARγ1 and 2 in benign PNT2 
cells were set at 1; levels in the other prostate cells were obtained by comparison with 
those in PNT2. For each Western blot, anti-β-actin was incubated with the same blot 
to normalize for possible loading errors. Results (mean ± SE) were obtained from 3 
separate experiments and the differences between the benign PNT2 cells and other 
cells in each experiment were assessed by 2-tailed unpaired Student’s t test. **, P < 
0.001.  
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centrifuged and the protein concentration was measured using Bradford assay. Proteins 
from cell lysates were subjected to SDS-PAGE and the proteins were transferred to 
nitrocellulose membrane. PC3-M cells were treated with SBFI26, PPARγ antagonist 
GW9662, PPARγ agonist Rosiglitazone, dmrFABP5 and a combination of SBFI26 
and dmrFABP5 for 24 hours (Fig. 5.13, A). If levels of p-PPARγ1 and p-PPARγ2 in 
untreated cells were set at 1 and 1, the levels after treatment with SBFI26, GW9662 
and dmrFABP5 were reduced significantly by 44% and 46%; 52% and 51%; and 50% 
and 65%, respectively (Student's t test, p< 0.001). Interestingly, treatment with a 
combination of SBFI26 and dmrFABP5 dramatically reduced the level of p-PPARγ2 
by 90%, whereas it also reduced the levels of p-PPARγ1 by 52%. However, those 
treated with rosiglitazone, significantly increased levels of both p-PPARγ isoforms 
were observed (Student's t test, p < 0.01) (Fig. 5.13, B). For LNCaP cells which 
expressed low levels of p-PPARγ1 and 2, treatments with wtrFABP5 increased levels 
of both isoforms by 1- and 0.9- fold, respectively. However, these increases were 
reversed completely by adding dmrFABP5. Furthermore, addition of dmrFABP5 even 
reduced the level of p-PPARγ2 by 5-times (Student's t test, p < 0.001) to a level lower 
than that obtained in pretreatment (Fig. 5.14, A and B). When treatments with 
wtrFABP5, SBFI26 and dmrFABP5 were tested in androgen-sensitive 22RV1 cells 
(Fig. 5.15, A), wtrFABP5 significantly increased levels of both p-PPARγ1 and 2 
(Student's t test, P < 0.01) (Fig. 5.15, B). However, treatments with the inhibitors 
suppressed the levels of both p-PPARγ isoforms.  
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Figure 5.13 Effects of inhibitors and activators on levels of p-PPARγ in PC3-M 
cells. A, Effect of 24 h treatments with SBFI26, PPARγ antagonist (GW9662), PPARγ 
agonist (Rosiglitazone), dmrFABP5 and a combination of SBFI26 and dmrFABP5 on 
levels of p-PPARγ1 and 2 in PC3-M cells. B, Quantitative assessment of p-PPARγ1 
and 2 levels in PC3-M cells after treatments with SBFI26, GW9662, Rosiglitazone, 
dmrFABP5, and a combination of SBFI26 and dmrFABP5. Levels of both p-PPARγ1 
and 2 in untreated PC3-M cells were set at 1; levels in the other treated cells were 
obtained by comparison with those in untreated PC3-M. For each Western blot, anti-
β-actin was incubated with the same blot to normalize for possible loading errors. 
Results (mean ± SE) were obtained from 3 separate experiments and the differences 
between the control and the treatments in each experiment were assessed by 2-tailed 
unpaired Student’s t test. *, P < 0.05; **, P < 0.001.  
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Figure 5.14 Effects of wtrFABP5 and dmrFABP5 on levels of p-PPARγ in LNCaP 
cells. A, Effect of 24h treatments with wtrFABP5 and a combination of wtrFABP5 
and dmrFABP5 on levels of p-PPARγ1 and 2 in LNCaP cells. B, Quantitative 
assessment of levels of p-PPARγ1 and 2 in control (untreated) and in treated LNCaP 
cells. Levels of p-PPARγ1 and 2 in control LNCaP cells were set at 1; levels in the 
other treated cells were obtained by comparison with those in control. For each 
Western blot, anti-β-actin was incubated with the same blot to normalize for possible 
loading errors. Results (mean ± SE) were obtained from 3 separate experiments and 
the differences between the control and the treatments in each experiment were 
assessed by 2-tailed unpaired Student’s t test. *, P < 0.05; **, P < 0.001.  
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Figure 5.15 Effects of wtrFABP5 and FABP5 inhibitors on levels of p-PPARγ in 
22RV1 cells. A, Effect of 24 h treatments with wtrFABP5, SBFI26 and dmrFABP5 
on levels of p-PPARγ1 and 2 in 22RV1 cells. B, Quantitative assessment of levels of 
p-PPARγ1 and 2 in 22RV1 cells. Levels of both p-PPARγ1 and 2 in the control were 
set at 1; levels in the other treated cells were obtained by comparison with those in 
controls. For each Western blot, anti-β-actin was incubated with the same blot to 
normalize for possible loading errors. Results (mean ± SE) were obtained from 3 
separate experiments and the differences between the control and the treatments in 
each experiment were assessed by 2-tailed unpaired Student’s t test. *, P < 0.05; **, 
P < 0.001.  
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5.4 Discussion  
Previous work on investigating the molecular mechanisms involved in the tumour-
promoting role of FABP5, our research team identified a FABP5-PPARγ-VEGF 
signalling transduction axis, and it is this axis, rather than AR modulated route, is the 
dominant signalling route in CRPC cells (217). It has been identified that prostate 
cancer cell lines and clinical samples exhibit elevated levels of PPARγ (249,250). To 
find out the possible molecular mechanisms on how SBFI26 and dmrFABP5 inhibited 
the malignant progression of the prostate cancer cells, we investigated the role of the 
PPARγ antagonist, GW9662, on tumour suppression in mouse. Our results showed 
that the treatment of PC3-M cells with GW9662 produced a similar suppression of 
tumour growth to those produced by SBFI26 and dmrFABP5 (Student's t test, p < 
0.0001) (Fig. 5.4) (Fig. 5.6). These results indicate that SBFI26 and dmrFABP5 may 
played their suppressive role through affecting PPARγ and thus the suppressive 
mechanisms of both inhibitors may be related to the FABP5-PPARγ-signal 
transduction pathway. 
In this work, no difference on the tumour-suppression effect was observed when the 
administration of the inhibitors started either at day 1 or at day 7 after the inoculation 
of the cancer cells (Fig. 5.1). No significant difference was observed in tumour-
suppression effect obtained by each inhibitor alone or by the combination of both (Fig. 
5.3) (Fig. 5.6). These results suggested that there was no synergistic treatment effect 
when both inhibitors were used in a combined manner. 
In the work described in chapter 3, the highly binding affinity of SBFI26 with FABP5 
was found when DAUDA displacement assay was performed. In this set of 
experiments, we used the BODIPY-labelled fatty acid analogues to test the effect of 
SBFI26 and dmrFABP5 on fatty acid uptake of the CRPC cells. The results showed 
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that fatty acid uptake by the highly malignant PC3-M cells was 25% higher than that 
by the benign prostate PNT2 cells (mean ± SE) (Student's t test p < 0.001) (Fig. 5.7) 
(Fig. 5.8), indicating that the increased fatty acid uptake is positively related to the 
high degree of malignancy. When the possible effect of SBFI26 on fatty acid uptake 
was studied, 100µM of SBFI26 produced a reduction of fatty acid uptake by 25% in 
30 min incubation (mean ± SE) (Student's t test p < 0.001) (Fig. 5.9, A) (Fig. 5.10). 
These results suggest that SBFI26 may be a competitive inhibitor of fatty acids which 
competitively binds to FABP5 and hence prevent extra amount of intra- and extra-
cellular fatty acids from being transported into the cytoplasm. The reduced fatty acid 
uptake produced by SBFI26 may result in a remarkable reduction or cessation of the 
stimulation of PPARγ by fatty acids. Thus PPARγ may no longer be able to upregulate 
the down-stream cancer-promoting genes, such as VEGF, and to suppress apoptosis 
(251,252). Surprisingly, dmrFABP5 did not produce any noticeable changes in fatty 
acid uptake of PC3-M cells (Fig. 5.9, B) (Fig. 5.10), which suggests that dmrFABP5 
acts through a mechanism different from that of SBFI26. 
Over expression of FABP5 and PPARγ has been observed in malignant prostate cancer 
cells. Therefore, suppression the biological activity of FABP5 may limit the expression 
of PPARγ and hence inhibit the expression of its down-stream controlling genes such 
as VEGF. In this axis, the role of PPARγ is essential. Although the total PPARγ 
expressed in the malignant cell lines was not higher than that in the benign PNT2 cells 
(Fig. 5.11, A and B), the biologically-active PPARγ isoforms (or phosphorylated 
PPARγ) p-PPARγ1 and p-PPARγ2 (250,253) both increased with increasing cellular 
malignancy (Fig. 5.12, A and B). Both activated PPARγ isoforms were increased by 
wtrFABP5 stimulation and these increases were inhibited by dmrFABP5 (Fig. 5.14, A 
and B) in LNCaP cells which expressed low levels of activated PPARγ. In contrast, 
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PPARγ isoforms in PC3-M cells, which expressed high levels, were further increased 
by rosiglitazone (PPARγ agonist). But their levels greatly reduced by treatments with 
SBFI26, dmrFABP5, GW9662, and by SBFI26 plus dmrFABP5 (Fig. 5.13, A and B). 
These results suggest that both SBFI26 and dmrFABP5 may act as inhibitors to block 
the stimulation of fatty acids transported by natural wild type FABP5 and hence 
prevent activation of PPARγ.  
In androgen-responsive, moderately-malignant 22RV1 cells, both SBFI26 and 
dmrFABP5 produced a reduction in both PPARγ activated isoforms by an average of 
33.5% (Fig. 5.15, A and B). This level of reduction was much smaller than that caused 
by SBFI26 and dmrFABP5 in the androgen-independent, highly malignant PC3-M 
cells (average reduction was about 50%). These results suggest that the proportion of 
activated PPARγ regulated by the FABP5-related pathway was much higher in PC3-
M cells than that in 22RV1 cells, a result which suggests that treatment by suppression 
of the FABP5-pathway is more effective in CRPC cells.  
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Chapter Six 
General discussion, Conclusions and Future work 
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6.1 General discussion 
Since it was discovered that prostate cancer cell growth is dependent on the promoting 
effect of male hormone supplied through peripheral blood circulation (108), ADT 
targeting AR and circulating male hormone has been the main therapeutic method to 
treat prostate cancer patients during the past 4 decades. ADT is an effective treatment 
as an initial therapy. However, the disease relapses within a period of time with a more 
aggressive form, called androgen-independent prostate cancer or CRPC, this does not 
respond to ADT effectively since the growth and progression of CRPC cells do not 
rely on circulation hormone anymore. The conversion of androgen-dependent cancer 
cells to androgen independent CRPC cells is a fundamental change and the molecular 
mechanisms involved in this change is not fully understood. Currently, there are 
several different hypotheses on how the androgen-dependent cells were transformed 
to androgen-independent cells. The main theory is that the biological sensitivity of AR 
is amplified after the first round of ADT to such an extent that even micro-quantities 
of remaining hormone in peripheral blood can still promote the malignant progression 
of CRPC cells (254,255). Thus, further ADT on CRPC was a general clinical practice. 
However, an opposite opinion to this practice was proposed recently to suggest that 
ADT may lead to a treatment dead end (256). Our previous work suggested that AR 
may not be relevant to malignant progression of CRPC and that targeting FABP5-
PPARγ-VEGF axis, rather than the AR-mediated signalling pathway, which was 
gradually replaced by the FABP5-related pathway, could be a more effective way for 
CRPC treatment (217). It has been found that ADT had little effect to suppress fatty 
acid synthase expression which is important enzyme for the control of fatty acid 
synthesis (188). It has been confirmed that cancer cells rely on fatty acids as cellular 
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building and production of signalling molecules (233) and play an important role in 
carcinogenesis and metastasis of cancer cells (234). 
High expression of FABP5 has long been considered as a promoter for cell growth and 
metastatic in prostate cancer (190). FABP5 delivers fatty acids and enhance the 
transcriptional activity of their nuclear receptor PPARγ in prostate cancer cells 
(211,217,257). Targeting FABP5 biological function may constitute a new way for 
therapy of CRPC. Although, siRNA knockdown of FABP5 was previously shown an 
effectively inhibit CRPC cells growth in vivo (216), the efficient delivery of siRNA 
remains problem and very unstable and thus loss their function quickly. Here for the 
first time, we targeted the FABP5 and its related signal transduction pathway and 
successfully used both a chemically-synthesized inhibitor (SBFI26) and a bio-inhibitor 
(dmrFABP5) for FABP5 to treat CRPC in nude mice by suppressing the biological 
activity of FABP5. 
6.1.1 DmrFABP5 and SBFI26 can be used as a bio-inhibitor and a lead 
chemical inhibitor of FABP5  
The malignancy-promoting function of FABP5 in CRPC cells depends on its structural 
integrity of the 3 key amino acids which consist of the fatty-acid-binding motif 
(192,226,229). In this work, we produced a biologically inactive FABP5 (dmrFABP5) 
by making double mutation to change 2 of the 3 key amino acids in the fatty acid-
binding motif and used it as a bio-inhibitor of the wild type FABP5 to treat CRPC. The 
mutant protein dmrFABP5 has the same structure as wtrFABP5, but it is incapable of 
binding to fatty acids (Fig. 2.9) (Fig. 2.10). Our results confirmed that dmrFABP5 
incapable of binding to fatty acids can be used as a bio-inhibitor to inhibit the 
biological activity of the native FABP5 inside the CRPC cells. The chemically-
synthesized inhibitor SBFI26 can competitively bind to the wtrFABP5 in a similar 
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affinity to that of the best fatty acid (Linoleic acid) (Fig. 3.4). Linoleic acid and SBFI26 
are the best fatty acid and lead compound with high binding affinity Ki value 1.58 and 
1.69 µM respectively (Table 3.1). Therefore, SBFI26 can be used as a FABP5 
inhibitor to prevent the excessive amounts of fatty acids being transported to activate 
PPARγ in CRPC cells.  
6.1.2 SBFI26 and dmrFABP5 are potent inhibitors on malignant 
characteristics of PC3-M cells in vitro and in vivo 
PC3-M (CRPC cells) is an extremely malignant cell line and expressing high levels of 
FABP5 and PPARγ (217,245,246). Suppression of FABP5 biological functions may 
be a therapeutic approach for treatment of CRPC. SBFI26 and dmrFABP5, the potent 
inhibitors of FABP5 function allowed us to test the effects on the growth and 
metastasis of PC3-M cell lines in vitro and in vivo. 
In vitro results showed that both SBFI26 and dmrFABP5 can suppress the malignant 
characteristics of PC3-M CRPC cells via inhibiting the biological activity of FABP5. 
When tested in vivo, SBFI26 and dmrFABP5 were highly effective in suppressing both 
the primary tumours growing in the prostate gland (by 4.9-fold and 13-fold, 
respectively) (Fig. 4.13) and subcutaneous tumours growing in the flank (by 52% and 
75%, respectively) (Fig. 5.1). In addition, SBFI26 and dmrFABP5 treatment 
suppressed metastases of the tumours growing in the prostate gland by 50% and 100%, 
respectively compared to 0% in the control group (Fig. 4.14). Comparing with SBFI26, 
the anti-tumour effect of dmrFABP5 was 2.7-fold higher in tumours growing in the 
prostate gland (Fig. 4.13), and 30% higher in tumours growing in the flank (Fig. 5.1). 
In addition, the anti-metastatic effect of dmrFABP5 was 2-folds of that of SBFI26 
(Fig. 4.14). 
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The migrating ability and invasiveness are essential characteristics for cancer cells to 
be able to metastasise to the secondary sites of the body (258). Cancer cells own a 
unique ability to adapt themselves to different secondary environments (259). After 
cancer cells acquire the ability to penetrate the tissues, the process of invasion is 
initiated as these motile cancer cells pass through the basement membrane and 
penetrate the vascular circulation (260). The pathological processes of cancer cell 
invasion and metastasis is regulated by a number of molecules that have been 
identified as having important roles to play in modulating signalling pathways leading 
to malignant progression (260). It has been confirmed that high level of fatty acids 
uptake provided an important source of signalling molecules that led to the promotion 
of cell migration and invasion (261). Our results in this study showed that suppression 
the biological function of FABP5 by both inhibitors inhibited the migration and 
invasion of PC3-M cells in vitro and in vivo. These results suggest that both SBFI26 
and dmrFABP5 are potent inhibitors on malignant progression of CRPC cells in vitro 
and in vivo and the suppression effect of the bio-inhibitor dmrFABP5 is much stronger 
than that of the chemically synthesised SBFI26. 
6.1.3 Possible problems to use PPARγ agonist and antagonist as direct 
therapeutic agents for CRPC  
Investigations in the past few years established that there is a novel FABP5-PPARγ-
VEGF signalling pathway leading to malignant progression of CRPC cells (217). 
PPARγ  is highly expressed in adipose tissue and plays an important role to regulate 
adiposity and insulin sensitivity (262). The potential of using PPARγ as a direct target 
for cancer treatment has been widely investigated during the past decade but still 
remains debatable. Both PPARγ agonist and antagonist have shown some anticancer 
effect through PPARγ-dependent and -independent pathways (263,264). However, 
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there are safety concerns: side effects, including dose limited side effects linked to 
PPARγ drug treatments, increased the risk of cardiac failure and potential 
carcinogenicity in rodents (265). It has been found that PPARγ stimulation using 
synthetic agonists (high doses) suppresses in vitro and in vivo growth of PC3 prostate 
cell lines (246,266,267). However, evidence suggested that these agonists may work 
through a PPARγ-independent pathway to induce cell cycle arrest and apoptosis in 
prostate cancer (264,266,268). In addition, PPARγ agonist inhibitors have been shown 
to suppress cell growth and induce apoptosis of prostate cancer cells by both PPARγ-
dependent (genomic) and - independent (non-genomic) signalling pathways. Thus, it 
remains unclear whether the non-genomic effects are essentially on PPARγ pathways 
(269). On the other hand, although most of Thiazolidinediones (TZDs) are potent 
PPARγ agonists, they also have some affinity to PPARα or PPARβ/δ (270,271). In 
addition, it has been showed that TZDs had inhibitory effects on cholesterol 
biosynthesis, independently from PPARγ pathway (272). 
It was proved that the irreversible, potent and specific PPARγ antagonist (GW9662) 
prevented activation of PPARγ, suppressed growth of cancer cells and efficiently 
blocked tumour growth in an animal model (263,273,274). However, the results from 
another study indicated that GW9662 has a protective role in cancer by blocking 
cannabinoids-induced apoptosis in xenograft-induced tumours in mice (275). It was 
found that down-regulation of PPARγ using the GW9662 compound reduced the 
malignant characteristic of PC3 and PC3M cells (276). GW9662 has a significant 
effect on adipose tissue weight and glucose metabolism in vivo. Gene expression 
analyses showed that GW9662 suppressed the expression of many lipogenic genes, for 
example FASN which is important for fatty acid synthesis (273). If GW9662 is 
administrated continuously for a long time, it can reduce weight and suppress any 
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increase in the amount of visceral adipose tissue (277). In addition, GW9662 
upregulates the expression of several genes associated with the transcription, 
processing, splicing and translation of RNA (278). Thus, due to PPARγ versatile 
nature, directly targeting PPARγ by its agonists and antagonists as a treatment for 
CRPC is difficult to achieve.   
6.1.4 Possible problems to use anti-VEGF therapy in the treatment of CRPC  
VEGF protein has been detected in prostate cancer, but not in BPH or normal prostate 
samples (279). Over-expression of FABP5 induced metastasis through up-regulation 
of VEGF and thus VEGF played a crucial role in malignant progression of CRPC cells 
(190,191). It is known that increases in uptake of fatty acids will contribute to the 
switch in energy production from aerobic to anaerobic sources as well as the 
downstream effect of increased production of VEGF to stimulate angiogenesis. These 
changes are induced by increased expression levels of FABP5 and may contribute to 
the amelioration of the effects of chronic hypoxia which is known to occur as prostate 
cancer develops (280,281). Suppressing FABP5 gene in CRPC cells has reduced the 
expression of VEGF and down-regulated angiogenesis (189,190). In androgen-
dependent prostate cancer cells, androgen has mediated the up-regulation of VEGF 
expression through a Sp1/Sp3 binding site in the VEGF core promoter (282). However, 
in CRPC cells, it has been found that androgen-Sp1/Sp3-VEGF signalling pathway 
disappeared as the cells gradually lost their androgen dependency and was replaced by 
the FABP5-PPARγ-VEGF pathway (217). It was suggested that the suppression of 
tumorigenicity of CRPC cells by knocking down PPARγ gene was achieved through 
inhibiting the biological activity of VEGF (217). Anti-angiogenic treatment with 
VEGF inhibitors such as Bevacizumab, Sunitinib or Sorafenib reduced progression 
rate of CRPC and increased patient survival time (283). However, anti-VEGF therapy 
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in the treatment of cancer can be accompanied by a variety of side effects, which are 
increased by concurrent chemotherapeutic agents (284). The most common adverse 
effect for anti-angiogenic treatment are hypertension, proteinuria, upper respiratory 
infection, epistaxis,  anorexia, headache, dyspnea, stomatitis, fatigue (285). Infrequent 
serious side events include haemorrhage, arterial thromboembolic events, 
gastrointestinal perforation, wound healing difficulties, nephrotic syndrome, and 
congestive heart failure (286). Thus, due to the side effect of anti-VEGF therapy, 
directly targeting VEGF by its inhibitors as a treatment for CRPC is difficult to 
achieve.   
6.1.5 PPARγ antagonist, GW9662, produced a similar suppression of tumour 
growth to that obtained by SBFI26 and dmrFABP5  
To compare the effect of SBFI26 and dmrFABP5 with GW9662 which is specific 
target to PPARγ on tumour suppression in mice. The results in current work showed 
that the treatment of CRPC cells with GW9662 produced a similar suppression of 
tumour growth to that obtained by SBFI26 and dmrFABP5 (Fig. 5.4) (Fig. 5.6). This 
result suggests that the suppressive mechanisms of both inhibitors may be similar to 
that achieved by GW9662 which is related to the FABP5-PPARγ-signal transduction 
pathway. In addition, we did not observe similar changes when tumour was treated 
with first and seven-days after inoculation, indicate that there is no effect in the tumour 
incidence (Fig. 5.1). Furthermore, the results showed that no significant changed in 
tumour growth between combination treatment and each inhibitor alone (Fig. 5.3) 
(Fig. 5.6). Although our results in this study showed that GW9662 produced 
significant reduction in the sizes of primary tumours developed from cancer cells 
inoculated subcutaneously in flanks of the mice, using GW9662 as a therapeutic 
reagent is hardly possible because of its none-specificity. 
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After SBFI26 and dmrFABP5 treatment, primary tumours became much smaller in the 
treated mice. The reduction in the number of metastases in the treated mice may be 
related to the decrease in sizes of primary tumours. It has been reported that reduction 
in the size of primary tumour in a patient with prostate metastasis may be used as a 
further therapeutic indication for a relatively prolonged patient survival time (287). 
From biological point of view, growth and expansion of primary tumours request 
increased level of blood supply and hence the increased angiogenesis. The newly 
increased blood vessels can provide increased escaping routes by which cells can leave 
the primary tumour and arrest in a new organ in the secondary sites (288). It has been  
known that treatment of primary tumour may not only have a inhibitive effect on the 
localized tumour growth but also in the distant tumours that grow as metastasis (289). 
Thus, the results obtained in this work suggest that both inhibitors may delay the 
progression of metastatic disease and may translate to prolonged survival, especially 
when treated with dmrFABP5. 
6.1.6 SBFI26 inhibited the biological function of FABP5 through block its 
transportation of fatty acids  
Based on the highly binding affinity of SBFI26 with FABP5, we identify a mechanism 
of cellular inhibition whereby SBFI26 suppress FABP5 to transport fatty acids by 
using BODIPY-labelled fatty acid analogues. BODIPY binds to FABPs with high 
affinity at a site similar to that for the natural fatty acid, endoplasmic reticulum, 
mitochondria, and lipid droplets in cells (248).  
Our results of FABP5 expression in benign and malignant prostate cells using 
BODIPY observed that the highly malignant prostate cancer PC3-M cells were 25% 
higher uptake of BODIPY compared to benign prostate PNT2 cells (Fig. 5.7) (Fig. 
5.8). This results suggest that the highly expression of FABP5 seems to be the cause 
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of that difference in PC3-M and the other 75% BODIPY uptake is related to bind with 
other cellular compartments and the similar results have been observed by others 
(290). It has been confirmed that BODIPY provide a useful drug discovery tool as a 
competitor to screen for inhibitors of FABPs into a variety of cell types (291). The 
results of fatty acid uptake assay using BODIPY-labelled fatty acid analogues showed 
that addition of SBFI26 to PC3-M cells inhibited BODIPY uptake (Fig. 5.9, A) (Fig. 
5.10). However, dmrFABP5 did not produce any noticeable changes in fatty acid 
uptake of PC3-M cells (Fig. 5.9, B) (Fig. 5.10). These results suggested that the 
mechanism of action of SBFI26 is directly prevent FABP5 from transporting fatty 
acids. SBFI26 prevented the natural cellular fatty acids from being transported into the 
cells and being delivered to PPARγ and may result in a reduction of the stimulation of 
PPARγ by fatty acids. Therefore, PPARγ is no longer able to upregulate the down-
stream cancer-promoting genes and to suppress apoptosis or promote angiogenesis 
(251,252). Since dmrFABP5 did not reduce the fatty acid uptake by PC3-M cells, it 
may act through a mechanism different from SBFI26 to interfere PPARγ.   
6.1.7 SBFI26 and dmrFABP5 act as inhibitors to prevent PPARγ to be 
activated by fatty acids transported by FABP5 
Recent study showed that the FABP5-PPARγ-VEGF signalling transduction axis, not 
the AR-initiated pathway, is a dominant route for transduction of malignant signals in 
CRPC cells (217). When FABP5 expression is increased, excessive amounts of fatty 
acids are transported into the nucleus, where they act as signalling molecules to 
stimulate their nuclear receptor PPARγ. It has been identified that prostate cancer cell 
lines and clinical samples exhibit elevated levels of PPARγ (249,250). Two 
biologically active isoforms of PPARγ, PPARγ1 and PPARγ2, are expressed in human 
tissues (250,253). In this work, for accurate quantitation of Western blots, results were 
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depended on a linear relationship between the signals (OD) and the amount of protein 
loaded. Our results showed that low malignant prostate LNCaP cells expressed low 
levels of PPARγ isoforms. Treatment of LNCaP cells with wtrFABP5 increased the 
expression of two isoforms. However, this expression was abolished by dmrFABP5 
treatment (Fig. 5.14, A and B). In addition, CRPC PC3-M cells expressed high levels 
of two PPARγ isoforms. Treatment of PC3-M cells with SBFI26 or dmrFABP5 
reduced the expression of two isoforms (Fig. 5.13, A and B). These results suggest 
that both SBFI26 and dmrFABP5 may act as inhibitors to block the stimulation of 
PPARγ by fatty acids transported by FABP5. Previous work suggested that the 
dependency of the prostate cancer cells on the FABP5-related pathway was gradually 
increased with a correspondingly reduced dependency on the AR-initiated pathway 
until the former became completely dominant (217). The results of this work showed 
that both SBFI26 and dmrFABP5 produced a reduction in both PPARγ isoforms in 
androgen-responsive, moderately-malignant 22RV1 cells by an average of 33.5% 
(Fig. 5.15, A and B). The level of PPARγ isoforms reduction in 22RV1 cells after 
treatment with SBFI26 and dmrFABP5 was much smaller than that caused in CRPC 
PC3-M cells (average reduction was about 50%). These results suggest that treatment 
by suppression of the FABP5-pathway is more effective in CRPC cells. These results 
support the previous finding that ADT would lose its effect gradually as the cancer cell 
become more independent of androgen for growth (217,256). 
6.1.8 Suppression of FABP5 and its downstream pathways reduced the 
tumorigenicity and metastases of CRPC cells 
In normal condition FABPs including FABP5 are responsible for binding hydrophobic 
ligands (fatty acids) and for transporting these ligands to the appropriate compartments 
within the normal cells (292). As fatty acids are essential for the formation of 
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membrane components, energy sources, and the stimulation of cellular signalling 
molecules during normal cell proliferation (182,199), over expression of FABP5 might 
play an important role in cancer cell proliferation. Our previous work found that 
FABP5 acted with PPARγ in a coordinated manner to promote malignant progression 
in CRPC cells and hence, PPARγ is more likely to be the receptor for the fatty acids 
transported by FABP5 (192). PPARγ is a fatty acid receptor localised in the nuclear 
membrane (198,293,294). It has been suggested that transporting fatty acids to PPARγ 
through FABP5 may be a short delivery process, after which FABP5 may return to the 
cytoplasm, rather than staying on the nuclear membrane (217). However, it has been 
confirmed that the expression of FABP5 in prostate cancer tissues localised in the 
cytoplasm and nucleus (211). It has been demonstrated that a high affinity with 
structural molecular interaction between FABPs and PPARs families by protein-
protein contacts (198,295). In addition, it was confirmed that the observed interaction 
of both proteins is independent of ligand binding (198).  
In our results, the inhibition of phosphorylation of PPARγ by SBFI26 is likely to cause 
inhibition of fatty acid uptake. It has been suggested that SBFI26 is a weak agonist of 
PPARγ (223). Since SBFI26 suppressed fatty acid uptake by replacing fatty acids 
which bind to FABP5, it is possible that some SBFI26 may be delivered to activate 
PPARγ in a weaker way than with the fatty acids. This may be the reason why SBFI26 
is a less effective inhibitor than dmrFABP5. Thus, SBFI26 interferes with the FABP5 
signalling pathway at the initial stage of this signal by binding directly to FABP5 to 
inhibit cellular fatty acid uptake. Since the structure of dmrFABP5 is very similar to 
native wild type FABP5, it is possible that dmrFABP5 may occupy the same binding 
site as native wild type FABP5 so as to prevent it from delivering fatty acids to PPARγ. 
Therefore, dmrFABP5 indirectly suppresses FABP5, works by blocking PPARγ 
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receptor and prevents it from activating the down-stream regulated cancer-promoting 
genes. Since the inhibitory effects of SBFI26 and dmrFABP5 are exerted at 2 different 
points in the same signal transduction pathway, no further suppression is anticipated 
when used in combination. 
6.1.9 Potential clinical implementation of FABP5 inhibitors in CRPC 
Clinically, ADT is a main therapy against prostate cancer, because growth of prostate 
cancer is dependent on androgen at early stages of treatment. ADT alone does not fully 
cure prostate cancer and prolonged therapy often make conversion to CRPC. 
Therefore, based on results in this study and other studies, right treatment at early 
stages of prostate cancer is important. Previous pathological studies have shown that 
FABP5 overexpression is strongly associated with prostate cancer progression and 
metastasis. Interestingly, this study indicates that inhibition the biological functions of 
FABP5 can be an effective treatment to suppress multiple steps that are important in 
tumour progression and metastasis in nude mice. The results obtained from targeting 
FABP5 biological function provided important clues for the treatment of human 
patients with CRPC and a theoretical basis for resolving some possible problems raised 
from the treatment by targeting PPARγ or VEGF. 
In summary, we have targeted the FABP5-PPARγ signalling pathway by suppressing 
the biological activity of FABP5 so that the signalling molecules fatty acids cannot be 
passed to PPARγ.  Thus, this signalling axis is ceased to functioning due to the lack of 
fatty acids stimulation. Therefore, the FABP5 inhibitors suppressed the malignant 
progression of CRPC by cutting off the FABP5-related signalling transduction chain 
and they may be candidate reagents for a CRPC treatment. 
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6.2 Conclusion  
 
Based on the data achieved in this study, several important findings have been 
established: 
1- This study clearly establishes that a mutated FABP5 (dmrFABP5) incapable of 
binding to fatty acids can be used as a bio-inhibitor to suppress the biological 
activity of FABP5. 
2- SBFI26, a lead inhibitor selected from a group of chemical compounds, has a 
highly binding affinity with FABP5. 
3- Both novel inhibitors of FABP5 (SBFI26 and dmrFABP5) can suppress the 
proliferation, migration, invasion and colony formation of castration resistant 
prostate cancer PC3-M cells in vitro. 
4- Both inhibitors produce a highly significant suppression of both primary 
tumours and metastases of cancer cells implanted orthotopically into the mouse 
prostate gland. DmrFABP5, incapable of binding to fatty acids, produced a 
greater suppression of both primary tumour and metastases than the chemical 
inhibitor SBFI26. 
5- SBFI26 competitively binds to FABP5 and hence suppresses cellular fatty-acid 
uptake. SBFI26 directly suppresses the biological function of FABP5 and work 
as a weak agonist to PPARγ to suppress the CRPC by inhibiting fatty acid 
uptake. 
6- DmrFABP5 indirectly suppresses the biological function of FABP5, works by 
blocking the fatty-acid stimulation of PPARγ and prevents it from activating 
the down-stream regulated cancer-promoting genes.   
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6.3 Future work  
 
In this work, we suppressed the malignant progression of CRPC by using FABP5 
inhibitors to cut off the FABP5-PPARγ related signalling transduction chain at two 
different points. SBFI26 interferes with this pathway at the original stage of the initial 
signal transduction by binding competitively to FABP5 to inhibit cellular fatty acid 
uptake. The mechanism involved in the biological action of SBFI26 is now fully 
understood. The bio-inhibitor dmrFABP5 indirectly suppresses the biological function 
of FABP5 and works by blocking the fatty-acid stimulation of PPARγ to prevent it 
from activating the down-stream regulatory cancer-promoting genes. Since the exact 
route of fatty-acid delivery to PPARγ is not known, how dmrFABP5 inhibits PPARγ 
is not fully understood. Further study is needed to understand fully the detailed 
molecular mechanisms involved in the suppressive effect of dmrFABP5 on PPARγ 
activation. In addition, further preclinical work on toxicity and pharmacokinetics 
studies are needed before the true clinical application of these inhibitors.  
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A. Reagents 
Reagents                                                            Supplier 
………………………………………………………………………………………… 
A.1 Reagents for general molecular biology 
Absolute ethanol                                                BDH, England, UK 
Agarose                                                              Genflow, Fradley, UK 
Ampicillin                                                          Invitrogen, CA, USA 
BL21 E. coli bacteria                                         Invitrogen, CA, USA 
DH5α E. coli bacteria                                        Invitrogen, CA, USA 
DNA marker III                                                 Roche, England, UK 
DNA marker XIV                                              Roche, England, UK 
E. coli BL21 cells                                              InvivoGen, USA 
E. coli DH5α cells                                             InvivoGen, USA 
Glucose                                                              Sigma, USA 
Glycerol                                                             Sigma, USA 
IPTG (Isopropylthiogalactoside)                       Sigma, USA 
Isopropanol                                                        BDH, England, UK 
LB agar                                                              Sigma, USA 
LB broth                                                             Sigma, USA 
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Reagents                                                            Supplier 
………………………………………………………………………………………… 
Ligation enzyme buffer                                     New England BioLabs 
Magnesium chloride                                          Sigma, USA 
Magnesium sulphate                                          Sigma, USA 
MOPS                                                                Sigma, USA 
pBluescript II SK vector                                   InvivoGen, USA  
Potassium acetate                                              Sigma, USA 
Potassium chloride                                            Sigma, USA 
pQE-32 vector                                                  InvivoGen, USA 
QIAGEN Ni-NTA Fast Start Kit                       QIAGEN, CA, USA 
QIAGEN Plasmid mini-preparation kit             QIAGEN, CA, USA 
Restriction enzyme buffers                                New England BioLabs 
Restriction enzymes                                           New England BioLabs 
Safe View (Nucleic Acid Stain)                        NBS Biological, Cambridgeshire, UK 
SDS                                                                    Sigma, USA 
T4 DNA ligase                                                   New England BioLabs 
Tryptone                                                            Sigma, USA 
Wizard DNA Clean-Up System                        Promega, WI, USA 
Yeast extract                                                      Fisher scientific, Loughborough, UK 
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Reagents                                                            Supplier 
………………………………………………………………………………………… 
A.2 Reagents for Western blot 
Ammonium persulfate (APS)                            Sigma, USA 
Bradford reagent                                                Sigma, USA 
Bromophenol blue                                             Sigma, USA 
CelLytic-M                                                        Sigma, USA 
Commassie brilliant blue                                   Bio-Rad GmbH, Munchen, Germany 
ECL detection kit                                              GE Healthcare, Buckinghamshire, UK 
Glycine                                                              Melford, UK 
Kodak Developer                                               Sigma, USA 
Kodak film                                                         GE Healthcare, Buckinghamshire, UK 
Kodak Fixer                                                       Sigma, USA 
Methanol                                                            Fisher scientific, Loughborough, UK 
Next Gel 12.5%                                                 Amresco, OH, USA  
Ponceau solution                                                Sigma, USA 
PVDF membrane                                               Millipore, USA 
TEMED                                                             Sigma, USA 
Tris base ultrapure                                             Melford, UK 
Tween-20                                                           Sigma, USA 
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Reagents                                                            Supplier 
………………………………………………………………………………………… 
β-mercaptoethanol                                             Sigma, USA 
A.3 Reagents for fluorescence displacement assay 
DAUDA                                                             Cayman, USA 
Lipidex-1000 (Hydroxyalkoxypropyl-Dextran) Sigma, USA 
A.4 Reagents for cell culture 
DMSO                                                                Sigma, Germany 
Fetal calf serum (FBS)                                       Biosera, East Sussex, UK 
FuGENE HD transfection reagent                     Promega, USA 
Hygromycin                                                       InvivoGen, CA, USA 
L-Glutamine                                                      Lonza, Belgium 
Opti-MEM I medium                                         Gibco, Invitrogen, Paisley, UK 
Penicillin/Streptomycin                                     Lonza, Belgium 
pGL4.50 [luc2/CMV/Hygro] vector                 Promega, USA 
Phosphate buffered saline (tablet)                     Gibco, Invitrogen, Paisley, UK 
Potassium D-luciferin                                        Promega, USA 
RPMI 1640                                                        Gibco, Invitrogen, Paisley, UK 
Sodium pyruvate                                                Sigma, USA 
Trypsin                                                               Gibco, Invitrogen, Paisley, UK 
Trypsin/EDTA solution                                     Gibco, Invitrogen, Paisley, UK 
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Reagents                                                            Supplier 
………………………………………………………………………………………… 
Versene                                                              Gibco, Invitrogen, Paisley, UK 
A.5 Reagents for cell proliferation assay     
MTT                                                                   Sigma, USA  
DMSO                                                                Sigma, Germany 
A.6 Reagent for soft agar assay                                  
Low melting point agarose                                Genflow, Fradley, UK                                        
MTT                                                                   Sigma, USA        
A.7 Reagents for cell invasion assay  
Crystal violet                                                     Sigma, USA 
A.8 Reagents for tumorigenicity and metastasis in vivo        
Isofluorane                                                         Hoechst, German 
Novalgin                                                            Hoechst, Germany 
Potassium D-luciferin                                        Promega, USA 
A.9 Reagents for histology 
Acetone                                                              Sigma, USA            
Ethanol (IMS)                                                    GENTA, Tockwith, UK 
Formaldehyde                                                    Sigma, USA            
Haematoxylin                                                    Sigma, USA 
Xylene                                                               GENTA, Tockwith, UK 
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Reagents                                                            Supplier 
………………………………………………………………………………………… 
A.10 Reagents for fatty acid uptake assay           
BODIPY 558/568C12                                         Invitrogen, USA 
 
B. Buffers 
B.1 Molecular Biology  
LB medium  
LB broth 20g 
dH2O 1 Lit  
Autoclaved  
 
LB agar  
LB agar 35g  
dH2O 1 Lit  
Autoclaved  
 
RF1 buffer (pH 5.8)  
KCl 7.456g (100mM)  
MgCl2.4H2O 9.9g (50mM)  
CaCl2 1.5g (10mM)  
K-acetate 2.94g (30mM)  
Glycerol (v/v) 150ml (15%)  
dH2O up to 1 Lit  
Adjust the pH and sterilized by filtration  
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RF2 buffer (pH 6.8)  
MOPS 2.1g (10mM)  
CaCl2 11g (75mM)  
KCl 0.745g (10mM)  
Glycerol (v/v) 150ml (15%)  
dH2O up to 1 Lit  
Adjust the pH and sterilized by autoclave 
  
Glucose 20%  
Glucose 20g  
dH2O 10ml  
Sterilized by filtration 
 
Magnesium salt solution (2M)  
MgSO4 2.465g (1M)  
MgCl2 2.033g (1M)  
dH2O 10ml  
Sterilized by filtration  
 
SOB medium (pH 7)  
NaCl 0.5g 
Tryptone 20g  
Yeast extracts 5g  
KCl 0.186g  
dH2O up to 1 Lit  
Adjust the pH and sterilized by autoclave  
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SOC medium  
SOB medium 4.850ml  
Mg2+ salt solution (2M) 50μl  
Glucose 20% 150μl  
 
Stock medium for bacteria  
Glycerol 5ml  
LB medium 4ml  
Bacteria culture 3ml  
 
10× TBE stock solution  
Boric acid 55g (890mM)  
Tris base 108g (890mM)  
EDTA 0.5M, pH 8 40ml (20mM)  
dH2O up to 1 Lit  
Adjust the pH and sterilized by autoclave 
 
100mM IPTG 
IPTG 238mg 
Sterile distilled H2O 10ml 
Filter sterilized 
 
6×DNA loading buffer  
Bromophenol blue 0.5% 0.5ml  
Xylene cyanol FF 0.5ml  
Glycerol in sterile dH2O (60%) 1ml 
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B.2 Western Blot  
1M Tris (pH 6.8) 
Tris base 12.1g 
dH2O 100ml  
pH adjusted with HCl  
 
10% (w/v) APS solution  
Ammonium persulfate 100mg  
dH2O 1ml  
 
10% (w/v) SDS solution  
Sodium Dodecyl Sulfate 10g  
dH2O 100ml  
 
5× SDS-PAGE sample loading buffer  
1M Tris-HCl (pH 6.8) 1.25ml  
Bromophenol blue 0.5% (w/v) 2.5ml  
Glycerol 40% (v/v) 15ml  
SDS 10% 5ml  
β-mercaptoethanol 1.25ml  
 
2× SDS-PAGE sample loading buffer  
1M Tris-HCl (pH 6.8) 2.5ml  
Bromophenol blue 0.5% (w/v) 0.8ml  
Glycerol 40% (v/v) 4ml  
SDS 10% 2ml  
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dH2O 4.7ml 
 
Transfer buffer (pH 8.3)  
Glycine 14.4g (192mM)  
Tris base 3.03g (25mM)  
Methanol 20% (v/v)  
dH2O up to 1Lit  
pH adjusted with HCl  
 
10× TBS buffer (pH 7.6)  
Sodium chloride 87.66g (1500mM)  
Tris base 60.58g (500mM)  
dH2O up to 1 Lit  
pH adjusted with HCl  
Autoclaved  
 
1×TBS-Tween 1%  
10× TBS buffer 100ml  
Tween 20 1ml  
dH2O up to 1 Lit  
 
TBS-T-milk 5%  
Dried milk 5g  
1×TBS-T 100ml 
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B.3 Fluorescence displacement DAUDA assay 
Delipidated solution 
Lipidex-1000 10g 
Tris HCL(10Mm) pH 7.5 
 
B.4 Cell Culture  
Routine cell culture medium  
RPMI medium 1640 500ml  
Fetal calf serum 10% (v/v)  
Penicillin-Streptomycin (5000 U/ml) 5ml  
L-Glutamine (20mM) 5ml  
Sodium pyruvate (100mM) 5ml  
 
Selective medium  
Routine medium with Hygromycin (200μg/mL) 
 
Culture medium for evaluation the fatty acid uptake  
PBS 500ml  
FCS 5% (v/v)  
BODIPY 2 µM 
 
Culture medium for identification of stably luciferase expressing PC3-M 
Routine cell culture medium 
D-luciferin150μg/mL 
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Freezing medium  
Routine cell culture medium 92.5% (v/v)  
DMSO 7.5% (v/v)  
 
Trypsin/EDTA solution (T/E) (2.5%)  
1× Versene 100ml  
Trypsin 2.5ml 
 
MTT solution (5mg/ml)  
MTT 50mg  
PBS 10ml  
 
PBS  
PBS one tablet  
dH2O 500ml  
Autoclaved 
 
C. Equipments  
AccuWeigh, WA, USA  
Portable Lab Scale  
 
Bandelin, Germany 
Sonicator 
 
BD Microlance 3, Ireland  
Needle  
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Syringes  
 
BD Biosciences, USA  
BD BioCoatTM Growth Factor Reduced (GFR) Matrigel TM Invasion Chamber  
 
BD Plastics, Sunderland, UK  
Syringes  
 
Beckman coulter, UK  
Microcentrifuge  
 
Beckman coulter, USA 
EPICS XL flow Cytometer  
 
Becton Dikinson, USA  
Falcon 2059 tube  
 
Berthold detection system, Germany  
Sirius Luminometer  
Bio-Rad, Hemel, UK  
Gel electrophoresis rig  
Mini-protein 3 cell system  
 
BioTek, USA  
Multiskan MS (plate reader)  
 
 
Borolabs, Basingstoke, UK  
CO2 incubator Model TC2323 
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Jenway, Genova, UK  
Spectrophotometer  
 
Flowgen, Nottingham, UK  
Gel drier  
 
Generier bio-one, UK  
Tissue culture pipettes (5-50 ml)  
Universal tube  
 
Grant Instruments, UK  
H2O bath  
 
GMI, MJ Research, MN, USA  
Thermal cycler (Peltier Thermal Cycler PTC-200)  
 
Heraeus Holding GmbH, Germany  
Labofuge 400R (centrifuge)  
 
Labtech International, Ringmer, UK  
NanoDrop spectrophotometer  
 
Leica, Germany  
Superior Adhesive slide  
 
Leitz Labovert, Luton, UK  
Light microscope  
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Microm, Oxford, UK  
Microtome HM355  
 
Merck Millipore, UK  
Immobilon, Transfer membrane 
 
Merck Millipore, UK 
D-Tube dialyzer  
 
Nalgene, UK  
Cryobox DNA 
 
New Brunswick Scientific, USA 
CO2 Shaking incubator 
 
Nunc, Denmark  
Cell culture filter cap flasks  
Cell culture plates  
Cryogenic vial  
 
Oxford Optronix, Oxford, UK  
GelCount  
 
 
Perkin Elmer, USA 
IVIS imaging system  
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QIAGEN, Crawley, UK  
Qiagen tip  
QIA Shredder spin column  
 
 
Shandon, UK  
Sequenza slide rack  
Coverslip (20×40mm)  
 
SLS Ltd., Nottingham, UK  
Haemocytometer  
Magnificent stirrer  
 
Starlab, Milton Keynes, UK  
Microtubes  
Pipette tips  
 
Surgipath, UK  
Microslide  
Tissue cassette  
 
Swann-Morton, Sheffeild, UK  
Carbon steel surgical blades 
 
Techne, England, UK  
Hot plate (Ori-Block 08-3)  
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Thermo Electron Corporation, Waltham, USA 
Varioskan Flash Spectral Scanning Multimode Reader 
 
Thermo Scientific, USA 
Shandon Citadel 1000 tissue processor 
 
Whatman, England, UK  
Whatman filter paper  
 
Weber scientific International, NJ, USA  
Haemocytometer slide 
 
 
 
 
 
 
 
